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ABSTRACT
ENGINEERING MESOTHELIN-BINDING PROTEINS AS TARGETED
CANCER DIAGNOSTICS AND THERAPEUTICS
SEPTEMBER 2020
ALLISON R. SIROIS, B.S., STONEHILL COLLEGE
M.S., SMITH COLLEGE
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Dr. Sarah J. Moore
Cancer is a significant global health concern; and traditional therapies, including
chemotherapeutics, are often simultaneously toxic yet ineffective. There is a critical need
to develop targeted cancer therapeutics which specifically inhibit molecules or molecular
pathways essential for tumor growth and maintenance. Furthermore, a targeted therapy is
only effective when a patient's tumor expresses the molecular target; therefore, companion
diagnostics, including molecular imaging agents, are a necessary counterpart of targeted
therapies.
Mesothelin (MSLN) is a cell surface protein overexpressed in numerous cancers,
including triple-negative breast, pancreatic, ovarian, liver, and lung, with limited
expression in normal tissues. Aberrant MSLN expression promotes tumor progression,
metastasis, and therapeutic resistance, and is correlated with poor prognoses. Promising
results from pre-clinical and clinical trials to target MSLN with antibodies, antibody
derivatives, immunotoxins, and antibody-drug conjugates for therapy demonstrate the
promise of MSLN-targeting methods; however, none are currently approved for routine
clinical use, and limitations are emerging for targeting agents under development. New
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targeted diagnostic and therapeutic approaches for MSLN-positive tumors have potential
for substantial impact in the clinic.
In this work, I used yeast-surface display and directed evolution to engineer novel
proteins based on the non-antibody fibronectin (Fn3) scaffold that bind to MSLN with high
affinity and specificity. Soluble engineered proteins were expressed and purified to high
yields from a bacterial system. In vitro cytotoxicity and apoptosis assays demonstrated the
potential of the proteins as targeted cancer therapeutics for MSLN-expressing tumors, and
the engineered proteins enhanced cancer cell sensitivity to chemotherapy. Towards the
goal of using engineered Fn3 variants for targeted drug delivery applications, in
collaboration with our collaborators, we synthesized and validated a novel protein-polymer
conjugate drug delivery system. Finally, I established and validated appropriate in vivo
tumor models to evaluate our engineered proteins as molecular imaging diagnostic agents.
My work has provided a candidate set of engineered proteins that can be used as
molecular targeted therapeutics, drug-delivery vehicles, and molecular imaging diagnostics
for MSLN-positive tumors, towards the ultimate goal of providing targeted treatment and
diagnostic options for cancer patients where no such treatments currently exist.
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CHAPTER 1
INTRODUCTION

1.1 Overview of Cancer
Cancer is a global health concern and is expected to rank as the leading cause of
death, and the most important obstacle to increasing life expectancy worldwide, in the 21st
century [1]. Global cancer incidence and mortality rates are increasing and reflect the
growth and aging of the population, and changes in the prevalence and distribution of
established risk factors, many of which are associated with socioeconomic development
[2]. There were an estimated 18.1 million new cancer diagnoses and 9.6 million cancer
deaths worldwide in 2018 [3]. While cancer mortality rates in the U.S have continuously
decreased since 1991, cancer remains the second leading cause of death and 1.8 million
new diagnoses and over 600,000 cancer deaths are expected in 2020 (Figure 1.1) [4].

1.1.1 Motivation for developing targeted cancer therapeutics
For the majority of patients suffering from a malignant disease, intravenous
chemotherapeutics remain an integral component of their treatment regimen. These
ubiquitous, cytotoxic agents eradicate cancer cells by targeting rapidly dividing cells
through interruption of essential cell cycle events, such as DNA replication and cellular
division (Figure 1.2) [5]. These traditional chemotherapeutics, however, are limited by
narrow therapeutic windows due to severe toxicities from indiscriminately targeting
rapidly dividing healthy cells, and are frequently associated with acquired resistance, both
of which represent key clinical challenges (Figure 1.3) [6]. There is a critical need to
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develop targeted cancer therapeutics which specifically target tumor cells by inhibiting
molecules or molecular pathways essential for tumor growth and maintenance [6–9].
Improved understanding about the specific molecular drivers of cancers and their
growth mechanisms has drastically changed treatment criteria and standards. As opposed
to the once heavily pursued “silver bullet” drug that could be used for all patient
populations, cancer care has been revolutionized by the implementation of “precision
medicine”, in which specific information about an individual person’s tumor is used to
guide treatment plans, monitor the effectiveness of treatments, and make prognoses [10].
Targeted therapies have made significant contributions towards more personalized
medicine, and have resulted in increased treatment efficacy and reduced toxicities [8]. At
present, over 100 targeted therapies have been approved for clinical use as treatments for
a variety of diseases, including malignancies [7].

1.1.1.1 The molecular hallmarks of cancer
Normal cells require the production and release of growth-promoting signals that
govern their entry into, and progression through, a tightly-regulated cell cycle, to
proliferate in a controlled manner and maintain tissue homeostasis [11]. Old or damaged
cells undergo programmed cell death, or apoptosis, and are removed and replaced with new
cells [12].

Cancer cells, however, acquire numerous mutations, or hallmarks, that

dysregulate these ordered processes, resulting in a survival advantage (Figure 1.4) [13].
The rapidly expanding repertoire of targeted therapies can be organized according to their
effects on a particular cancer hallmark; if a hallmark is indeed important for a tumor, then
its inhibition should impair the growth and progression of that tumor [14].
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These survival advantages include the overexpression of cell surface receptors
which are subsequently stimulated by different growth factors to promote progression
through the cell cycle (Figure 1.5A). One of the first targeted cancer therapies, Tamoxifen,
was approved in the 1970’s and provided an effective treatment option for estrogen
receptor (ER)-positive breast cancer patients [15]. Tamoxifen binds to ER, thereby
preventing estrogen from binding, and inhibits cell proliferation signaling propagated by
ER. Another example of a growth factor inhibitor Trastuzumab, was approved in 1998 to
similarly target the overexpression of the human epidermal growth factor receptor 2
(HER2) [16].
In addition to sustained proliferative signaling, evasion of growth suppressors, and
resistance to cell death, other cancer hallmarks include replicative immortality, invasion
and metastasis (the spread of cancer cells throughout the body), metabolic reprogramming,
and angiogenesis (the formation of new blood vessels) [14]. Towards the goal of inhibiting
angiogenesis and a cancer’s ability to acquire necessary nutrients, Bevacizumab was
developed as a leading clinical therapy and targets vascular endothelial growth factor
(VEGF) (Figure 1.5B) [17,18]. Finally, one of the newest types of targeted therapy
incorporated into the clinic includes immunotherapies, designed to inhibit a tumor’s ability
to evade our immune system. A central role of the immune system is to distinguish
between normal or “self” cells from those seen as “foreign”, and to attack only the foreign
cells [19]. To distinguish self from foreign, immune cells, such as T cells, rely on their
checkpoint molecules; cell surface proteins that need to be activated (or inactivated) to
mount an immune response. One checkpoint protein in particular, PD-1, is commonly
expressed on T cells and when engaged with its ligand, PD-L1, maintains the T cells in an
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“off” state. Cancer cells often overexpress the PD-L1 ligand on their surfaces to keep T
cells turned off, and efficiently avoid being attacked. Therapies that target either PD-1 or
PD-L1, known as checkpoint inhibitors, help activate T cells and enhance the immune
response against cancer cells (Figure 1.5C) [20].

1.1.1.2 Targeted drug delivery systems
Cancer therapies are often associated with unfavorable pharmacokinetics, poor
targeting of cancer cells, and several physiological and chemical limitations that ultimately
decrease their therapeutic efficacy. Specific targeting of cancer therapies to tumor cells
using a targeted drug delivery system could address these limitations currently caused by
the systemic distribution of drugs in the body [21,22]. Furthermore, delivery vehicles have
also been shown to increase drug solubility, protect against degradation and elimination,
and decrease toxicity [21].
Receptor mediated endocytosis is a promising approach being developed to use
native transport pathways to shuttle diverse therapeutic molecules into cells [23,24]. To
deliver therapeutics with receptor targeting, a drug is shuttled through a native protein
trafficking pathway as the cargo of a molecule that engages with the cell surface protein.
Therefore, a successful targeted drug delivery complex requires a targeting domain that
binds the trafficking receptor and is then internalized, a therapeutic entity, and some
approach to link the targeting domain to the drug (Figure 1.6). Protein-polymer conjugate
systems are already routinely used in the clinic in the form of protein therapeutics
conjugated to polyethylene glycol (PEG) and offer a system that can be easily tailored for
targeted drug delivery to a variety of disease-specific cell types.
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1.1.2 The need for companion diagnostics
Targeted therapy is only effective when a patient's tumor expresses the specific
molecular target; therefore, companion diagnostics, including molecular imaging agents,
which can be used non-invasively, are a necessary component for developing targeted
therapies. The rapid development of these companion diagnostics can also be used to
efficiently evaluate novel drugs, stratify patients based on expected responses or side
effects, and monitor patient responses to therapy [25,26].
Moving a candidate therapeutic through the process from idea to clinical use is
expensive and time consuming, with many opportunities for failure. A recent study
concluded that developing an approved therapeutic is currently estimated to cost $2.6
billion, and while the average time to complete clinical trials has decreased, the rate of
success has also decreased to just 12% [27]. A companion diagnostic may improve the
economics of the drug development process by identifying the appropriate patients for each
clinical trial, thereby reducing costs and shortening the time to approval [28]. Using the
same targeting molecule for multiple purposes, such as for both diagnosis and treatment,
is also highly desirable and economically advantageous.
There is also increased confidence that a patient will respond to a drug when using
a companion diagnostic because it will directly identify the patients that have the exact
molecule and binding site that a drug is targeting. A companion diagnostic can also be
selective; it can rule out those patients who either will not benefit, or may experience
negative side effects, from a specific therapeutic (Figure 1.7) [9,28,29]. Further, with a
companion diagnostic, the molecular-level response of the patient to the therapy can be
monitored, providing earlier data on whether a treatment regimen is working compared to
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traditional endpoints such as macroscale tumor regression. For example, a positive
response can be indicated by a significant change in the level of the molecular target
following therapy, while no change in the molecular target may imply the drug has had no
effect on the cancer cells [29].
Towards the goal of delivering the right therapy to the right patient at the right time,
the first U.S Food and Drug Administration (FDA) approval of co-developing a therapeutic
and a companion diagnostic was Trastuzumab and HercepTest. As previously discussed,
Trastuzumab is an approved therapy used to treat HER2-overexpressing breast cancers.
HercepTest is a semi-quantitative immunohistochemistry (IHC)-based test used to
determine the expression level of the HER2 biomarker on patients’ tumors [25]. Currently,
the majority of in vitro laboratory diagnostics are similarly restricted to tissue samples that
can be obtained for analysis, severely limiting the predictive value of these diagnostics
[30].

A biopsy sample from a primary tumor, for example, does not provide any

information regarding tumor metastasis or recurrence, both of which may influence a
particular treatment regimen. Further, a biopsy of a single site of a tumor may not be
representative of the entire burden of disease because patients, especially those with
advanced disease, may demonstrate tumor heterogeneity [31]. Varied target expression,
either within a single tumor or between tumors, can lead to incomplete therapeutic
response. While blood samples can provide some complementary insight into disease
progression, normal blood values cannot always exclude the presence of disease, cannot
differentiate between localized and diffuse tumor recurrence, and provide no spatial
information [30,32]. There is a critical need to better monitor active disease in real time.
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1.1.3 Role of molecular imaging in cancer
Molecular imaging is the visualization, characterization and measurement of
biological processes at the molecular and cellular levels in living subjects, and plays a
central role in clinical oncology [33,34]. While conventional anatomic imaging platforms,
including computed tomography (CT) and magnetic resonance imaging (MRI), provide
high resolution details regarding tumor location, size, and morphology, they provide little
information about tumor physiology [35]. Conversely, molecular imaging modalities,
including positron emission tomography (PET), can provide important insight into a
tumor’s biological function. For example, because cancer cells heavily rely on aerobic
glycolysis (“the Warburg effect”) to generate the energy needed for cellular processes, a
glucose-analog PET tracer, fluorodeoxyglucose (FDG), can be used to detect aberrant
metabolic activity (Figure 1.8). PET, therefore, can offer several advantages over anatomic
imaging modalities, and frequently distinguishes benign and malignant lesions when CT
and MRI cannot. Indeed, the average sensitivity and specificity of FDG-PET across all
oncology applications have been estimated at 93% and 96%, respectively [36].
Unfortunately, despite its high sensitivity and specificity, PET alone is limited by its low
spatial resolution. Accordingly, the introduction of multi-modality imaging platforms,
such as PET/CT, have revolutionized cancer imaging by integrating the benefits of imaging
both tumor biology and anatomic structures (Figure 1.9) [37,38].

1.1.3.1 Cost-effectiveness of PET/CT
With its need for high-end equipment (PET/CT systems can range in price from
$2.5 to $3.0 million), radiotracer production, and operational costs, PET/CT scans are
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expensive procedures. Of the $32.1 billion total Medicare cancer expenditures, imaging
accounted for approximately 4.6% of those costs; 1% of which was incurred from PET/CT
[36,39]. Individual costs, however, do not necessarily reflect the cost-effectiveness of a
diagnostic test. PET/CT use continues to increase at stable rates for all cancer types, and
in 2019, an estimated 2.86 million PET/CT scans, a 7% increase from the previous year,
were performed in the U.S. This is because PET/CT has been determined to improve
patient management across a variety of cancers, which subsequently reduces downstream
costs associated with incorrect management decisions [36,37,40–44]. In one study, the
National Oncologic PET Registry (NOPR) determined that the results from PET/CT scans
changed patient management in 49.3% of the study’s patients. These patient management
changes included switching to a different therapy (26.5%), adjusting the dose or duration
of a therapy (16.6%), or switching to observation or supportive care (6.2%). These studies
are not without limitations, however, and only discussed intended changes in patient
management; no data on how frequently physicians carried out these changes were
provided. Further, it is unknown whether any changes in management led to better clinical
outcomes.
Additionally, molecular imaging is routinely used in later stages of drug
development to select patients that are most likely to benefit from a potential treatment.
For example, the ZEPHIR clinical trial (NCT01565200) determined the predictive value
of a pretreatment with a Trastuzumab PET agent, a HER2-targeting molecule, in metastatic
breast cancer patients before treatment with the corresponding treatment TDM-1. TDM-1
is an effective but expensive therapeutic, and the PET imaging was able to both measure
HER2 expression for the entire disease burden, and identified non-responding patients.
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1.1.3.2 PET/CT has expanded capabilities
There is tremendous incentive for detecting cancer at its earliest stages, and
PET/CT imaging allows sensitive and specific monitoring of key molecular events
associated with early carcinogenesis [45–47]. While molecular imaging is unlikely to
replace biopsies in the initial assessment of target expression, imaging should be used to
complement such biopsies because of its ability to better assess tumor heterogeneity. In
one study evaluating PD-L1 expression on tumors [48], PET/CT imaging demonstrated
that while tracer uptake was generally high in tumors, it was also heterogeneous, often
varying among lesions, patients and tumor types. Further, the authors concluded that
patient responses were better correlated with the imaging studies than with IHC- or
sequencing-based studies.
PET/CT imaging can evaluate and inform treatment regimens in real time because
its non-invasive nature allows for repeat assessments while avoiding the risk of
complications associated with serial biopsies [29]. Finally, molecular processes affected
early after therapy initiation, including tumor cell proliferation and angiogenesis, can be
quantified by molecular imaging before traditional end points, such as tumor growth or
shrinkage are observed by traditional anatomically-based imaging [29,49]. For example,
for a patient undergoing chemotherapy, anatomical changes in tumor size that can be
observed by MRI or CT frequently occur over the time scale of weeks to months.

1.2 Mesothelin is a novel tumor biomarker
Mesothelin (MSLN) is a cell surface protein originally identified using the K1
monoclonal antibody (mAb) generated by immunization of mice with the OVCAR-3 cells,
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a human ovarian carcinoma cell line [50,51]. Since its discovery, MSLN has been shown
to be overexpressed in many ovarian [50,52–56], breast [57–62], pancreatic [63–66], liver
[67–69] and lung tumors [70–73], among others [74] (Figure 1.10). MSLN expression is
limited in normal tissue, with only low levels expressed on mesothelial cells lining the
pleura, peritoneum, and pericardium [75]. The normal developmental role of MSLN
remains unclear.

Mice with an inactivated MSLN gene display no distinguishable

phenotype, and both male and female mice lacking MSLN are able to produce offspring
normally, suggesting MSLN is non-essential for growth and reproduction [76].

1.2.1 MSLN structure and regulation
The MSLN gene (chromosomal location 16p21) encodes a 69-kDa precursor
protein

which

is

proteolytically

cleaved

by

furin

into

the

40-kDa,

glycosylphosphatidylinositol (GPI)-linked, membrane-bound MSLN, and a 31-kDa shed
fragment called megakaryocyte-potentiating factor (MPF) which is released from the cell
(Figure 1.11) [50]. A soluble form of MSLN, suspected to result from cleavage of the GPI
anchor, has also been detected in the serum and pleural effusions of mesothelioma patients,
and the serum and ascites of ovarian carcinoma patients [77]. While several prediction
programs have recently attempted to determine the three-dimensional structure of both the
precursor and mature MSLN, the structure remains unknown [78].
At the epigenetic level, hypomethylation of CpG sites in promoters typically
increases gene transcription, whereas hypermethylation is associated with transcriptional
silencing [79]. Indeed, in pancreatic cancers, hypomethylation of the MSLN promoter
correlates with increased expression and transcription, and MSLN-negative pancreatic cell
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lines treated with demethylating agents is sufficient to induce MSLN expression [80]. In
ovarian, endometrial, and mesotheliomas, however, while the MSLN promoter was
hypomethylated, MSLN expression was not associated with the methylation status of the
promoter [81].
Transcription of the MSLN gene is driven by a promoter, CanScript, located
upstream from the transcriptional start site [82]. The cancer-specific upregulation of
MSLN in several cancers has been attributed to binding of a transcription factors, TEF-1
and YAP1, to MCAT and SP1-like motifs within CanScript, respectively [82–84]. These
transcription factors, however, were determined to be necessary but not sufficient to induce
MSLN expression, suggesting the existence of other unknown cofactors.
Finally, at the post transcriptional level, microRNA-198 (miR-198) is known to
regulate MSLN expression. Loss of miR-198 leads to upregulation of MSLN and is
correlated with poor survival, whereas its reconstitution reduces tumor growth and
metastasis and is correlated with increased survival [85].

1.2.2 The MSLN-MUC16 binding interface
The extracellular portion of MSLN binds tumor biomarker MUC16, also known as
CA125 (cancer antigen 125). A 64 amino acid region of MSLN (residues 296-359) has
been identified as the minimal domain responsible for binding MUC16 with a KD = 3.35
nM [86]. MUC16, a member of the human mucin family, is a large (2500 – 5000 kDa),
membrane-associated protein expressed in mucous membranes of several tissues, including
the upper respiratory tract and reproductive organs, and functions as a lubricant for these
epithelial luminal surfaces [87]. MUC16 domains are heavily glycosylated, with both O-
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and N-linked oligosaccharides [88]. The N-linked glycans are responsible for the high
affinity binding to MSLN as treatment with peptide-N-glycosidase (PNGaseF), which
removes the N-linked glycans, has been shown to inhibit MSLN-MUC16 binding [55].
The interaction between MUC16 and MSLN has been shown to facilitate both
homotypic and heterotypic cell adhesions, leading to increased tumor progression and
metastasis. This interaction is especially prominent in ovarian cancer metastasis in which
ovarian cancer cells, which express both MSLN and MUC16, are uniquely shed from the
primary tumor and disseminate throughout the peritoneal cavity, which is lined by MSLNexpressing mesothelial cells (Figure 1.12).

1.2.3 Signaling pathways influenced by MSLN
Several mechanisms suggest MSLN aids in cancer progression by promoting
cancer cell survival and proliferation (Figure 1.13) [53,65,89–92]. Interleukin-6 (IL-6) is
a pro-inflammatory cytokine implicated in cancer cell survival, and overexpression of
MSLN leads to high IL-6 production by NF-κB activation. High IL-6 levels result in higher
expression levels of the cyclin E/cyclin-dependent kinase (CDK2) complex, thereby
speeding the G1-S cell cycle transition [65,91]. In one study of pancreatic cancer, the
overexpression of MSLN was found to significantly increase cancer cell proliferation and
migration and resulted in larger tumors forming in mouse models, while silencing MSLN
led to decreased proliferation and slower entry into S phase [90,91]. In models of
malignant mesothelioma, MSLN-silencing by siRNA was shown to decrease the
proliferation rate and reduce the invasive capacity and sphere formation in MSLNoverexpressing cell lines.
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More recently, MSLN has been shown to contribute to epithelial-to-mesenchymal
transition (EMT) and control cancer stem cell (CSC) properties in a variety of cancers
(Figure 1.14) [70]. While EMT is traditionally an important developmental process by
which epithelial cells acquire more mesenchymal and, therefore, motile characteristics,
accumulating evidence suggests an important role for EMT events in malignant
transformation and cancer progression [93,94]. MSLN overexpression upregulates both
mesenchymal and CSC regulatory genes which are known to promote self-renewal,
anchorage-independent growth, migration and invasion.
Finally, MSLN expression may also aid in cancer cell survival by conferring
resistance to certain chemotherapy drugs, including paclitaxel [95] and TNF-α [65].
MSLN signaling via PI3K/Akt or MAPK/ERK activation, in addition to NF-κB signaling,
is known to inhibit production of pro-apoptotic factors such as Bad, Bax and Bim, while
promoting the expression of anti-apoptotic genes, including Mcl-1, Bcl-xl and Bcl-2.
Additionally, when MSLN-siRNA was combined with cisplatin, a common
chemotherapeutic, there was a significant increase in apoptosis, compared to cells treated
with each therapy alone, suggesting inhibiting MSLN further sensitizes cancer cells to
chemotherapy [65].

1.2.4 MSLN-targeting therapies currently in development
MSLN has broad potential as a novel tumor target because of its differential
expression pattern and its strong humoral and adaptive immunogenicity (Figure 1.15)
[75,90]. Pancreatic cancer patients vaccinated with granulocyte-macrophage colonystimulating factor (GM-CSF) were shown to generate dose-dependent antitumor immune
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responses against autologous tumors and strong MSLN-specific CD8+ T cell responses
[96]. Mesothelioma and ovarian cancer patients were shown to have elevated levels of
MSLN-specific antibodies compared to normal control populations [97]. The observed
immunogenicity of MSLN is associated with its high expression on the tumor cell surface,
as more than half of patients with MSLN-positive immunostaining had MSLN-specific
antibodies while less than 10% of patients with negative staining had MSLN-specific
antibodies [97]. This association was further confirmed when only 2 of 50 (4%) patients
with pharynx/larynx squamous cell carcinoma, a malignancy with very low MSLN
expression, were shown to develop IgG antibodies against MSLN [98]. Additionally,
antigen-targeted immune responses are implicated in the survival of cancer patients.
MSLN-specific, T cell-directed immune responses were shown to correlate with extended
survival of patients with brain metastasis arising from various primary solid tumors,
including melanoma and lung and ovarian cancers [99].

1.2.4.1 Monoclonal Antibody (MORAb-009)
One of the first therapies developed against MSLN was MORAb-009, a highaffinity chimeric mAb capable of killing MSLN-expressing cell lines via antibodydependent cell cytotoxicity (ADCC) and inhibiting the MSLN-MUC16 binding interface
[100,101]. In vivo, MORAb-009 demonstrated only modest anti-tumor activity against
MSLN tumor xenografts, which was markedly increased when used in combination with
chemotherapeutic agents.

The safety and tolerability profile of MORAb-009 was

determined in a Phase I trial [102] before initiation of Phase 2 trials with mesothelioma
(NCT00738582) [103] and pancreatic cancer (NCT00570713) [104] patients.
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Because chimeric antibodies have limited use due to the increased likelihood of
immunogenicity, fully human antibodies, m912 and HN1, were developed [105,106]. Both
antibodies bind MSLN with high affinity and specificity while conferring cell death by
ADCC, and are capable of preventing MSLN binding to MUC16.

1.2.4.2 Recombinant Immunotoxin (SS1P)
Recombinant immunotoxins (RIT) are proteins composed of a tumor-targeting
antibody domain fused to a bacterial toxin [107,108]. Pseudomonas exotoxin A, derived
from Pseudomonas aeruginosa, inhibits protein synthesis and induces cell death via
apoptosis. The engineered antibody domain specifically targets the immunotoxin to tumor
cells, and once internalized, the molecule is degraded and the toxin is released [107].
SS1P is a 63-kDa RIT targeted against MSLN-expressing tumors. When tested in
a Phase 1 clinical trial (NCT00006981), which included patients with advanced MSLNexpressing malignancies (mesothelioma, ovarian, pancreatic, lung), SS1P demonstrated a
favorable safety profile. Unfortunately, efficacy of the single agent was significantly
limited because majority of patients developed neutralizing antibodies against the PE toxin
after just one round of therapy [109].

More recently, SS1P has been evaluated in

combination with a lymphocyte-depleting agent (NCT01362790), and patients with
chemotherapy refractory mesothelioma were shown to develop major responses and
required no subsequent therapy for more than 20 months [110].
To make the RIT less immunogenic and prevent the development of neutralizing
antibodies, a variety of mutations were introduced into the toxin to remove all human Bcell epitopes. RG7787 was developed incorporating this new generation toxin, and was
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shown to have similar stability and in vitro activity, while reacting less with human antisera [111]. RG7787 has been clinically tested in a variety of MSLN-expressing cancers
including triple negative breast, [112], pancreatic [113], lung [114], and ovarian [115].

1.2.4.3 Therapeutic cancer vaccine (LRS-207)
The presence of MSLN-specific antibodies in a significant number of patients with
MSLN-expressing cancers supports the development of a therapeutic cancer vaccine.
Unlike prophylactic vaccines which are administered to prevent the onset of a disease,
therapeutic vaccines are designed to strengthen a patient’s immune response to eradicate
existing cancer cells [116]. CRS-207 is a bacterium-based vaccine developed using a live,
attenuated Listeria monocytogenes strain engineered to express MSLN [117,118].
Preclinical studies demonstrated the ability of CRS-207 to stimulate the innate immune
system and induce MSLN-specific cellular responses in mice and cynomolgus monkeys,
and exhibited therapeutic efficacy in tumor-bearing mice [118]. While vaccination with
CRS-207 extended the survival of pancreatic cancer patients with minimal toxicity in a
Phase 2a clinical trial (NCT01417000) [119], a following Phase 2b trial (NCT02004262)
did not meet the primary endpoint of improvement in overall survival for patients with
metastatic pancreatic cancer who had received at least two prior treatments [120].

1.2.4.4 Antibody-Drug Conjugate (BAY-94-9343)
An antibody-drug conjugate (ADC) is comprised of a targeting antibody, a stable
linker with labile bonds, and a cytotoxic payload [121]. Upon antigen recognition and
binding, the ADC is internalized and trafficked through endosomal vesicles to the lysosome
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[122]. The low pH of the lysosome triggers degradation of the antibody and hydrolysis of
the linker, thereby releasing the drug [123].

Anetumab Ravtasine (BAY 94-9343)

[124,125] incorporates a human anti-MSLN antibody conjugated to DM4, a tubulin
polymerase inhibitor, via a disulfide-containing linker. In vitro studies demonstrated
specific cytotoxicity of MSLN-expressing cells (IC50 = 0.72 nM), while in vivo studies
confirmed MSLN-positive tumor growth-inhibition in mice xenograft models.
Additionally, BAY 94-9343 was shown to induce bystander-killing effect on neighboring
MSLN-negative cancer cells without affecting non-proliferating cells, a benefit ideal for
heterogeneous antigen-expressing tumors or when ADC penetration into solid tumor is
limited [124].

Clinical trials involving patients with a variety of cancers including

pancreatic [126], ovarian [127], mesothelioma [128], and NSCLC [129] are ongoing.

1.2.4.5 CAR-T Cell
Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapeutic approach
which involves genetically modifying a patient’s T cells to express a tumor-specific CAR
and promote T-cell function and persistence [74]. Because of its high expression on tumors
and low expression on normal tissues, MSLN has a favorable safety profile and represents
an ideal cancer antigen for targeted immunotherapy, and has been targeted by a variety of
CAR-T cells [130–133]. Thus far, Phase I clinical trials have been completed to evaluate
the safety and efficacy of CAR-T cells in patients with mesothelioma (NCT01355965),
pancreatic cancer (NCT01897415), and ovarian cancer (NCT02159716). Patients with
chemotherapy-refractory pancreatic cancer experienced no dose-limiting toxicities and
some disease stabilization with increased progression-free survival was observed [134].
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1.3 Overview of protein engineering
As life has evolved, the molecular basis of living organisms, including proteins, has
also undergone distinct diversification. As a result of that diversification, there is a vast
number of different protein molecules in nature, each with unique structural and functional
properties (Table 1.1) [135]. Once we understand how these molecules are structured and
operate within nature, they can be further developed or engineered for novel applications
in research, medicine, and biotechnology.

1.3.1 Engineering proteins by directed evolution
Directed evolution is a valuable technology for engineering proteins with improved
or novel characteristics [136]. Directed evolution recapitulates the selection and
accumulation of desirable mutations that occurs through natural selection over millions of
years and compresses it into a few weeks or months in the laboratory. In order to explore
such vast protein sequence space, large protein diversities must be generated, followed by
identification and selection of variants with improved or new phenotypes (Figure 1.16)
[137]. Frequently used methods for the generation of these diverse libraries include genetic
recombination, site-directed mutagenesis and random mutagenesis [138]. Random
mutagenesis by error-prone PCR (epPCR) involves using an error-prone, thermostable
polymerase lacking proofreading ability (Taq polymerase) in combination with unnatural
nucleotide analogs capable of pairing with multiple canonical nucleotides [139]. Selection
of mutant proteins of interest is typically carried out in phage, bacteria, or yeast to allow
for high transformation efficiency, single-cell cloning and rapid molecular manipulation
[140–142].
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1.3.2 Yeast surface display platform for protein engineering
Since its initial development [141], yeast surface display (YSD) has been used to
engineer proteins for enhanced binding affinity, improved specificity, proper folding, and
stability for a wide range of proteins [143]. Proteins that have been engineered using YSD
include, but are not limited to, single-chain variable fragments (scFvs) [144], Fab antibody
fragments [145], single-chain T-cell receptors [146], cytokines [147], epidermal growth
factor receptor (EGFR) domains [148] and fibronectin type III (FN3) domains [149,150].
Within the YSD platform (Figure 1.17), the protein to be engineered is expressed
as a genetic fusion to the Aga2p mating agglutinin protein. Aga2p is linked to the Aga1p
protein by two disulfide bonds, which is covalently linked to the yeast cell wall. The
protein of interest is flanked by an N-terminal hemagglutinin (HA) and C-terminal c-myc
epitope tags, which are used for both expression confirmation of the construct on the yeast
cell surface and to quantitate expression levels [151].
The YSD platform requires two main components: the yeast, EBY100 [141], and
the plasmid, pCT. EBY100 lacks the machinery necessary to synthesize the amino acid
tryptophan and contains the Aga1 gene at high copy number in its genome. The pCT
plasmid encodes (1) the TRP1 gene, which is needed for tryptophan synthesis, (2) the
Aga2p protein fused to the protein of interest, and (3) ampicillin resistance, for plasmid
production in E. coli [152]. When properly transformed with the pCT plasmid, yeast will
grow in selective media deficient in tryptophan, whereas untransformed EBY100 will not.
To induce proper display of the protein of interest, the yeast must be switched from a
glucose-rich medium, to a galactose-rich medium. Each yeast cell is capable of expressing
about 50,000 copies of a single protein variant on its surface [141]. Combinatorial libraries
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ranging from 107 - 108 transformants are routinely created by homologous recombination,
and high-throughput screening of yeast-displayed variants allows for the rapid isolation of
proteins with desired properties.
The YSD platform offers unique advantages over other display technologies, such
as phage display or mRNA display. First, the presence of the yeast endoplasmic reticulum
provides a quality control mechanism so that only properly folded proteins are displayed
on the cell surface. The use of eukaryotic expression machinery makes YSD specifically
useful for displaying and engineering proteins that are difficult to produce in other formats
[152]. The yeast platform is also capable of incorporating post-translational modifications
such as glycosylation and disulfide bond formation [153]. Secondly, YSD successfully
incorporates the use of traditional panning methods, including magnetic particle separation.
A final and chief benefit of YSD is the ability to use dual color fluorescent-activated cell
sorting (FACS) for quantitative discrimination between protein variants [154]. Because
FACS simultaneously provides analysis data, it eliminates the need for separate expression
and analysis steps after each round of sorting, and equilibrium binding constants and
dissociation rate constants measured by YSD are in quantitative agreement with those
measured in vitro [155]. Plasmid DNA can be recovered from individual yeast clones,
providing a link between a protein variant and its DNA sequence which allows amino acid
mutations to be identified following library screening.

1.3.3 Screening yeast-displayed libraries
Protein engineering is heavily dependent on the ability to selectively capture the
members of the protein library with the desired properties. Different methodologies exist
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for different display systems to ensure recovery of favorable mutants. Magnetic-activated
cell sorting (MACS) is a simple and convenient method for screening yeast-displayed
libraries before using more quantitative sorting methods. MACS efficiently reduces cell
number and library diversity (expected number of unique sequences in the library) while
enriching the library for binders to the target of interest in a few rounds of sorting [156].
Traditionally, bare streptavidin-coated magnetic beads are first used to deplete the library
of yeast cells that non-specifically bind biotin, and then the beads are incubated with a
biotinylated target of interest to capture yeast cells displaying clones that bind the target
antigen. An important limitation of MACS is the high likelihood of binding clone loss,
which should be compensated for by oversampling of library diversity. In addition to
oversampling, clonal loss can be minimized through optimization of parameters such as
density of cell suspension, incubation times and the absence of a magnetic field during
wash steps [157].
FACS is a type of flow cytometry in which cells are sorted, one cell at a time, based
on the specific light scattering and fluorescent characteristics of each cell [138]. Measuring
yeast surface display levels by labeling of either the N- or C-terminal epitope tags allows
for improved stability, since yeast cell surface expression is correlated with thermal
stability and expression levels [146]. Moreover, dual color FACS is used for library
screening, where one fluorescent label is used to detect the c-myc epitope tag to verify fulllength expression, and a second fluorescent label is used to measure the interaction of the
engineered protein against the binding target of interest (Figure 1.18). This allows yeast
expression levels to be normalized with binding affinity so that a yeast cell displaying a
protein variant with poor expression but high binding affinity can be distinguished from a
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yeast cell displaying a protein variant with high expression levels but weak binding affinity.
Therefore, a two-dimensional flow cytometry plot of expression versus binding results in
a diagonal population of yeast cells that bind the target of interest. Finally, once library
screening is complete, titration experiments to determine binding affinity and thermal
stability can be performed while proteins are still displayed on the yeast surface,
eliminating the need to solubly express and purify individual clones [144]. Initial sorting
of large yeast-displayed libraries is limited with FACS due to technical considerations of
the flow cytometer, which typically sort at 107 to 108 cells per hour [144]. Because it is
important to oversample the library diversity to ensure binding clone selection, library size
must usually be reduced by other sorting methods before screening with FACS.

1.4 Overview of the fibronectin scaffold

1.4.1 Rationale for a non-antibody approach
Growing understanding of the molecular events responsible for the initiation and
progression of diseases has enhanced the opportunities to develop novel agents that can
improve the sensitivity and specificity of diagnosis and treatment. For over a century,
mAbs have, almost exclusively, acted as the natural biomolecular scaffold for basic science
and biomedical applications. Due to their high affinity and exquisite specificity, low
immunogenicity (when of mostly human origin), optimal pharmacokinetics, and low
toxicity profiles due to limited off-target effects, mAbs have contributed to many clinical
successes [158]. Within the past five years, mAbs have become the best-selling drugs in
the pharmaceutical market, and are projected to generate $150 billion in revenue by 2025
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[158]. As of December 2019, over 79 therapeutic mAbs have been approved by the US
FDA, including 30 mAbs for the treatment of cancer (Table 1.2) [159].
As research, biotechnology and medical uses have expanded, however, the
fundamental disadvantages of antibodies for certain applications have become more
apparent.

Antibodies are large (150 kDa) molecules composed of two different

polypeptides (light and heavy chain), critical disulfide bonds, and functionally important
post-translational modifications, including glycosylation (Figure 1.19).

This defined

structure necessitates complex cloning steps and expensive recombinant production in
mammalian cells, and can complicate additional manipulation such as for bispecific
formats, conjugates, or immunotoxins [160].

Further, when considering in vitro

diagnostics, highly stable engineered proteins may be superior to antibodies, which can be
susceptible to aggregation or unfolding without proper handling, such as refrigeration
throughout production and distribution.
The therapeutic effects exerted by mAbs are executed by a variety of mechanisms
(Table 1.3) [161], but are almost exclusively limited to cells bound by antibody (exceptions
include bystander effects, as reviewed in [162]). Therefore, every cell in the target tissue
(i.e. a tumor), must be targeted to achieve a complete therapeutic response [163].
Heterogeneous distribution and/or penetration of mAbs can leave subpopulations of cells
untargeted, significantly reducing the therapeutic efficacy of the mAbs.

Efficient

penetration and homogeneous distribution can be especially difficult in solid tumors
because of their abnormal vasculature, high interstitial fluid pressure, and high viscosity of
the tumor blood supply [164]. The large size of mAbs limits their permeability and
diffusion, thereby limiting their physiological distribution [161,163,165–168].
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Antibodies also demonstrate limited effectiveness as molecular imaging agents. A
molecular imaging agent must provide high target to background ratios, meaning it
accumulates in target tissues while quickly clearing from non-target tissues [169].
Unfortunately, because of their large size, antibodies surpass the renal clearance threshold
(70 kDa), increasing their retention time in circulation [160,167]. Antibodies also have a
prolonged circulation time due to capture and recycling by neonatal Fc binding receptors
[166]. Because of this slow clearance, tumors can only be visualized several days after the
mAb injection, and patients can be burdened with significant travel and expenses to
accommodate the protocol.
Based on such limitations, there has been great interest in developing alternative
protein scaffolds that can be engineered for a variety of functions [170]. These alternative
scaffolds, including affibodies [171,172], Designed Ankyrin Repeats (“DARPins”)
[173,174], fibronectins (“Adnectin” and “monobody”) [175,176], knottins [151,177], and
lipocalins (“Anticalins”) [178] incorporate diverse binding paratopes and conserved
structural framework in generally small, disulfide-free, stable, single domains capable of
evolution (Table 1.4) [160,170,179].

1.4.2 The fibronectin scaffold for protein engineering
Fibronectins are a family of large glycoproteins with important roles in ECM
formation and regulation of cellular processes, including adhesion, migration,
differentiation, and proliferation, through interactions with integrins and non-integrin cell
surface proteins [180]. Fibronectins consists of many repeats of three types of small
modules, arranged into several functional and protein-binding domains (Figure 1.20) [180].
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The protein scaffold based on the tenth domain of fibronectin type III (10Fn3, Fn3)
(also known as a monobody or Adnectin) was first described in 1998 [181]. Since then,
Fn3 has become one of the most widely used non-antibody scaffold for engineering novel
binding proteins [175,182]. The Fn3 domain is a small (94 amino acids, ~ 10 kDa),
monomeric protein consisting of two β-sheets of seven β-strands, all connected by three
solvent-exposed loops: BC, DE, and FG. While the Fn3 scaffold lacks sequence homology
with antibodies, its hydrophobic, β-sandwich structure closely resembles that of
immunoglobulin (Ig) domains, providing a stable framework structure and high
thermostability (Tm = 88°C) [183], and its solvent-exposed loops are structurally
analogous to the Ig’s complementarity-determining regions (CDRs) (Figure 1.21)
[184,185]. The Fn3 scaffold also contains neither disulfide bonds nor post-translational
modifications, which allow it to preserve its stability under reducing conditions [149].
Moreover, the Fn3s can be expressed at high levels in E. coli (50 mg/L) [186], facilitating
inexpensive production.

1.4.3 Fn3 proteins as molecular imaging agents
The small size and high stability of fibronectin proteins have translated into optimal
pharmacokinetic and biodistribution properties for molecular imaging applications, namely
high tumor uptake and rapid clearance from non-target tissues. Fn3 proteins can be evolved
to bind a variety of cancer biomarkers, the absence of native cysteine or disulfide bonds
facilitates easy functionalization, and they are amenable to same-day imaging protocols
[160,179].
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Fn3 proteins engineered to bind several tumor receptors have shown promise as
diagnostic molecular imaging agents [160,169,179]. An anti-CD20 molecule engineered
for PET imaging of B-cell lymphomas has been evaluated in human CD20 tumor-bearing
mice [187]. Within 4 h following injection, the Fn3 molecules demonstrated high and
specific accumulation in tumors with low uptake in healthy tissue. More recently, an antiPD-L1 Fn3 molecule was developed and evaluated for PET-CT imaging in human patients
with lung cancer [188]. The tracer was shown to be safe and its biodistribution was well
correlated with PD-L1 expression. Engineered Fn3 molecules have also been used to target
microbubbles and image VEGFR on tumor neovasculature with ultrasound [189]

1.5 Significance and specific aims
While the availability of targeted cancer diagnostics and therapeutics has increased
in recent years, there are patients who do not currently have effective targeted therapeutic
options. As novel tumor biomarkers continue to be identified, it is essential to translate
their discovery into improved clinical outcomes. MSLN is a cell surface protein that is
overexpressed in several cancers with limited expression in healthy tissue. Increased
MSLN expression promotes tumor progression, motility, invasion and metastasis in these
cancers. The collective data emphasize the importance of MSLN in cancer progression
and the need for MSLN-targeting agents, but no targeted diagnostics or therapeutics are
currently FDA-approved. Addressing this unmet need would have a significant impact and
on the lives of patients with MSLN-expressing tumors.
This dissertation describes work to engineer stable MSLN targeting agents using
the fibronectin non-antibody protein scaffold for use as targeted therapeutics, for targeted
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drug delivery applications, and as molecular imaging diagnostics. To achieve the overall
objective proposed, the following four specific aims were pursued:

Specific Aim 1: Engineer mesothelin-binding Fn3 proteins as tumor targeting agents.
Directed evolution and yeast surface display were used to engineer high affinity (singledigit nanomolar dissociation constant) MSLN-binding proteins based on the fibronectin
protein scaffold (Figure 1.22). We established methods to express and purify soluble
engineered proteins for further characterization and applications.

Specific Aim 2: Evaluate the therapeutic effects of anti-mesothelin Fn3 proteins.
Downstream signaling attributed to MSLN expression promotes tumor growth, invasion,
and metastasis. In vitro cell proliferation, apoptosis, and caspase-activation assays were
used to assess the potential of our proteins as targeted cancer therapeutics for MSLNexpressing tumors. Engineered Fn3 proteins were assessed in combination with
chemotherapeutic mitomycin C (MMC) to evaluate whether the engineered proteins further
sensitized cancer cells to chemotherapy.

Specific Aim 3: Develop protein-polymer conjugates for targeted drug delivery
strategies. Model protein-polymer conjugates were synthesized using a novel proteinpolymer conjugate system, towards enabling cytotoxic drugs incorporated into the polymer
to be selectively delivered to MSLN expressing tumor cells.
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Specific Aim 4: Assess diagnostic potential of Fn3 proteins as molecular imaging
agents. Targeted therapies are only as successful as the ability to identify the appropriate
patient populations to receive such therapies. Mouse xenograft models were established
and validated to evaluate the potential of the anti-MSLN proteins as molecular diagnostic
agents.

This work will further validate the Fn3 scaffold and provide the foundation for
development of other targeted diagnostic/therapeutic molecules and protein-polymer
conjugates for targeted drug delivery strategies.
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1.7 Tables
Table 1.1 Classifications of proteins and their functions [190].
Function
Catalysis

Class of protein
Enzymes

Defense

Immunoglobulins
Toxins
Cell surface antigens
Transport Circulating Transporters

Membrane Transporters
Support

Fibers

Examples
Hydrolytic enzymes
Proteases
Polymerases
Kinases
Antibodies
Cytokines
MHC proteins
Hemoglobin
Myoglobin
Cytochromes

Examples of use
Cleave macromolecules
Break down proteins
Produce nucleic acids
Phosphorylation
Neutralize foreign pathogens
Immune signaling molecules
“Self” recognition
Carry O2 and CO2 in blood
Carry O2 and CO2 in muscle
Electron transport

Na-K pump
Proton pump
Glucose transporters
Collagen
Keratin
Fibrin

Excitable membranes
Chemiosmosis
Transport sugar into cells
Forms cartilage
Forms hair and nails
Forms blood clots
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Table 1.2 Examples of U.S FDA-approved monoclonal antibodies on the market [158].
mAb
Adalimumab

Brand Name
Humira

Target
TNFa

Bevacizumab
Brentuximab
vedotin
Cetuximab
Denosumab
Dupilumab
Emicizumab
Erenumab

Avastin
Adcentris

VEGF-A
CD30

Erbitux
Xgeva, Prolia
Dupixent
Hemlibra
Aimovig

EGFR
RANKL
IL-4Ra
Factor IXa, X
CGRPR

Guselkumab
Omalizumab
Pembrolizumab
Risankizumab
Rituximab

Tremfya
Xolair
Keytruda
Skyrizi
MabThera, Rituxan

IL-23 p19
IgE
PD-1
IL23 p19
CD20

Secukinumab
Trastuzumab
Trastuzumab
emtansine
Ustekinumab
Vedolizumab

Cosentryx
Herceptin
Kadcyla

IL-17a
HER2
HER2

Stelara
Entyvio

IL-12/23
a4b7 integrin

30

Indication
Rheumatoid
arthritis
Colorectal cancer
Hodgkin lymphoma
Colorectal cancer
Bone loss
Atopic dermatitis
Hemophilia A
Migraine
prevention
Plaque psoriasis
Asthma
Melanoma
Plaque psoriasis
Non-Hodgkin
lymphoma
Psoriasis
Breast cancer
Breast cancer
Psoriasis
Ulcerative colitis,
Crohn’s disease

Table 1.3 Mechanisms of action of antitumor mAbs [161].
Class
Direct induction of cell death:
Activation of a death program as
direct consequence of antibody
binding

Inhibition of tumor-promoting
growth or survival signals:
Quiescence, autophagy or indirect
cell death due to deprivation of
growth of survival signals
Recruitment of FcgR-positive
immune cells:
Immune cells expressing FcgRs can
mediate ADCC or phagocytosis
Complement activation:
Complement activation may have
negative effects: infusion toxicity,
inhibition of ADCC, tumor growthpromoting effects
Promotion of an adaptive antitumor immune response

Subclass
mAbs inducing non-apoptotic cell death:
Induction of death mediated by lysosome
membrane permeabilization and production of
ROS
Anti-TRAIL/DR mAbs:
Induction of apoptotic cell death with FcgRpositive immune cells promoting mAbmediated clustering of the TRAIL-R to drive
apoptotic signaling
Neutralization of tumor-promoting ligands:
Anti-angiogenic growth factors
Binding to cell surface receptors of coreceptors:
Example: Lack of activity of anti-EGFR mAbs
in the presence of activating KRAS mutations

Inhibition of immune suppressive pathways:
Limited number of patients (typically 10-15%)
respond. Many responders have immunerelated (“autoimmune-like”) adverse effects
Direct promotion of active antitumor
immunization:
Induction of active anti-tumor immunity plays a
still ill-defined role in the overall efficacy of
these mAbs
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Table 1.4 Examples of non-antibody based alternative protein scaffolds [160].
Scaffold

Origin

Size

Topology

Affibody

Z domain from S.
aureus Protein A

6 kDa

3 helix
bundle

PDB Structure

PDB 2M5A

DARPin

Diverse organisms:
mediates proteinprotein interactions

b turns
connecting
14 kDa
a-helical
repeats
PDB 5OOS

Fibronectin

Human ECM protein
domain

10 kDa

Ig-like b
sandwich
PDB 1TTG

Knottin

EETI (squash seeds)
AgTx (spider toxin)
Cone snail

3 kDa

Knotted
3-disulfide
core
PDB 2ETI

Lipocalin

Diverse organisms:
storage and transport
of compounds like
vitamins and steroids

20 kDa

b-barrel
PDB 1LNM
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1.8 Figures

Figure 1.1 The ten leading cancer types for the estimated new cancer cases and deaths
by sex in the US in 2020. Cancer is a global health concern and the second leading cause
of death in the US. Prostate, lung and colorectal cancers account for 43% of all cases
diagnosed in men, with prostate cancer representing more than one in five new diagnoses.
The three most common cancers in women are breast, lung, and colorectal, with breast
cancer accounting for 30% of female cancers. Estimates are rounded to the nearest 10.
Ranking is based on modeled projections and may differ from the most recent observed
data [4].
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Figure 1.2 Mechanisms of traditional chemotherapeutics. Chemotherapeutics target
rapidly dividing cells by disrupting their cell cycle. Antimetabolites block the formation
and/or use of nucleic acids needed for DNA replication, while alkylating agents interfere
with proper DNA base pairing. Topoisomerase inhibitors prevent DNA uncoiling and
taxanes or vinca alkaloids inhibit microtubules required for mitosis. Adapted from [6].
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Figure 1.3 Traditional chemotherapy is toxic and ineffective. Chemotherapeutic drugs
act on rapidly dividing cells, which include normal tissues (hair, gastrointestinal
epithelium, bone marrow) in addition to cancer cells. This leads to many of the side effects
associated with chemotherapy, such as hair loss, gastrointestinal distress, and bone marrow
suppression. Development of chemoresistance is also a persistent problem during the
treatment of local and disseminated disease. Chemotherapy resistance may be a result of
an acquired mutation due to continuous drug exposure, or it may be an inherent mutation
in a subpopulation of cancer cells.
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Figure 1.4 The hallmarks of cancer that promote tumorigenesis. Most cancers acquire
a set of functional capabilities during their development. The manifestations of these
essential alterations in cell physiology collectively dictate malignant growth. (1)
Sustaining proliferative signaling: cancer cells can stimulate their own growth; (2) invasion
and metastasis: cancer cells can invade local tissue and spread to distant sites; (3) Evading
growth suppressors: cancer cells can resist inhibitory signals that would otherwise stop
their growth; (4) evading immune detection; (5) enable replicative immortality: cancer cells
can divide indefinitely; (6) tumor-promoting inflammation; (7) induce angiogenesis:
cancer cells stimulate the growth of blood vessels to acquire nutrients; (8) genomic
instability: cancer cells generate random mutations, and therefore, genetic diversity that
can expedite acquisition of hallmarks; (9) Resisting apoptosis: cancer cells evade
programmed cell death; (10) reprogramming energy metabolism: cancer cells can
reprogram their glucose metabolism, and therefore their energy production, to better fuel
their growth and division [14].
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Figure 1.5 Targeted therapeutics act on molecules or molecular pathways necessary
for tumor growth and maintenance. (A) Growth factor receptors, including ER and
HER2 and (B) angiogenic proteins, such as VEGFR, are heavily explored drug targets.
New targeted therapies include (C) checkpoint inhibitors, including PD-1/PD/L1 and
epigenetic modulation. ER, estrogen receptor; HER2, human epidermal growth factor
receptor; VEGFR, vascular endothelial growth factor receptor; PD-1, programmed cell
death protein 1; PD-L1, programmed death ligand 1. Adapted from [8].
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Figure 1.6 Protein-polymer conjugates as targeted drug delivery vehicles. A
successfully designed drug delivery complex requires a targeting molecule that binds the
cancer antigen specifically expressed on the surface of cancer cells, a therapeutic entity
such as loaded drug molecules, and some approach to link the targeting molecule to the
therapeutic entity, such as a functionalized polymer.

38

Figure 1.7 Companion diagnostics are critical components of developing targeted
therapies. Patient populations must be stratified to identify those most likely to benefit,
those who will experience little to no benefit, or those who may experience adverse effects
from a particular therapy. Companion diagnostics, which can include sequencing, cellbased assays, molecular imaging, and immunological assays, can help deliver the right
drug to the right patient [191].
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Figure 1.8 18F-fluorodeoxyglucose (18F-FDG) mechanism of localization is by
metabolic trapping. 18F-FDG, a glucose analog, is taken up by cells with high rates of
glycolysis, such as cancer cells. Phosphorylation of FDG by hexokinase prevents its
entrance into glycolysis and remains trapped inside the cell. The 2-hydoxyl group in normal
glucose is required for further glycolysis, but is missing in 18F-FDG which cannot be
further metabolized in cells.
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Figure 1.9 PET/CT scans pinpoint the anatomic location of abnormal metabolism.
Physiological information obtained by PET, which depicts spatial distribution of metabolic
activity, can be precisely correlated with anatomical information obtained by CT. (Left)
Coronal CT image demonstrating organs and bones. (Middle) Coronal PET image
exhibiting metabolic hyperactivity of mediastinal lymph nodes. Normal biodistribution of
tracer includes brain, heart, and kidneys. (Right) Coronal PET/CT fused image, showing
exact location of abnormal cell activity [192].
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Figure 1.10 Frequency and distribution pattern of mesothelin in solid malignancies.
MSLN is expressed in many solid tumors. For most cancers, MSLN expression is
homogeneously distributed on the cell surface. For stomach and lung cancers, MSLN is
also frequently expressed in the cytoplasm in addition to the cell surface [74].
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Figure 1.11 Schematic of mesothelin protein maturation. MSLN precursor protein is
synthesized as a 71-kDa polypeptide. The precursor protein has four predicted
glycosylation sites, a glycosylphosphatidylinositol (GPI) anchor, and a furin cleavage site.
Cleavage at this site produces membrane-bound MSLN (purple) and secretory
megakaryocyte potentiating factor (MPF) (green) [193].
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Figure 1.12 Model for cancer cell implantation and metastasis through MSLNMUC16 interaction. MSLN, expressed at low levels on mesothelial cells and high levels
on tumor cells, binds to tumor biomarker MUC16 on tumor cells. MSLN-MUC16
interaction mediates homotypic and heterotypic cell adhesion to promote tumor
progression and metastasis. This interaction is prominent in ovarian cancer metastasis in
which ovarian cancer cells are uniquely shed from the primary tumor and disseminate
throughout the peritoneal cavity which is lined by mesothelial cells.
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Figure 1.13 Molecular role of mesothelin in cancer progression. Overexpression of
MSLN allows for cancer cell proliferation via NF-κB activation, while aiding in cancer
cell survival by promoting the expression of anti-apoptotic factors and inhibiting the
production of pro-apoptotic factors [194].
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Figure 1.14 MSLN regulates EMT and cancer stem cell characteristics. MSLN
depletion upregulates adhesion molecules such as E-cadherin and caveolin, and
downregulates mesenchymal and cancer stem cell (CSC) genes that aid in self-renewal,
proliferation, and metastasis. MSLN depletion, therefore, promotes an epithelial-like
phenotype. In contrast, MSLN overexpression upregulates mesenchymal and stem cell
traits and stimulates anchorage-independent growth, migration, and invasion.

46

Figure 1.15 Mesothelin-targeted therapies currently in development. Several strategies
have been developed for targeting MSLN on tumors: 1) therapeutic cancer vaccine, 2)
recombinant immunotoxin, 3) monoclonal antibody, 4) antibody-drug conjugate, 5) CAR
T cell therapy. GM-CSF, granulocyte-macrophage colony-stimulating factor; GVAX,
irradiated allogenic cell line-secreting GM-CSF; ADCC, antibody-dependent cell
cytotoxicity [74].
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Figure 1.16 Directed evolution mimics natural selection to evolve proteins for novel
applications. A diverse library of genes is translated into a corresponding library of gene
products. This library is subjected to iterative rounds of high throughput screening and
selection (isolating variants with improved or desired properties), replication, and
diversification (generation of diverse sequence library) [137].
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Figure 1.17 Schematic of the yeast surface display platform. (A) Open reading frame
of the YSD genetic construct. Relevant restriction enzymes are indicated in italics. (G4S)3
= (Gly4Ser)3 linker. (B) The protein to be engineered (Displayed Protein) is a C-terminal
fusion to the Aga2p protein and flanked by two epitope tags: an N-terminal hemagglutinin
(HA) and a C-terminal c-myc. The Aga2p protein forms two disulfide bonds with the
Aga1p protein, which is covalently anchored to the yeast cell wall. Binding to target protein
can be measured against a fluorescently labeled target antigen. Reproduced with
permission from [151].

49

Figure 1.18 FACS separates a population of cells into sub-populations based on
fluorescent labeling. Cells are labeled with fluorescent antibodies and laser light excites
the dye which emits a different wavelength of light that is detected by the light detector.
Information collected from the light (scatter and fluorescence) determines which cells are
to be separated and collected, and an electrical charge is applied to the cells. The charged
cell is deflected left or right by oppositely charged electrodes into sample collection tubes
or waste [195].
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Figure 1.19 The structure of a typical antibody molecule. Antibodies are roughly Yshaped molecules constructed from paired heavy and light polypeptide chains. The two
heavy chains are linked to each other by disulfides bonds at the hinge region, and each
heavy chain is linked to a light chain by a disulfide bond. The antigen-binding sites are
located at the tips of each arm. The amino acid sequence of the variable region, located at
the amino termini of the heavy and light chains, determines the antigenic specificity of the
antibody. Antibodies incorporate glycosylation sites on the Fc region.
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Figure 1.20 The modular structure of fibronectin and its binding domains. Fibronectin
(FN) is a glycoprotein of the extracellular matrix composed of repeating domains of three
types of protein modules (I, II, III). FN binds membrane-spanning receptor proteins called
integrins and extracellular components such as heparin, fibrin, syndecan, and collagen.
Between type I and type III repeats there is another alternately spliced domain termed
variable region (V). SS indicates C-terminal cysteines. Adapted from [196].
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Figure 1.21 Comparison of the topology and structures of an immunoglobulin (a, c)
and the fibronectin scaffold (Fn3) (b, d). The natural physiological function of Fn3,
integrin binding, is mediated by an RGD tripeptide sequence in the FG loop, and loss of
this sequence by mutagenesis or library diversification permits production an inert, nontoxic and non-immunogenic carrier of engineered, target-binding loops [149].
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Figure 1.22 Specific aim 1 design. A naïve yeast surface displayed fibronectin library was
engineered and matured using directed evolution to isolate Fn3 variant that bind tumor
biomarker MSLN for use as targeted therapeutics, drug delivery vehicles and molecular
imaging diagnostics.
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CHAPTER 2
FN3 PROTEINS ENGINEERED TO RECOGNIZE TUMOR BIOMARKER
MESOTHELIN INTERNALIZE UPON BINDING

as written by Sirois A.R., Deny, D.A., Baierl, S.R., George, K.S., and Moore, S.J.,
PLoS One 2018

2.1 Abstract
Mesothelin is a cell surface protein that is overexpressed in numerous cancers,
including breast, ovarian, lung, liver, and pancreatic tumors. Aberrant expression of
mesothelin has been shown to promote tumor progression and metastasis through
interaction with established tumor biomarker CA125.

Therefore, molecules that

specifically bind to mesothelin have potential therapeutic and diagnostic applications.
However, no mesothelin-targeting molecules are currently approved for routine clinical
use. While antibodies that target mesothelin are in development, some clinical applications
may require a targeting molecule with an alternative protein fold. For example, nonantibody proteins are more suitable for molecular imaging and may facilitate diverse
chemical conjugation strategies to create drug delivery complexes. In this work, we
engineered variants of the fibronectin type III domain (Fn3) non-antibody protein scaffold
to bind to mesothelin with high affinity, using directed evolution and yeast surface display.
Lead engineered Fn3 variants were solubly produced and purified from bacterial culture at
high yield. Upon specific binding to mesothelin on human cancer cell lines, the engineered
Fn3 proteins internalized and co-localized to early endosomes. To our knowledge, this is
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the first report of non-antibody proteins engineered to bind mesothelin. The results validate
that non-antibody proteins can be engineered to bind to tumor biomarker mesothelin, and
encourage the continued development of engineered variants for applications such as
targeted diagnostics and therapeutics.

2.2 Introduction
In recent years, the focus in cancer drug development has shifted from relatively
non-specific cytotoxic agents, to selective, rationally designed, and mechanism-based
therapies [1].

Targeted cancer compounds, which are designed to inhibit specific

molecular targets or molecular pathways critical for tumor growth and maintenance, are
associated with greater efficacy and fewer side effects compared to traditional
chemotherapies [2]. Currently, over 75 targeted therapies are approved for clinical use as
essential treatments for a variety of malignancies [3,4]. For many cancers, however,
targeted therapeutics are not yet available, and it is imperative to develop targeted therapies
for patients who do not currently have this treatment option. Furthermore, it has been
recognized that a targeted therapy is only effective when a patient’s tumor expresses the
molecular target; therefore, companion diagnostics, including molecular imaging agents,
are a critical component for developing targeted therapies [5].
Mesothelin (MSLN) is a cell surface protein shown to be overexpressed in many
ovarian [6–8], breast [8–10], pancreatic [11–14], liver [15], and lung [16–18] tumors,
among others [19], with limited expression in healthy tissues [20]. MSLN has been shown
to bind with established cell surface tumor marker MUC16, also known as CA125, leading
to increased tumor cell proliferation and metastasis [8,12,21]. Promising results from
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ongoing efforts in pre-clinical and clinical trials to target MSLN with antibody and
antibody derivatives for therapy demonstrate the promise of MSLN-targeting methods
[16,17,22]. However, no MSLN-targeting agents have thus far received approval from the
US Food and Drug Administration (FDA).
Directed evolution by yeast surface display (YSD) has been used extensively in
protein engineering to improve the molecular recognition, biophysical, and catalytic
properties of target proteins [23–25]. Directed evolution relies on the generation of mutant
libraries followed by identification of mutants with improvements in a desired phenotype
by high-throughput screening and selection. The YSD platform offers unique advantages
over other directed evolution display formats, including the ability to incorporate posttranslational modifications such as glycosylation and disulfide bonds, eukaryotic protein
quality control processes, and compatibility with fluorescent-activated cell sorting (FACS)
for quantitative discrimination between protein variants. YSD has been used for a wide
range of protein classes for a variety of applications, including affinity maturation [26,27],
improving thermal stability [28], selecting against cell-based targets [29–31], and epitope
mapping [32,33].
While antibodies are widely used for a variety of research and clinical indications,
non-antibody protein scaffolds are being developed for research, biotechnology, and
medical applications where the inherent properties of antibodies may be limiting. For
example, oncological molecular imaging allows clinicians to non-invasively obtain
information such as a tumor’s molecular behavior and a patient’s response to treatment
[34]. An optimal molecular imaging agent should efficiently localize to the tumor, while
rapidly clearing from non-target tissues and organs [35]. Unfortunately, because of their
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large size and long clearance half-life, antibodies tend to produce undesirable images with
high background signals and low contrast [36]. The complex structure of antibodies also
poses many challenges when developing chemical strategies for conjugating polymers or
drugs for drug delivery applications, such as in the development of antibody-drug
conjugates [37].
Efforts to engineer non-antibody, alternative protein scaffolds for molecular
recognition have led to binding affinities and specificities once thought to be unique to
antibodies [38–43]. Here, we report the engineering of MSLN-binding proteins based on
the non-antibody scaffold Fn3, derived from the tenth domain of human fibronectin type
III. The hydrophobic core of the immunoglobulin-like fold of Fn3 provides a stable
framework structure and high thermostability (Tm = 88° C), while the solvent exposed
loops of Fn3 are amenable to high diversification (Figure 2.1A) [44,45]. The Fn3 scaffold
has shown great versatility for its ability to be engineered to recognize a variety of targets
including ubiquitin [44], epidermal growth factor receptor (EGFR) [46], carcinoembryonic
antigen (CEA) [47], human Fc gamma receptors [46], and Abelson kinase Src homology 2
(Abl SH2) domain [48]. Further, engineered Fn3 variants have recently been used for
molecular imaging applications, demonstrating the potential of this scaffold as a molecular
diagnostic [49,50]. An Fn3 protein that is an antagonist of vascular endothelial growth
factor receptor 2 (VEGFR-2) has advanced to Phase II clinical trials, demonstrating the
protein scaffold’s promise as a targeted therapeutic [51,52].
While engineered Fn3 clones have high affinity for their targets, some engineered
variants have also exhibited oligomeric states or instability [53,54]. Hackel and colleagues
demonstrated that an Fn3 YSD library engineered using loop length diversity and recursive
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mutagenesis could yield highly stable variants that recognized a variety of targets with high
affinity [55].

Woldring et al. developed a second generation YSD Fn3 library by

incorporating amino acid distributions that recapitulated binding antigens found in nature,
which they termed the Gradient 2 (Gr2) library [56] (Figure 2.1B). The Gr2 library also
incorporated Fn3 framework mutations that increased variant hydrophilicity towards the
goal of more desirable in vivo biodistribution for molecular imaging applications [57].
Therefore, the Gr2 Fn3 library is as large in diversity as its parent library, and is designed
to be a higher quality protein library. The sequence space sampled is biased toward
sequences that are likely to be more successful for identifying high affinity binding variants
and for applications in molecular imaging.
Here, we report the engineering of Fn3 variants that bind with high affinity to the
MSLN tumor cell surface protein, beginning with the naïve fibronectin YSD Gr2 library.
The binding interaction of MSLN and MUC16 is facilitated by non-covalent interactions
between the many carbohydrate chains decorating the surface of MUC16 and a minimal
binding domain of approximately 64 amino acids on MSLN [58]. Therefore, there is no
known native polypeptide sequence that recognizes MSLN, necessitating the use of a naïve
protein library as an initial point for our studies. To our knowledge, this is the first nonantibody protein engineered to bind MSLN. The engineered Fn3 variants were expressed
and purified at high yields (~10 mg/L) using bacterial culture. Soluble Fn3 variants
demonstrated high-affinity binding to tumor cells positive for MSLN expression, and were
internalized into tumor cells upon binding.

The work described here validates the

engineered binding proteins for further development as targeted therapeutics and
companion molecular imaging agents (Figure 2.1C).
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2.3 Materials and Methods

2.3.1 Reagents and cell lines
PBSA buffer was composed of phosphate buffered saline (PBS) and 0.1% bovine
serum albumin (BSA). Escherichia coli (E. coli) XL1-Blue Supercompetent cells and E.
coli BL21(DE3) cells were purchased from Agilent Technologies and New England
Biolabs, respectively. The Gr2 YSD library (generously provided by B. Hackel, University
of Minnesota) was grown in selective SD-CAA media containing 20 g/L glucose, 6.7 g/L
yeast nitrogen base without amino acids, 5 g/L casamino acids, 7.4 g/L citric acid
monohydrate, 10.4 g/L sodium citrate, pH 4.5. SG-CAA media for yeast induction
contained 18 g/L galactose, 2 g/L dextrose, 6.7 g/L yeast nitrogen base without amino
acids, 5 g/L casamino acids, 5.4 g/L Na2HPO4, 8.6 g/L NaH2PO4×H2O, pH 6.0. A431/H9
cells (gift of M. Ho, National Cancer Institute, 2016) [59] were cultured in RPMI-1640
(Gibco) supplemented with 10% FBS, 1% penicillin-streptomycin and 700 µg/mL
Geneticin selective antibiotic (G418) (Thermo Fisher).

KB-3-1 cells (gift of M.

Gottesman, National Cancer Institute, 2016) [60], and MCF-7 cells (ATCC #HTB-22, gift
of S. Peyton, UMass Amherst, 2017) were cultured in DMEM (Gibco) supplemented with
10% FBS and 1% penicillin-streptomycin.

2.3.2 Maturation and evolution of mesothelin binders
The naïve Gr2 library (2.8 x 109 diversity), in which EBY100 yeast cells were
transformed with the pCT surface display vector encoding for Fn3 variants [56], was sorted
and affinity matured generally as previously described [61]. Briefly, the induced library
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was sorted twice by magnetic bead selection with depletion of non-specific binders using
Dynabeads Biotin Binder magnetic beads (Life Technologies). This step served as a
negative selection by depleting yeast that displayed Fn3 binders to bare beads or
streptavidin. The negative sort was followed by enrichment of specific binding variants by
magnetic beads functionalized with biotinylated Fc-tagged recombinant human MSLN
(Acro Biosystems #MSN-H826x). The magnetic sorts were followed by a fluorescentactivated cell sorting (FACS) selection for full-length clones using an antibody against the
C-terminal c-myc epitope tag (clone 9E10, Life Technologies, 1:50) and a goat anti-mouse
phycoerythrin (PE) conjugate (Sigma #P9670, 1:25). Full-length clones were induced and
incubated with a chicken anti-c-myc antibody (Gallus Immunotech #ACMYC, 1:330) and
the biotinylated Fc-tagged MSLN. To increase the sorting stringency, concentrations of
MSLN were decreased over sorting rounds from 300 nM in the first generation sorting to
10 nM by the fourth sort of the second generation library. Cells were washed and incubated
with a goat anti-chicken Alexa Fluor 647 (AF647) conjugate (Thermo Fisher #A-21449,
1:250) and either Alexa Fluor 488 (AF488)-conjugated streptavidin (Thermo Fisher
#S11223, 1:700) to detect the biotin molecules of the biotinylated Fc-tagged MSLN, or a
goat anti-human IgG Fc FITC conjugate (Thermo Fisher #A18830, 1:500) to detect the
human Fc domain of the biotinylated Fc-tagged MSLN. Alternating between the two
sorting detection methods served to minimize the likelihood of engineering Fn3 variants
that bound streptavidin. Cells were washed and double-positive yeast cells were collected
on a BD BioSciences FACSAria II. Four iterative rounds of enrichment were performed.
Plasmid DNA from the enriched library was recovered using a Zymoprep Yeast Plasmid
Miniprep II kit (Zymo Research) following manufacturer’s protocol, transformed into
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bacteria, and individual clones were sequenced by standard Sanger DNA sequencing
methods. Plasmid DNA was subsequently mutated by error-prone PCR of either the entire
Fn3 gene or the paratope loops using nucleotide analogues, 8-oxo-2’-deoxyguanosine-5’triphosphate (8-oxo-dGTP) (TriLink Biotechnologies) and 2’deoxy-p-nucleoside-5’triphosphate (dPTP) (TriLink Biotechnologies) [62]. All error prone PCR reactions were
conducted using primers previously reported [56]. Reaction components and cycling
conditions were identical to those previously described [61] with the following exceptions:
Standard Taq (Mg-free) Reaction Buffer (New England Biolabs) was substituted as the
reaction buffer and MgCl2 (New England Biolabs, 1.5mM) was added to each reaction. All
error prone PCR reactions were conducted as both 10 and 20 cycle reactions to vary the
extent of mutagenesis. Mutated plasmid DNA was then amplified and reintroduced into
yeast by electroporation with homologous recombination [61].

2.3.3 Binding affinity measurements of yeast surface displayed variants
Plasmids for Fn3 variants 1.4.1 and 2.4.1, as well as wild type Fn3 (Fn3 WT), were
transformed into EBY100 yeast using the Frozen-EZ Yeast Transformation Kit II (Zymo
Research) following manufacturer’s protocol. Yeast were grown in SD-CAA media at
30°C and induced with SG-CAA media at 20°C with aeration. Aliquots of 106 yeast cells
were simultaneously labeled with 9E10 mouse anti-c-myc antibody (1:50) and a range of
concentrations of either biotinylated MSLN-Fc or biotinylated Fc fragment in a total
volume of 50 µL PBSA and incubated for 45 minutes with gentle rotation at 23°C. Cells
were washed with PBSA and then incubated with a goat anti-mouse PE (1:25) and
streptavidin-Alexa Fluor 488 (1:700) for 20 min with gentle rotation on ice in a total
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volume of 25 µL PBSA, protected from light. Cells were washed with PBSA, pelleted,
and resuspended in PBSA for analysis on an EMD Millipore Guava easyCyte flow
cytometer. Mean fluorescence intensity for MSLN binding was determined for yeast cells
displaying full length protein using InCyte software (EMD Millipore). Data was plotted
and fit with a sigmoidal curve using KaleidaGraph software (Synergy). Dissociation
constants (KD) were determined as the half-maximal value of the sigmoidal fit for three
separate experiments for each protein variant, and the mean and standard deviation for the
KD values are reported.

2.3.4 Engineered Fn3 protein production and purification
Engineered Fn3 genes 1.4.1 and 2.4.1 were cloned into the NheI and BamHI sites
of a pET24b(+) expression vector modified to include a C-terminal His6-KGSGK tag [61]
(provided by B. Hackel, University of Minnesota) and expressed in BL21(DE3) E. coli.
Cultures were grown in LB media at 37°C to an optical density at 600 nm of 1.0 before
induction with 0.5 mM Isopropyl-b-D-thiogalactopyranoside (IPTG). Fn3 proteins were
induced for 3 h at 30°C. Cells were harvested by centrifugation for 15 min at 3,200g, and
resuspended in lysis buffer (35 mM Na2HPO4×dibasic, 15 mM Na2HPO4×monobasic, 500
mM NaCl, 5 mM CHAPS, 25 mM imidazole, 5% glycerol) supplemented with protease
inhibitor (cOmplete, Roche). Cells were incubated on ice for 30 min, lysed by repeated
freezing and thawing, then centrifuged at 12,000g for 10 min and passed through a 0.45micron filter. Fn3 proteins were purified by nickel affinity chromatography with Ni-NTA
agarose resin (Thermo Fisher). Fn3 variant 1.4.1 was further purified by size exclusion
chromatography (SEC) on a Superdex 75 10/300 column (GE Healthcare Life Sciences).
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Fractions of interest were pooled and concentrated with a centrifugal filter unit with a 3
kDa molecular weight cutoff (EMD Millipore). Due to likely nonspecific adsorption onto
our SEC column, Fn3 variant 2.4.1 was alternatively further purified by reversed phase
high-performance liquid chromatography (HPLC) on a Hypersil ODS C18 column
(Thermo Fisher) using a linear gradient of 90% acetonitrile in water containing 0.1%
trifluoroacetic acid. Fn3 variant 2.4.1 fractions were pooled, lyophilized, and resuspended.
All protein samples were analyzed by SDS-PAGE on a BioRad ChemiDoc MP imaging
system using Image Lab 6.0 software (BioRad).

2.3.5 Alexa Fluor-488 dye conjugation
Pure, folded Fn3 proteins (1 mg/mL) were incubated with AF488 tetrafluorophenyl
ester (TFP) (Thermo Fisher) in a 0.1 M sodium bicarbonate solution, pH 8.3, at an 8:1
dye/protein molar ratio for 1 hr at 23°C with rotation and protected from light. The
resulting AF488-labeled 1.4.1 protein was purified by extensive buffer exchange with PBS
using a 3 kDa centrifugal filter unit. Because of likely adsorption onto the membrane of
the centrifugal filter unit, AF488-labeled 2.4.1 protein was purified with an alternative
method, using fluorescent dye removal columns (Thermo Fisher #22858), according to
manufacturer’s protocol. Concentrations and degree of labeling (DOL) were determined
using UV-Vis spectroscopy, measuring dye absorption at 494 nm (e = 71,000 cm-1 M-1).

2.3.6 Binding affinity measurements of Fn3 protein for MSLN-positive tumor cells
A431/H9 and MCF-7 cells were cultured to 80% confluency, as described above,
and detached by 0.25% trypsin-EDTA (Gibco). Aliquots of 105 cells were washed and
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pelleted at 200g for 5 min at 4°C. MSLN expression was detected by a mouse anti-MSLN
antibody (clone K1, Abcam, 1:50) and a goat anti-mouse PE conjugate (1:25). Cells were
incubated with a range of concentrations of AF488-labeled 1.4.1 and 2.4.1 in a total volume
of 25 µL PBSA for 1 h at 23°C with rotation and protected from light. Cells were washed
and pelleted as above, resuspended with ice cold PBSA, and fluorescence was analyzed
using a Guava easyCyte flow cytometer. Mean fluorescence intensities for Fn3 variant
binding were determined using InCyte software. Data was plotted and fit with a sigmoidal
curve using KaleidaGraph software. Dissociation constants (KD) were determined as the
half-maximal value of the sigmoidal fit for three separate experiments, and the mean and
standard deviation for the KD are reported.

2.3.7 Imaging flow cytometry
KB-3-1, A431/H9, and MCF-7 cells were cultured and harvested as described
above. Aliquots of 2.5 x 106 cells were washed, pelleted, and incubated with AF488labeled 1.4.1 or 2.4.1 (1 µM) in a total volume of 25 µL for 1 hr at either 23°C or 37°C
with rotation and protected from light. Cells were washed with ice cold PBSA and pelleted
as above. Cells were fixed with 4% paraformaldehyde (PFA) in PBS for 15 min at 23°C
followed by permeabilization with 0.2% Tween 20 in PBS (PBST) for 20 min at 23°C.
Cells were washed twice and pelleted then incubated with an AF647-conjugated rabbit
anti-EEA1 antibody (Abcam #196186, 1:50) in a total volume of 50 µL PBST for 30 min
at 23°C with rotation and protected from light. EEA1 is an early endosomal marker. Cells
were washed, pelleted, and resuspended in 100 µL PBSA. Images were acquired on an
Amnis ImageStream X Mark II (EMD Millipore) with a 40X magnification. Collected
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data (5000 images) were analyzed with IDEAS 6.2 software (EMD Millipore).

A

compensation matrix was created using single color controls acquired with the brightfield
laser turned off. Cells were gated for focused cells with the Gradient RMS feature and for
single cells with the area and aspect ratio. Co-localization quantification was determined
by the Bright Detail Similarity (BDS) metric in IDEAS software.

2.4 Results

2.4.1 MSLN-binding Fn3 proteins engineered using yeast surface display and directed
evolution
Yeast surface display has been previously shown to be a robust method for
engineering proteins with improved biophysical, catalytic, and molecular recognition
properties [23–25,63]. To engineer MSLN-binding proteins, a naïve Gr2 YSD library of
2.8 x 109 variants was screened. Fn3 expression levels were monitored using an antibody
to the terminal c-myc epitope tag. Following two rounds of MACS and a FACS sort for
full-length expression to eliminate truncated protein variants, four iterative rounds of dualcolor FACS were performed for binding to MSLN normalized by full length protein
expression. An enriched population of variants was isolated that demonstrated selective
affinity to MSLN, compared to no visible binding in the unsorted naïve library (Figure
2.2). This enriched population of Fn3 variants was then subjected to a single round of
mutagenesis and transformed back into yeast for further enrichment and selection as a
second generation library. An enriching population of yeast cells displaying full length
protein that bound MSLN was observed throughout rounds of sorting (Figure 2.2). We
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note that our initial efforts to engineer Fn3 variants to bind to a small, 64-amino acid
domain of MSLN responsible for binding to MUC16 and using an earlier variation of the
Fn3 library were unsuccessful, resulting only in variants that bound to the streptavidin
secondary reagent and no engineered variants that bound to the MSLN minimal binding
domain. To overcome this challenge, we changed our target reagent from this small domain
of MSLN to a full-length extracellular domain of MSLN to provide additional surface
topology that Fn3 variants could interact with, and alternated sorting detection methods to
only use streptavidin as a reagent in some sort rounds, thereby limiting the likelihood of
engineering streptavidin binders.
From E. coli transformed with plasmids obtained from the engineered first and
second generation libraries of enriched MSLN-binding Fn3 variants, 30 independent
clones from each generation were randomly chosen and sequenced. Following four rounds
of dual-color FACS sorting of the first generation library, there were 10 unique sequences.
Of those sequences, one unique clone dominated, representing 18 of the 30 clones
sequenced, which we refer to as clone 1.4.1, denoting the first generation library, with four
rounds of sorting by FACS, clone number one. Following four rounds of sorting of the
second generation library, a second unique clone, variant 2.4.1, emerged. Fn3 variants
1.4.1 and 2.4.1 differ only by their FG loop and incorporate a single K63N framework
mutation compared to the library wildtype framework sequence (Figure 2.3A). Plasmids
for all unique clones were transformed back into EBY100 yeast and their specific binding
to 200 nM MSLN was assessed by flow cytometry.

Clones 1.4.1 and 2.4.1 had

substantially greater binding to MSLN compared to all other variants, and were
subsequently selected for further study.
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To measure the binding affinity of these two clones for soluble MSLN extracellular
domain, titration binding assays with the Fn3 variants expressed on the surface of yeast
were performed (Figure 2.3B). Clone 1.4.1 exhibited a binding affinity of KD= 700 ± 300
nM, and clone 2.4.1 exhibited a binding affinity of KD = 290 ± 40 nM, while Fn3 WT
displayed no specific binding to MSLN. Furthermore, clones 1.4.1 and 2.4.1 exhibited no
binding to a biotinylated, Fc fragment alone, demonstrating their specific binding
interaction with MSLN (Figure 2.3C). While further rounds of directed evolution to obtain
higher affinity clones will be necessary for eventual clinical translation, we sought to
characterize these two variants to learn more about their interaction with tumor cells
expressing MSLN, to inform further engineering of Fn3 clones to recognize MSLN.

2.4.2 Engineered Fn3 proteins were recombinantly produced
To further develop and characterize engineered Fn3 proteins for future diagnostic
and therapeutic applications, lead variants were solubly expressed and purified. Fn3
variants 1.4.1 and 2.4.1 were expressed in bacteria with a C-terminal hexahistidine tag and
purified by nickel affinity chromatography and either SEC or HPLC. Chromatograms
indicated protein elution at expected retention times for Fn3 variant 1.4.1 on SEC (Figure
2.4A) and Fn3 variant 2.4.1 on HPLC (Figure 2.4B). Analysis by SDS-PAGE confirmed
high purity > 99% for 1.4.1 and 2.4.1 and (Figure 2.4C), with routine yields of ~ 10 mg/L.

2.4.3 Soluble engineered Fn3 variants bound tumor cells expressing MSLN
We established a tumor cell binding assay to measure the binding affinities of
soluble engineered Fn3 variants for MSLN-expressing cancer cells. The A431/H9 cell line
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is an A431 (human epidermoid carcinoma) cell line transfected to stably overexpress
MSLN on its surface [16]. MCF-7 is a human breast cancer cell line reported not to express
MSLN on its surface [7]. Using an anti-MSLN antibody (clone K1, Abcam), high
levels of MSLN were confirmed on the surface of A431/H9 cells compared to the MCF-7
cell line expected to be negative for human MSLN (Figure 2.5A).
Direct equilibrium binding titrations of the engineered 1.4.1 and 2.4.1 Fn3 variants
on the A431/H9 and MCF-7 carcinoma cells were performed (Figure 2.5B). The Fn3
variants were directly conjugated to Alexa Fluor 488 and incubated over a range of
concentrations with cells for 1 h at 23°C and analyzed by flow cytometry. Equilibrium
binding constant (KD) values were obtained by fitting plots of AF488-labeled 1.4.1 and
AF488-labeled 2.4.1 concentrations versus the mean fluorescence intensity. Consistent
with the yeast surface display binding data, Fn3 variant 1.4.1 bound to A431/H9 cells with
a binding affinity of KD = 510 ± 90 nM, while Fn3 variant 2.4.1 bound to A431/H9 cells
with a binding affinity of KD = 440 ± 30 nM. Neither Fn3 variant displayed binding to the
MSLN-negative MCF-7 cell line, with only expected, non-specific binding observed at the
highest concentrations analyzed.

2.4.4 Fn3 variants co-localized to early endosomes following binding to MSLN
Future application of an engineered Fn3 variant for drug delivery to cancer cells
could benefit from the internalization of the targeting molecule upon target binding to
effectively deliver a conjugated payload into the cells. Mesothelin has been previously
reported to efficiently internalize [64–66]. Using imaging flow cytometry, we sought to
assess whether engineered Fn3 variants 1.4.1 and 2.4.1 could be internalized into cancer
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cells following binding to surface MSLN. The KB-3-1 cell line is a human cervical
carcinoma cell line reported to express MSLN on its surface [67]. Using an anti-MSLN
antibody (clone K1) and a PE-conjugated secondary antibody, MSLN was confirmed on
the surface of KB-3-1 cells while no MSLN expression was detected on the surface of the
MCF-7 cell line (Figure 2.6A, B).
KB-3-1 cells and MCF-7 cells were incubated with either AF488-labeled 1.4.1
(Figure 2.6C) or 2.4.1 (Figure 2.6D) at 37°C and then fixed and permeabilized before
incubation with an AF647-conjugated antibody against the early endosomal marker, EEA1.
Co-localization of EEA1 antibody and engineered variants was quantified using the Bright
Detail Similarity (BDS) metric, which uses a modified Pearson’s correlation coefficient to
quantify the degree of similarity between the AF488-labeled 1.4.1 or 2.4.1 image and the
AF647-EEA1 endosomal image. Cells with increased AF488-labeled 1.4.1 or 2.4.1
trafficking to early endosomes have higher similarity values as a result of greater colocalization of the two fluorescent channel signals.

Imaging flow cytometry data

demonstrated that when KB-3-1 cells were incubated with AF488-labeled 1.4.1 (Figure
2.6C, top) or 2.4.1 (Figure 2.6D, top), the AF488-labeled 1.4.1 and 2.4.1 was internalized
and co-localized with early endosomes with a BDS = 1.31 and 0.919, respectively, for 5000
cells. Further, efficient binding and subsequent internalization is not observed when
AF488-labeled 1.4.1 (Figure 2.6C, bottom) or 2.4.1 (Figure 2.6D, bottom) is incubated
with the MSLN-negative MCF-7 cell line. BDS values were not determined for the
negative control cell line as this metric requires a substantial population of double positive
cells, which was not present for the negative control cell line. In an additional imaging
flow cytometry study, MSLN was again confirmed on the surface of KB-3-1 and A431/H9
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cells, and AF488-labeled 1.4.1 internalized and co-localized with early endosomes when
the experiment was conducted at 23°C (Figure 2.7).

2.5 Discussion
Mesothelin has broad potential as a novel tumor target for both diagnosis and
therapy, yet no MSLN-targeting molecules are currently FDA approved. Thus, there
remains critical need for MSLN-targeting therapeutics and for molecular diagnostics that
can identify patients who are most likely to respond to such therapies. In this work, we
used directed evolution and a yeast surface display library to engineer Fn3 variants that
bind specifically to MSLN, for future application in diagnosis and therapy. Variants 1.4.1
and 2.4.1 demonstrate specific affinity for the MSLN tumor marker present on the surface
of tumor cells, and, upon MSLN binding, are internalized and co-localize with early
endosomes.

Internalization could be valuable for delivery of cytotoxic molecules

conjugated to engineered Fn3 variants into tumor cells. The work described here validates
our approach for engineering MSLN-binding variants, using yeast surface displayed Fn3
libraries and directed evolution.

The results demonstrating specific binding to, and

internalization into, a tumor cell line encourage further engineering of higher affinity
variants towards clinical applications. To our knowledge, this is the first report of a nonantibody protein engineered to bind MSLN.
In an initial protein engineering strategy, we sought to engineer Fn3 variants that
were selected to bind to a 64-amino acid domain of MSLN previously reported to be the
minimal domain for binding to MUC16 [58]. It was expected that an Fn3 variant that
targeted this binding domain would likely block MSLN and MUC16 interactions,
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enhancing therapeutic activity of such Fn3 variants. MSLN and MUC16 binding has been
reported to enhance tumor cell proliferation and metastasis [8,12,21]. This initial protein
engineering strategy did not successfully yield MSLN binding variants, potentially due to
insufficient binding topography on the 64-amino acid domain, and, instead, resulted in Fn3
variants that bound the streptavidin secondary reagent. While we had attempted to prevent
selecting streptavidin-binding variants by using negative magnetic sorts, this method is not
always adequate to influence the selection towards the desired interaction with target
protein. Because naïve libraries are not based on pre-existing binding interactions, such
libraries display no initial bias toward a specific target molecule or epitope [68]. We were
ultimately successful in engineering Fn3 variants that bound to our target protein by using
the full-length extracellular domain of MSLN and by avoiding the use of streptavidin in
some FACS rounds. Determining the epitopes on MSLN that the engineered variants bind
is of interest to further evaluate therapeutic potential of the Fn3 proteins.
Diagnostic molecular imaging is one promising application for non-antibody
proteins engineered to bind MSLN positive tumors. While antibodies can be engineered
to bind to a variety of targets with high affinities, their large size and slow clearance from
circulation can often result in low contrast images [69]. Instead, non-antibody scaffolds
have been explored and have demonstrated promising results in preclinical and clinical
evaluations [70]. Recently, Fn3 proteins engineered to bind EGFR and EphA2 have been
shown to identify tumors expressing their respective molecular target in murine molecular
imaging models [50,71,72]. The cystine-knot, or knottin, protein scaffold has also been
engineered for tumor targeting applications and has shown promise for molecular imaging
in pre-clinical studies targeting tumors and tumor vasculature expressing integrins [73–77].
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Likewise, affibodies and DARPins engineered to bind human epidermal growth factor 2
(HER2) or EGFR have been used to image tumor xenografts in mice [78–80]. Recently, a
novel Gp2 scaffold has been developed for molecular imaging of EGFR [81]. In each of
these studies, the imaging agents were proteins engineered to have picomolar to singledigit nanomolar dissociation constants for their targets, and the importance of this high
affinity for tumor targeting applications is further supported by theoretical modeling [82],
motivating additional rounds of mutagenesis and directed evolution for our engineered
proteins targeting the novel tumor target MSLN.
There is also sustained interest around using engineered proteins as drug delivery
agents, such as by conjugating cytotoxic molecules or polymeric systems to proteins that
recognize a tumor biomarker [83,84]. Current drug delivery strategies, such as antibodydrug conjugates (ADCs), take advantage of the specificity of antibodies to selectively
deliver cytotoxic drugs to antigen-expressing cancer cells [85].

ADCs, including

AdcentrisÒ (Seattle Genetics) [86] and KadcylaÒ (Genentech)[87], have received FDA
approval for targeted treatment of relapsed Hodgkin Lymphoma and Her-2 positive breast
cancer, respectively. ADCs are comprised of a targeting antibody, a stable linker with acid
labile bonds, and the cytotoxic payload [88]. Upon antigen recognition and binding, the
ADC is internalized via receptor-mediated endocytosis and trafficked through endosomal
vesicles to the lysosome [89]. The low pH of the lysosome will trigger degradation of the
antibody and hydrolysis of the linker, thereby releasing the drug to exert its cytotoxic effect
[85]. Dose-limiting toxicities, however, can limit penetration of ADCs into solid tumors,
whereas small non-antibody scaffolds may be advantageous by efficiently delivering
cytotoxic payloads deep within a tumor while maintaining rapid clearance from circulation
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[90]. The observed internalization of the MSLN-targeting Fn3 variant is intriguing toward
the goal of delivering a payload across the membrane of MSLN-positive tumor cells.
Further understanding of the trafficking of engineered proteins that bind MSLN will inform
development of anti-MSLN therapeutic strategies.
In summary, we demonstrate that the Fn3 protein scaffold is suitable for
engineering targeting molecules for the underdeveloped tumor target MSLN. To our
knowledge, this is the first report of a non-antibody protein engineered to bind MSLN. Our
data demonstrating specific binding of the engineered variants to tumor cells positive for
MSLN, followed by subsequent internalization of the engineered Fn3 proteins, establishes
the potential for further development of MSLN-targeting Fn3 proteins for a variety of
clinically relevant applications in diagnosis and therapy.
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2.7 Figures

Figure 2.1 Approach to engineering Fn3 proteins to recognize tumor biomarker
MSLN for diagnostic and therapeutic applications. (A) The tenth domain of human
fibronectin type III (Fn3) (PDB 1TTG) is a highly stable protein structure with three loops
(BC, DE, and FG) broadly tolerant of mutation to confer novel binding properties.
Structure was rendered in PyMOL. (B) We employed a previously developed hydrophilic
Fn3 yeast surface display library [56] that incorporates a range of loop lengths and biased
amino acid composition to mimic the diversity of naturally occurring antibody
complementarity-determining regions. (C) Fn3 proteins that bind cell surface protein
MSLN have numerous potential clinical applications, such as through diagnostic imaging,
internalization for drug delivery, and metastatic reduction by blocking MSLN-MUC16
interactions. Stars represent conjugated imaging or therapeutic molecules.
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Figure 2.2 Directed evolution of a naïve yeast surface display library yielded Fn3
variants that bind soluble MSLN. We started with a naïve yeast surface display library
with 2.8 x 109 variants of the Fn3 non-antibody scaffold. The library was sorted for fulllength protein expression, detected by an antibody to a terminal c-myc epitope tag, and
binding to MSLN using MACS and FACS. Red polygon indicates example cell population
collected for further enrichment and analysis. Additional diversity was introduced into the
enriched library through a single round of mutagenic PCR and sorting of this second
generation library resulted in further enrichment for MSLN binding variants. A doublenegative population of yeast cells is characteristic of yeast surface display.
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Figure 2.3 Yeast displayed Fn3 variants 1.4.1 and 2.4.1 bound specifically to tumor
biomarker MSLN. (A) Two dominant Fn3 variants, 1.4.1 and 2.4.1, were recovered from
a first generation and second generation Fn3 library, respectively. (B) Individual clones
and Fn3 WT were displayed on the surface of yeast and incubated with a range of
concentrations of soluble MSLN. Experimental triplicate data were collected, and the
dissociation constant is reported as the mean and standard deviation of the KD values
calculated for each replicate. A representative binding curve is shown for each variant.
(C) Individual clones were displayed on the surface of yeast and incubated with a range of
concentrations of a biotinylated, Fc fragment. Experimental triplicate data were collected.
A representative curve is shown for each variant.
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Figure 2.4 Production and characterization of selected Fn3 variants. Engineered Fn3
clones 1.4.1 and 2.4.1 were expressed in bacteria with a C-terminal hexahistidine tag and
a short peptide tag containing GKSK residues for later bioconjugation chemistry. (A) Fn3
protein 1.4.1 was purified by nickel affinity chromatography followed by SEC,
demonstrating desired product with retention time of ~ 42 min. (B) Fn3 protein 2.4.1 was
purified by nickel affinity chromatography followed by HPLC, demonstrating desired
product with retention time of ~30 min. (C) Proteins were purified to high purity > 99%
as analyzed by SDS-PAGE. Yields of Fn3 protein production were routinely ~ 10 mg/L.
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Figure 2.5 Engineered Fn3 protein variants bound cancer cells expressing MSLN.
A431/H9 cells, epidermoid carcinoma cells transfected to express high levels of MSLN,
and MCF-7 cells, breast cancer cells lacking surface MSLN, were used in all binding
assays. (A) Analysis by flow cytometry confirms MSLN presence on the surface of
A431/H9 cells as detected by an anti-MLSN antibody. The MCF-7 cell line does not
express MSLN. (B) Fn3 variants 1.4.1 and 2.4.1 were isolated and binding to MSLN was
measured using equilibrium binding assays. A431/H9 and MCF-7 cells were incubated
with a range of concentrations of soluble fluorescently labeled 1.4.1 or 2.4.1. The assays
were performed in experimental triplicate. Data from each replicate were fit to a sigmoidal
curve, and a KD value was calculated for each replicate. The KD is reported as the mean
+/- standard deviation. A representative binding curve of each clone for both cell lines is
shown.
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Figure 2.6 Engineered Fn3 protein variants 1.4.1 and 2.4.1 localized to early
endosomes upon binding MSLN. Analysis by (A) flow cytometry and (B) imaging flow
cytometry confirms MSLN presence on the surface of KB-3-1 cells compared to the
MSLN-negative MCF-7 cells, as detected by an anti-MSLN antibody. (C, D) KB-3-1 cells
(top) internalize AF488-labeled 1.4.1 (C) and AF488-labeled 2.4.1 (D), while MCF-7 cells
show no specific binding or internalization (C bottom, D bottom). Endosomes are detected
by an AF647-conjuated antibody recognizing the EAA1 early endosomal marker. Yellow
in the merged images indicate co-localization between AF488-1.4.1 or AF488-2.4.1 antiMSLN engineered proteins (green) and EEA1 (red). Original magnification 40X. Colocalization is quantified by the Bright Detail Similarity (BDS) metric, with values near 1
indicating co-localization. KB-3-1 BDS = 1.31 and 0.919 for AF488-1.4.1 and AF4882.4.1, respectively. BDS values are not quantifiable for the negative control cell line, due
to insufficient fraction of negative control cell population staining for binding or
internalization of engineered protein variants.
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Figure 2.7 Engineered Fn3 protein variant 1.4.1 localized to early endosomes in KB3-1 and A431/H9 cells upon binding MSLN. (A) Analysis by imaging flow cytometry
confirms MSLN on the surface of KB-3-1 (top) and A431/H9 (bottom) cells as detected by
an anti-MSLN antibody. (B) KB-3-1 (top) and A431/H9 (bottom) cells were incubated with
AF488-1.4.1 at 23°C for 1 hr. Cells were fixed and permeabilized, then incubated with an
AF647-conjugated antibody directed against the early endosomal marker EEA1. Yellow in
the merged image indicates co-localization between AF488-1.4.1 anti-MSLN engineered
protein (green) and EEA1 (red). Original magnification 40X. Quantification of colocalization was measured by BDS.
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CHAPTER 3
ENGINEERED FN3 PROTEIN HAS TARGETED THERAPUTIC EFFECT ON
MESOTHELIN-EXPRESSING CANCER CELLS AND INCREASES TUMOR
CELL SENSITIVITY TO CHEMOTHERAPY

as written by Sirois, A.R., Deny, D.A., Li, Y., Fall, Y.D., and Moore, S.J.
Biotechnology and Bioengineering 2019

3.1 Abstract
Mesothelin is a protein expressed at high levels on the cell surface in a variety of
cancers, with limited expression in healthy tissues. The presence of mesothelin on tumor
tissue correlates with increased invasion and metastasis, and resistance to traditional
chemotherapies, through mechanisms that remain poorly understood. Molecules that
specifically recognize mesothelin and interrupt its contribution to tumor progression have
significant potential for targeted therapy and targeted drug delivery applications. A number
of mesothelin-targeting therapies are in pre-clinical and clinical development, although
none are currently approved for routine clinical use.

In this work, we report the

development of a mesothelin-targeting protein based on the fibronectin type-III nonantibody protein scaffold, which offers opportunities for applications where antibodies
have limitations. We engineered protein variants that bind mesothelin with high affinity
and selectively initiate apoptosis in tumor cells expressing mesothelin. Interestingly,
apoptosis does not occur through a caspase-mediated pathway, and does not require
downregulation of cell-surface mesothelin, suggesting a currently unknown pathway
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through which mesothelin contributes to cancer progression. Importantly, simultaneous
treatment with mesothelin-binding protein and chemotherapeutic mitomycin C had a
greater cytotoxic effect on mesothelin-positive cells compared to either molecule alone,
underscoring the potential for combination therapy including biologics targeting
mesothelin.

3.2 Introduction
Mesothelin (MSLN) is a cell surface protein that is overexpressed in numerous
cancers, including ovarian [1–3], triple negative and other breast [4–7], lung [8–10], liver
[11,12], pancreatic [5,13–15], and mesothelioma [16]. The aberrant expression of MSLN
is known to promote tumor cell survival, progression, and metastasis in vitro and in vivo
[1,17–19]. MSLN expression is limited in normal tissue, with only low levels expressed
on the mesothelial cells of the pleura, peritoneum, and pericardium [20]. The role of MSLN
in normal development is currently still unknown. Mice with an inactivated MSLN gene
display no distinct phenotype and are capable of producing healthy offspring, suggesting
that MSLN is not essential for mammalian development [21]. The differential expression
in cancer and healthy tissue, and apparent non-essential role for MSLN in normal tissue,
makes MSLN a promising biomarker for cancer diagnosis and therapeutic targeting.
Previous studies have proposed a variety of mechanisms by which MSLN promotes
tumor progression [22]. Growing evidence indicates that MSLN aids in cell motility,
implantation, and metastasis through its interaction with another tumor surface protein,
CA125, also known as MUC16 [14,17,18]. The interaction of these two cell surface
proteins has been observed to facilitate metastasis in ovarian tumors [3,23], and promote
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cancer cell motility and invasion in pancreatic cancer [14]. The interaction between MSLN
and CA125 mediates heterotypic cell adhesion, important for tumor cell invasion and
metastasis [18]. Moreover, blocking the interaction of MSLN and CA125 with anti-MSLN
antibodies blocks the observed adhesion [18]. Overexpression of CA125 has been shown
to induce metastasis, but only when mediated by binding to MSLN [24]. MSLN expression
may also promote cancer cell survival and proliferation through the NF-kB signaling
pathway. MSLN expression in pancreatic cancer cells was correlated with constitutive
activation of the transcription factor STAT3, which lead to increased formation of the
cyclin E/cyclin-dependent kinase 2 complex, as well as increased G1-S transitions [25].
Several studies suggest MSLN expression is associated with chemoresistance, and shorter
progression-free survival and overall survival [26]. MSLN-induced NF-kB pathway
activation has been shown to mediate resistance to several chemotherapeutics through
upregulation of anti-apoptotic proteins, including Bcl-2 and Mcl-1 [27,28]. Altering MSLN
biochemical signaling pathways or interrupting the binding of MSLN and CA125 are
viable therapeutic strategies to reduce cancer progression and metastasis.
Promising results from pre-clinical and clinical trials to target MSLN with
antibodies, antibody derivatives, immunotoxins, antibody-drug conjugates, and CAR-T
cells for therapy demonstrate the promise of MSLN-targeting methods [29–35]. However,
no MSLN-targeting molecules are currently approved for routine clinical use. Targeted
therapeutics have made significant impacts in cancer treatment, resulting in increased
efficacy and reduced toxicity compared to traditional chemotherapies. Novel targeted
therapy approaches for MSLN-positive tumors have potential for substantial impact in the
clinic for patients who currently do not have a targeted therapy option.
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We have recently reported engineering protein variants based on the fibronectin
type III (Fn3) non-antibody protein scaffold that bind to MSLN with moderate affinities
(KD = 100’s nM) [36]. Fn3 variants that specifically bound to MSLN on human cancer
cells were internalized, and co-localized to early endosomes, indicating their promise for
drug delivery applications. MSLN has been previously shown to readily internalize bound
ligands, underscoring the potential of MSLN as a cell-surface target to mediate intracellular
drug delivery [37]. While antibody-based therapies have found great success for a variety
of clinical needs, there are some applications where other protein structures may be
advantageous and complement clinical contributions from antibodies, motivating the
development of non-antibody protein scaffolds for engineering molecular recognition,
including the Fn3 scaffold [38–42].
Here, we describe further evolved Fn3 variants with enhanced binding affinity for
MSLN. Our data show that treatment of MSLN-positive tumor cells with engineered
MSLN-binding Fn3 protein has cytotoxic effects on MSLN-expressing cancer cells,
leading to tumor cell apoptosis. Our results indicate that apoptosis is by a caspaseindependent pathway, and that the cytotoxic effects are not due to downregulation of
MSLN on the surface of cancer cells, revealing that a novel signaling pathway is potentially
being targeted by the engineered MSLN-binding protein, with implications for future drug
development efforts. Importantly, when MSLN-positive cells are simultaneously treated
with MSLN-binding Fn3 protein and established chemotherapeutic mitomycin C (MMC),
the tumor cells exhibit enhanced sensitivity to the chemotherapeutic agent with increased
apoptosis compared to MSLN-positive cells treated with MMC alone. These results
highlight the potential of targeting MSLN with biologic therapeutics in combination
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therapy with traditional chemotherapeutics for selective, synergistic treatment of tumors
expressing MSLN.

3.3 Materials and Methods

3.3.1 Reagents and cell lines
PBSA buffer was composed of phosphate buffered saline (PBS) and 0.1% bovine
serum albumin (BSA). A431/H9 cells (gift of M. Ho, National Cancer Institute, 2016) [43]
were cultured in RPMI-1640 supplemented with 10% FBS, 1% penicillin-streptomycin and
700 µg/mL Geneticin selective antibiotic (G418) (Thermo Fisher). KB-3-1 cells (gift of
M. Gottesman, National Cancer Institute, 2016) [44] were cultured in DMEM
supplemented with 10% FBS and 1% penicillin-streptomycin. T-47D cells (gift of S.
Smith-Schneider, Pioneer Valley Life Sciences Institute, 2019) [45] were cultured in
DMEM supplemented with 10% FBS, 0.2 units/mL human insulin (Sigma # I9278-5ML)
and 1% penicillin-streptomycin. OVCAR-3 cells (ATCC #HTB-161, 2015) were cultured
in RPMI-1640 supplemented with 20% FBS, 1% penicillin-streptomycin, and 0.01 mg/mL
human insulin. All cells were grown at 37°C in a humidified atmosphere containing 5%
CO2.

3.3.2 Maturation and evolution of Fn3 variant 3.4.4 by yeast surface display
A Gr2 library that we had previously evolved for MSLN-binding Fn3 variants was
further sorted and affinity matured as a third generation library using yeast surface display
[36,46]. Briefly, following error-prone PCR with nucleotide analogs, the library was sorted
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twice by magnetic bead selection (MACS) using biotinylated, Fc-tagged recombinant
human MSLN (Acro Biosystems #MSN-H826x) followed by a fluorescence activated cell
sorting (FACS) selection for full-length clones using an antibody against the C-terminal cmyc epitope tag. Full-length clones were incubated with a chicken anti-c-myc antibody
and the biotinylated Fc-tagged MSLN. To increase the sorting stringency, concentrations
of MSLN were decreased over four iterative rounds of enrichment, from 20 nM in the first
sort to 5 nM in the fourth sort. Cells were washed and incubated with a goat anti-chicken
Alexa Fluor 647 (AF647) conjugate and Alexa Fluor 488 (AF488)-conjugated streptavidin.
Cells were washed and double-positive yeast cells were collected on a BD BioSciences
FACSAria II. Plasmid DNA from the enriched library was recovered using a Zymoprep
Yeast Plasmid Miniprep II kit (Zymo Research) following manufacturer’s protocol,
transformed into bacteria, and individual clones were sequenced by standard Sanger DNA
sequencing methods.

3.3.3 Engineered Fn3 protein production and purification
MSLN-binding Fn3 variant 3.4.4 and negative control protein Fn3 RDG, in which
the RGD integrin-binding motif has been mutated to RDG (plasmid DNA provided by B.
Hackel, University of Minnesota), were prepared as previously described [36]. Briefly,
Fn3 genes were cloned into a pET vector with a C-terminal hexahistadine tag (plasmid
provided by B. Hackel, University of Minnesota) and expressed in BL21(DE3) E. coli.
Cultures were grown in LB and induced overnight at 20°C with 0.5 mM Isopropyl-b-Dthiogalactopyranoside (IPTG).

Cells were resuspended in lysis buffer (35 mM

Na2HPO4×dibasic, 15 mM NaH2PO4×monobasic, 500 mM NaCl, 5 mM CHAPS, 25 mM
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imidazole, 5% glycerol) supplemented with an EDTA-free protease inhibitor (Pierce), and
lysed by repeated freezing and thawing.

The soluble fractions were isolated by

centrifugation. Fn3 variant 3.4.4 was purified by cobalt affinity chromatography with
HisPur cobalt resin (Thermo Fisher) while Fn3 RDG was purified by nickel affinity
chromatography with Ni-NTA agarose resin (Thermo Fisher) followed by size exclusion
chromatography (SEC) on a Superdex 75 10/300 column (GE Healthcare Life Sciences).
Protein samples were analyzed for purity by SDS-PAGE on a BioRad ChemiDoc MP
imaging system.

3.3.4 Binding affinity measurements of soluble Fn3 proteins for MSLN-positive tumor
cells
A431/H9 and MCF-7 cells were cultured to 80% confluency, as described above,
harvested, washed, and pelleted at 200g for 5 min at 4°C. MSLN expression was detected
by a mouse anti-MSLN antibody (clone K1, Abcam, 1:50) and a goat anti-mouse PE
conjugate (1:25). Cells were incubated with a range of concentrations of 3.4.4. or Fn3
RDG in a total volume of 50 µL PBSA for 1 h at 23°C with rotation. Cells were washed
with PBSA and incubated with a mouse anti-His6 DyLight-488 antibody (Abcam
#ab117512, 1:50) for 20 min at 4°C and protected from light. Fluorescence was analyzed
using an EMD Millipore Guava easyCyte flow cytometer. Mean fluorescence intensities
for Fn3 variant binding were determined using InCyte software (EMD Millipore). Data
was plotted and fit to a sigmoidal curve using KaleidaGraph software. Dissociation
constants (KD) were determined as the half-maximal value of the sigmoidal fit for three
separate experiments, and the mean and standard deviation (SD) for the KD are reported.
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3.3.5 Cell viability measurements
Cell viability was determined using a Cell Counting Kit-8 (CCK-8, Dojindo
Laboratories, Japan), according to the manufacturer’s instructions. Briefly, cells were
seeded at 3 x 103 (KB-3-1) or 5 x 103 (T-47D) cells per well in 96-well plates and cultured
overnight in a final volume of 100 µL of medium. After overnight culture, the medium
was exchanged to serum-free medium containing various concentrations of 3.4.4 or Fn3
RDG (2, 20, or 200 nM). As a positive control, cells were treated with 10 µM mitomycin
C (MMC), a known chemotherapeutic agent. At 48 h post treatments, spent media was
removed and replaced with 100 µL of fresh media with 10 µL of CCK-8 reagent and the
cells were incubated at 37°C for an additional 2 h. The absorbance of each well was
measured at 450 nm on a Tecan Infinite M100 microplate reader. All treatments were
carried out as triplicates in three independent experiments. Data were analyzed using the
Magellan 7.0 software (Tecan). Measured absorbance was normalized with absorbance
values of the cell culture media that did not contain cells. Untreated cells were regarded as
control, and cell viability was calculated as the ratio of the absorbance of test and control
wells.

3.3.6 Apoptosis experiments
Apoptosis was determined using a Dead Cell Apoptosis kit with annexin V-AF488
and propidium iodide (PI) (Molecular Probes), according to the manufacturer’s
instructions. Briefly, KB-3-1 cells were seeded at 2.5 x 105 cells in 35 mm plates and
cultured overnight in a final volume of 3 mL of medium. After overnight culture, the
medium was exchanged to serum-free medium containing 200 nM of 3.4.4 or Fn3 RDG.
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At 48 h post treatment, cells were trypsinized, washed three times with PBS, and
resuspended in 1X binding buffer to a density of 1x106 cells/mL. 100 µL of this cell
suspension was incubated with 5 µL of the supplied annexin V-AF488 and 1 µL of PI (100
µg/mL) for 15 min while protected from light. The percentages of annexin V-AF488positive and PI-positive cells were determined from the fluorescence of 25,000 cells
measured on an EMD Millipore Guava easyCyte flow cytometer. All treatments were
carried out as triplicates. Data were analyzed using InCyte software (EMD Millipore).

3.3.7 Caspase-3/7 activation
Caspase induction was assessed using the Caspase-Glo 3/7 assay (Promega),
according to the manufacturer’s instructions. Briefly, KB-3-1 cells were seeded at 5 x 103
cells per well in 96-well plates and cultured overnight in a final volume of 100 µL of
medium. After overnight culture, the medium was exchanged to serum-free medium
containing 200 nM of 3.4.4 or Fn3 RDG. As a positive control, cells were treated with 10
µM MMC. At the specific time point of either 6, 12, 24, 36, or 48 h, 100 µL of Caspase3/7 reagent was added to each well, gently mixed at 300 rpm for 30 s, and incubated at
23°C for an additional 2 h. Luminescence was measured on a Tecan Infinite M100
microplate reader. All treatments were carried out as triplicates in three independent
experiments, unless otherwise noted. Data were analyzed using the Magellan 7.0 software.

3.3.8 Receptor downregulation
KB-3-1 cells were seeded at 3x104 cells per well in 96-well plates, grown overnight,
and serum starved for 12-16 h. Cells were treated with 200 nM 3.4.4 or Fn3 RDG for the
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indicated time between 0 and 48 h. Medium was removed and cells were washed with
PBS, detached with 0.05% trypsin-EDTA, and placed on ice for the remainder of the assay.
Cells were washed with PBSA and incubated with an anti-MSLN antibody raised in mouse
for 1 h on ice followed by a goat anti-mouse PE conjugate antibody. Cells were washed
and analyzed by flow cytometry. All treatments were carried out in triplicates. Levels of
cell surface MSLN expression were determined from the fluorescence of 25,000 cells
measured on a EMD Millipore Guava easyCyte flow cytometer. Data were analyzed using
InCyte software (EMD Millipore).

3.3.9 Combination therapy with engineered protein variant and MMC
The Dead Cell Apoptosis kit with annexin V-AF488 and propidium iodide (PI)
described above was used to determine whether treatment with Fn3 variant 3.4.4 could
enhance the susceptibility of MSLN-expressing cells to MMC-induced apoptosis. Briefly,
KB-3-1cells or OVCAR-3 cells were seeded at 1 x 105 cells in 12-well plates and cultured
overnight in a final volume of 1 mL of medium. After overnight culture, the medium was
exchanged to serum-free medium containing 200 nM Fn3 variant 3.4.4, 1 µM MMC, or 1
µM MMC with 200 nM Fn3 variant 3.4.4. At 48 h post treatment, cells were trypsinized,
washed three times with PBS, and resuspended in 1X binding buffer to a density of 1x106
cells/mL. 100 µL of this cell suspension was incubated with 5 µL of the supplied annexin
V-AF488 and 1 µL of PI (100 µg/mL) for 15 min at 23°C while protected from light. The
percentages of annexin V-AF488-positive and PI-positive cells were determined from the
fluorescence of at least 20,000 cells measured on an EMD Millipore Guava easyCyte flow
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cytometer. All treatments were carried out as triplicates. Data were analyzed using InCyte
software (EMD Millipore).

3.3.10 Statistical analysis
Statistical differences between groups were determined using an unpaired Student’s
two-tailed t-test. A p value of < 0.05 was considered statistically significant (* p < 0.05,
** p < 0.01, *** p < 0.001). All data are presented as mean ± SD.

3.4 Results and Discussion

3.4.1 Fn3 proteins from further evolved library bind MSLN with high affinity
Our previously reported MSLN-binding Fn3 proteins were engineered from a naïve
yeast surface display Fn3 library [36,47] (Figure 3.1A, B) and their moderate affinity for
cell surface MSLN motivated additional rounds of directed evolution.

Following

mutagenesis of our second generation library, the third generation library was subjected to
two rounds of MACS, a FACS sort for full-length expression and four iterative rounds of
dual-color FACS for binding to MSLN. The resultant population yielded enrichment of
evident MSLN-binding clones (Figure 3.1C). Sequence analysis of individual clones
identified three dominant variants: 3.1.6, 3.4.4 and 3.4.5 (Figure 3.1D). All three variants
included a shared single mutation in the BC binding loop compared to previously reported
Fn3 clones 1.4.1 and 2.4.1 [Sirois et al., “Fn3 Proteins Engineered to Recognize Tumor
Biomarker Mesothelin Internalize upon Binding.”36]. Single framework mutations N63K
and D3Y are incorporated into clones 3.1.6 and 3.4.4, respectively. In addition to the D3Y
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mutation, variant 3.4.5 incorporates three further framework mutations, including P64S,
S82Y, and D94N. These variants were transformed into EBY100 yeast surface display
strain and their binding to a range of MSLN concentrations was assessed by flow cytometry
(Figure 3.1E).

Variant 3.4.4 was selected for further binding and therapeutic

characterization.

3.4.2 Soluble Fn3 protein selectively binds the surface of MSLN-positive cancer cells
Fn3 variant 3.4.4 and the non-binding control, Fn3 RDG, both containing a Cterminal His6 tag, were solubly produced in E. coli and high purity of proteins following
metal affinity purification was verified by SDS-PAGE analysis (Figure 3.2A). Equilibrium
binding titrations of Fn3 variant 3.4.4 and Fn3 RDG on A431/H9 and MCF-7 cell lines
were performed (Figure 3.2B). The A431/H9 cell line is an A431 human epidermoid
carcinoma cell line transfected to stably overexpress MSLN on its surface and MCF-7 is a
human breast cancer cell line that does not express MSLN on its surface [2,31,36].
Previously reported Fn3 proteins engineered to bind cell surface MSLN demonstrated
moderate binding affinities (KD > 400 nM) [36]. The Fn3 variant reported here, 3.4.4,
binds to MSLN-expressing A431/H9 cells with a binding affinity of KD = 19 ± 1 nM, while
displaying no binding to the MSLN-negative control cell line, MCF-7. The nonbinding
control also showed no detectable binding to the A431/H9 cell line (Figure 3.2B).

3.4.3 Engineered Fn3 protein reduces the viability of MSLN-positive cancer cells
The effect of Fn3 variant 3.4.4 on cell viability was studied using the CCK-8 assay
based on WST-8, a water-soluble tetrazolium salt that is reduced by dehydrogenase to
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produce a yellow formazan dye. The amount of formazan dye generated by dehydrogenase
activity is directly proportional to the number of living cells.
The KB-3-1 cell line is a human cervical carcinoma cell line reported to express
moderate levels of MSLN on its surface [48], while the T-47D cell line is a human breast
carcinoma cell line that is not known to endogenously express MSLN [49]. While H9 cells
that were transfected to express high levels of MSLN were ideal for binding assays, we
chose the endogenously expressing KB-3-1 cells for therapeutic characterization of Fn3
3.4.4. Using an anti-MSLN antibody, high levels of MSLN were confirmed on the surface
of KB-3-1 cells, and no MSLN was detected on the surface of T-47D cells (Figure 3.3A).
We tested the cytotoxic effect of concentrations of 3.4.4 protein based on the measured
dissociation constant, selecting to test concentrations equivalent to the dissociation
constant (20 nM) and one order of magnitude above (200 nM) and below (2 nM) the
dissociation constant. After 48 h of treatment, Fn3 variant 3.4.4 significantly reduced (p <
0.05) the number of viable cells in the KB-3-1 cell line in a dose-dependent manner (Figure
3.3B), but did not affect viability of the T-47D cell line (Figure 3.3C). The non-binding
Fn3 RDG control demonstrated no effect on cell viability for either cell line. In contrast to
the MSLN-dependent effect of Fn3 variant 3.4.4, non-targeted chemotherapeutic MMC
significantly reduced (p < 0.001) the viability of both the MSLN-positive and MSLNnegative cell lines (Figure 3.3B, C).

3.4.4 Treatment with Fn3 protein induces apoptosis of MSLN-positive cancer cells
We evaluated the induction of apoptosis on KB-3-1 cells after 3.4.4 treatment,
measured by flow cytometry following staining with fluorescently labeled annexin-V and
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PI (Figure 3.4). Annexin V in combination with PI can discriminate between viable cells,
early apoptotic cells, late apoptotic cells, and cells in necrosis [50]. Cells that are viable
and intact do not stain with either annexin V or PI, cells that are in the early stages of
apoptosis undergo changes that alter the cell membrane and allow the incorporation of
annexin V but still exclude PI, and cells that are in the late stages of apoptosis are stained
with both annexin V and PI once PI can penetrate a degrading membrane and intercalate
into nucleic acids. Cells that are necrotic but not from apoptosis have a permeable
membrane and stain with PI but not with annexin V.
After 48 h of treatment, Fn3 variant 3.4.4 significantly increased the number of
apoptotic cells compared to vehicle-treated cells (Figure 3.4A, B). The number of early
and late apoptotic cells increased from the untreated levels when treated with Fn3 3.4.4 (p
<0.001 for increase in early apoptosis, p < 0.05 for increase in late apoptosis), and the
number of necrotic cells also increased with treatment (p < 0.001). Cells treated with the
non-binding control Fn3 RDG demonstrated no increase in apoptosis or necrosis compared
to vehicle-treated cells (Figure 3.4C, D).

3.4.5 Fn3 protein induces apoptosis of MSLN-positive cancer cells in a caspaseindependent manner
We examined whether the observed apoptosis of MSLN-positive tumor cells from
variant 3.4.4 treatment was executed via a caspase-mediated pathway. Caspases typically
play a key role in apoptosis [51,52], therefore we assessed the activity of the executioner
caspases, caspases-3 and -7 (Figure 3.5). KB-3-1 cells were treated with 3.4.4, Fn3 RDG,
or MMC. After 48 h of treatment, caspase 3/7 activities were significantly increased in the
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MMC-treated cells (p < 0.001) compared to vehicle-treated cells, while neither treatment
with Fn3 3.4.4 nor negative control Fn3 RDG demonstrated increased caspase activity over
vehicle treatment (Figure 3.5A).
The biochemical pathways associated with apoptosis, and the time required to
detect activation of these different biochemical pathways, are variable and dependent on
cell line, specific apoptosis inducer, biochemical events assayed, and the time at which
events are assayed [53]. To confirm 3.4.4 treatment did not induce caspase activation at
earlier time points, we monitored caspase-3/7 activities over an extended time course.
Compared with vehicle-treated cells, 3.4.4-treated cells showed no increase in caspase-3/7
activities when measured at 6, 12, 24, or 36 h (Figure 3.5B).

3.4.6 Decreased cell viability and increased apoptosis is not due to MSLN
downregulation
We investigated whether the observed 3.4.4-induced apoptosis was due to
downregulation of surface MSLN. Aberrant signaling via overexpressed receptors is
implicated in many cancers and interruption of this process can cause antitumor effects
[54].

Signaling abrogation mechanisms include blocking ligand binding, inhibiting

downstream signaling pathways following receptor binding, and receptor downregulation
[55,56]. Ligand-induced endocytosis and degradation of receptor is known to be a
significant process by which growth-promoting signals are interrupted [55,57–63]. There
is previous evidence that direct reduction of surface levels of MSLN by shRNA or siRNA
inhibits cell proliferation, migration, and invasion, and sensitizes cancer cells to
chemotherapeutics and induces apoptosis [19,25,27,28,64]. To examine if MSLN receptor
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downregulation contributed to the observed decrease in MSLN-positive tumor cell viability
and increase in apoptosis following 3.4.4 treatment, we measured levels of MSLN on the
surface of treated tumor cells using an antibody recognizing MSLN and flow cytometry.
We did not detect any changes in surface levels of MSLN on KB-3-1 tumor cells over a
time course of 48 h compared to untreated cells, when cells were treated with either variant
3.4.4 or non-binding negative control Fn3 RDG (Figure 3.6), indicating that apoptosis
induction was not mediated by receptor downregulation.

3.4.7 Fn3 protein enhances sensitivity of KB-3-1 and OVCAR-3 cells to
chemotherapeutic mitomycin C
We evaluated the combined effect of MSLN-binding Fn3 protein and standard
chemotherapeutic MMC on MSLN-positive KB-3-1 cells and OVCAR-3 cells. Having
observed that variant 3.4.4 increased MSLN-positive cell apoptosis, but not through
caspase activation and not through receptor downregulation, we hypothesized that 3.4.4
may act most directly on survival pathways of the tumor cells, accelerating the apoptosis
of cells that were naturally beginning down an apoptosis pathway. If 3.4.4 had this effect
of supporting apoptosis, then we hypothesized that treatment of MSLN-positive cells with
variant 3.4.4 could increase the sensitivity of cells exposed to a chemotherapeutic agent,
when the treatments were administered in combination. Combination therapy has become
standard practice in the clinic for cancer therapy [65]. Targeting multiple, essential tumor
pathways is often more effective than monotherapies, and can promote robust anti-cancer
effects while minimizing the likelihood that resistant cancer cells will develop [65,66].
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When MSLN-positive KB-3-1 cells were simultaneously treated with MSLNbinding Fn3 protein 3.4.4 and chemotherapeutic MMC, the cancer cells exhibited enhanced
sensitivity to MMC compared to KB-3-1 cells treated with either Fn3 3.4.4 or MMC alone
(Figure 3.7A, B). The percentage of total apoptotic cells increased significantly when
comparing cells treated with 200 nM Fn3 3.4.4 to cells treated with the combination of 1
µM of MMC and 200 nM of Fn3 3.4.4 (23 ± 3% and 62 ± 3%, p-value < 0.001) and when
comparing cells treated with 1 µM of MMC to cells treated with the combination of 1µM
of MMC and 200 nM of Fn3 3.4.4 (44 ± 5% and 62 ± 3%, p-value < 0.01) (Figure 3.7B).
To determine if a similar therapeutic effect would be observed for another MSLNpositive tumor cell line, we repeated the combination therapy experiment with OVCAR-3
ovarian carcinoma cells (Figure 3.7C, D), a cell line with a moderate level of MSLN
expression (Figure 3.8A). OVCAR-3 cells provide an interesting comparison to KB-3-1
cells because while KB-3-1 cells do not express CA125, which is a native binding partner
for MSLN, the OVCAR-3 cells do express high levels of CA125 (Figure 3.8B). The
percentage of total apoptotic cells increased significantly when comparing cells treated
with 200 nM Fn3 3.4.4 to cells treated with 1 µM of MMC and 200 nM of Fn3 3.4.4 (35 ±
1% and 71 ± 7%, p-value < 0.001) and when comparing cells treated with 1 µM of MMC
to cells treated with 1µM of MMC and 200 nM of Fn3 3.4.4 (42 ± 2% and 71 ± 7%, pvalue < 0.01) (Figure 3.7D).
These results highlight the potential of targeting MSLN with biologic therapeutics
in combination therapy with traditional chemotherapeutics for more selective, synergistic
treatment of tumors expressing MSLN. Such combination therapy can allow a reduction
in chemotherapeutic dose, reducing the nonspecific toxic side effects of non-selective
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cytotoxic agents. Building on the recent successes of antibody-drug conjugates, one
promising approach is to create a protein-drug conjugate, coupling a chemotherapeutic to
an engineered Fn3 variant that targets MSLN, merging targeted drug delivery with
combination therapy and further reducing nonspecific toxicities. We anticipate that the
highly stable structure of the Fn3 scaffold and the lack of native disulfide bonds will
facilitate the development of strategies to synthesize Fn3-drug conjugates for targeted
combination therapy of MSLN-positive tumors.

3.5 Conclusion
In summary, we have successfully engineered a non-antibody Fn3 protein that
binds cancer antigen MSLN with high affinity and specificity, and has a targeted
therapeutic effect on MSLN-positive tumor cells, reducing cell viability and increasing
apoptosis. Further, the Fn3 protein engineered to bind MSLN increases the sensitivity of
tumor cells to a common chemotherapeutic agent when used as a combination therapy. In
recently reported work, treatment with anetumab ravtansine, a MSLN-specific antibodydrug conjugate, not only inhibited tumor growth in ovarian cancer models as a
monotherapy, but also exhibited an additive effect when used in combination with targeted
agents and standard chemotherapeutics [32]. Together, this current report and the recent
results of related research validate that molecules developed to target MSLN are promising
for both monotherapy and combination therapy for patients who do not currently have any
targeted treatment options.
Interestingly, the apoptosis of KB-3-1 cells induced by the non-antibody Fn3
variant 3.4.4 does not occur via caspase activation, and we do not observe downregulation
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of levels of MSLN on the tumor cell surface of KB-3-1 cells following treatment with
3.4.4. The absence of these commonly observed pathways for targeted treatment of tumor
cells suggests that a currently unknown alternate pathway is engaged in the KB-3-1 tumor
cell response to variant Fn3 3.4.4. Future research exploring relevant pathways for 3.4.4induced tumor cell death, in the tumor cell lines used in this paper and in other cell lines
expressing MSLN, has the potential to uncover and further elucidate important signaling
pathways for MSLN-positive tumor cells, informing ongoing efforts to design effective
targeted treatments for patients with tumors expressing MSLN. We are also interested in
working to understand if and how Fn3 3.4.4 may modulate the interaction of MSLN and
native binding partner CA125, building on our observation that OVCAR-3 cells had
enhanced response to 3.4.4 treatment alone compared to the 3.4.4 treatment response of
KB-3-1 cells. This difference in response could be related to potential disruption of MSLN
and CA125 interactions by 3.4.4, which would only be relevant for the MSLN+/CA125+
OVCAR-3 cells. Combination therapy with molecules targeting MSLN and molecules
targeting CA125 is another approach warranting further study.
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3.7 Figures

Figure 3.1 Engineering and characterization of a third generation anti-mesothelin
Fn3 library. (A) The human fibronectin type III (Fn3) protein scaffold has a highly stable
structure with loops that are suitable for mutation to engineer novel molecular recognition
properties (PDB 1TTG). (B) The Fn3 library sequence [47]. (C) Indicated yeast libraries
displaying Fn3 variants were labeled with an antibody to a terminal c-myc epitope tag and
25 nM biotinylated, Fc-tagged MSLN. Unsorted refers to the original naïve library.
Generation 1 refers to the library following four rounds of FACS. Generation 2 refers to
the library following one round of mutagenic PCR and four rounds of FACS. Generation
3 refers to the library that has undergone mutagenic PCR twice, with four rounds of FACS.
(D) Selected clones from a third generation library demonstrate further evolved sequences
when compared to our previously reported clones. (E) Individual clones were displayed
on the surface of yeast and incubated with a range of concentrations of biotinylated, Fctagged MSLN. Experimental triplicate data were collected, and the dissociation constant is
reported as the mean ± SD of the KD values calculated for each replicate. A representative
binding curve is shown for each variant.
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Figure 3.2 Fn3 protein variant 3.4.4 selectively binds tumor cell-surface MSLN with
high affinity. (A) Engineered Fn3 clone 3.4.4 and Fn3 RDG were expressed in bacteria
and purified to high purity (>99%) as analyzed by SDS-PAGE. Fn3 3.4.4 expected
molecular weight: 13 kDa, Fn3 RDG expected molecular weight: 11 kDa. (B) Binding of
3.4.4 and Fn3-RDG to cell surface MSLN were measured using equilibrium binding
assays. H9 cells express MSLN, MCF-7 cells do not express MSLN. The assays were
performed as experimental triplicates. Data from each replicate were fit to a sigmoidal
curve, and a KD value was calculated as the concentration yielding the half-maximal value.
The KD is reported as the mean ± SD. Representative binding curves are shown.
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Figure 3.3 Fn3 protein decreases the viability of MSLN-positive cancer cells. (A)
Analysis by flow cytometry confirms MSLN presence on the surface of KB-3-1 cells
(white histogram, solid line) as detected by an anti-MSLN antibody. The T-47D cell line
does not express MSLN (gray histogram, solid line). Dashed line, unstained T-47D cells.
(B) KB-3-1 and (C) T-47D cells were treated with various concentrations of 3.4.4, Fn3
RDG, or MMC for 48 h. Treated cells were subjected to a CCK-8 assay to measure cell
viability, which was normalized to vehicle-treated cells. Error bars indicate mean ± SD (n
= 9); * p < 0.05, *** p < 0.001 as determined with an unpaired Student’s two-tailed t-test.
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Figure 3.4 Fn3 protein induces apoptosis in MSLN-positive cancer cells. Induction of
apoptosis of KB-3-1 cells following Fn3 3.4.4 treatment was evaluated by staining with
annexin-V and PI. (A, C) KB-3-1 cells were treated with 3.4.4 or Fn3 RDG, then stained
with annexin-V AF488 and PI and analyzed by flow cytometry. A representative plot of
each treatment is shown. Viable cells (annexin-V-/ PI-) are in the lower left quadrant, early
apoptotic cells (annexin-V+/ PI-) are in the lower right quadrant, late apoptotic cells
(annexin-V+/ PI+) are in the upper right quadrant, and necrotic cells (annexin-V-/ PI+) are
in the upper left quadrant. Vehicle varies slightly between two treatments, and each vehicle
control is shown separately. (B, D) Quantitative analysis of induction of apoptosis and
necrosis after treatments. Data are presented as the mean ± SD (n = 3). * p < 0.05, *** p <
0.001 as determined with an unpaired Student’s two-tailed t-test.
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Figure 3.5 Analysis of caspase 3/7 activation in MSLN-positive cells treated with Fn3
protein. (A) KB-3-1 cells were treated with 3.4.4, Fn3 RDG, or MMC for 48 h, and caspase
3/7 activation was analyzed. Positive control chemotherapeutic MMC induced caspase
activation, while Fn3 3.4.4 and negative control Fn3 RDG did not activate caspases. Error
bars indicate mean ± SD (n = 9). *** p < 0.001 as determined with an unpaired Student’s
two-tailed t-test. (B) Treatment of KB-3-1 cells with Fn3 3.4.4 also did not activate caspase
3/7 over the indicated time points. Error bars indicate mean ± SD (n = 3).
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Figure 3.6 Surface MSLN expression is not downregulated following treatment with
Fn3 variant 3.4.4. KB-3-1 cells that express MSLN were incubated with 3.4.4 (red square)
or Fn3 RDG (blue circle). At the specified time points, surface MSLN was quantified via
flow cytometry with an antibody that binds MSLN. Surface MSLN levels relative to
untreated KB-3-1 cells are plotted as a function of time. Error bars indicate mean ± SD (n
= 3). No significant downregulation of surface MSLN was observed, as determined with
an unpaired Student’s two-tailed t-test.
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Figure 3.7 Treatment with Fn3 variant 3.4.4 enhances sensitivity of KB-3-1 cells and
OVCAR-3 cells to chemotherapeutic. Induction of apoptosis of KB-3-1 cells and
OVCAR-3 cells following treatment with 3.4.4, MMC, or MMC in combination with Fn3
3.4.4 was evaluated by staining with annexin-V and PI. (A) KB-3-1 and (C) OVCAR-3
cells were treated with 200 nM Fn3 3.4.4, 1 µM MMC, or 1 µM MMC and 200 nM Fn3
3.4.4, then stained with annexin-V AF488 and PI and analyzed by flow cytometry. A
representative plot of each treatment is shown. Viable cells (annexin-V-/ PI-) are in the
lower left quadrant, early apoptotic cells (annexin-V+/ PI-) are in the lower right quadrant,
late apoptotic cells (annexin-V+/ PI+) are in the upper right quadrant, and necrotic cells
(annexin-V-/ PI+) are in the upper left quadrant. (B, D) Quantitative analysis of induction
of apoptosis in (B) KB-3-1 cells and (D) OVCAR-3 cells after treatments. Data are
presented as the mean ± SD (n = 3). ** p < 0.01, *** p < 0.001 as determined with an
unpaired Student’s two-tailed t-test.
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Figure 3.8 OVCAR-3 cells co-express mesothelin and CA125 on cell surface. (A)
Analysis by flow cytometry confirms MSLN presence on the surface of OVCAR-3 cells
(while histogram, solid line), as detected by an anti-MSLN antibody. (B) OVCAR-3 cells
also express CA125, as detected by an anti-CA125 antibody (while histogram, solid line).
The KB-3-1 cell line does not express CA125 (gray histogram). Dashed line indicates KB3-1 cells stained with secondary antibody only.
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CHAPTER 4
PROTEIN-POLYMER CONJUGATES SYNTHESIZED USING WATERSOLUBLE AZLACTONE-FUNCTIONALIZED POLYMERS ENABLE
RECEPTOR-SPECIFIC CELLULAR UPTAKE FOR TARGETED DRUG
DELIVERY
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4.1 Abstract
Conjugation of proteins to drug-loaded polymeric structures is an attractive strategy
for facilitating target-specific drug delivery for a variety of clinical needs. Polymers
currently available for conjugation to proteins generally have limited chemical versatility
for subsequent drug loading. Many polymers that do have chemical functionality useful
for drug loading are often insoluble in water, making it difficult to synthesize functional
protein-polymer conjugates for targeted drug delivery. In this work, we demonstrate that
reactive, azlactone-functionalized polymers can be grafted to proteins, conjugated to a
small molecule fluorophore, and subsequently internalized into cells in a receptor-specific
manner. Poly(2-vinyl-4,4-dimethylazlactone) (PVDMA) synthesized using reversible
addition-fragmentation transfer (RAFT) was modified post-polymerization with
substoichiometric equivalents of triethylene glycol monomethyl ether (mTEG) to yield
reactive water-soluble, azlactone-functionalized copolymers. These reactive polymers
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were then conjugated to proteins holo-transferrin and ovotransferrin. Protein gel analysis
verified successful conjugation of proteins to polymer, and protein-polymer conjugates
were subsequently purified from unreacted proteins and polymers using size exclusion
chromatography. Internalization experiments using a breast cancer cell line that
overexpresses the transferrin receptor on its surface showed that the holo-transferrinpolymer conjugate was successfully internalized by cells in a mechanism consistent with
receptor-mediated endocytosis. Our approach to protein-polymer conjugate synthesis
offers a simple, tailorable strategy for preparing bioconjugates of interest for a broad range
of biomedical applications.

4.2 Introduction
Treatment of numerous diseases could benefit from improved options for targeted
delivery of drugs to disease-specific locations. Two important challenges in medicine for
which targeted delivery could significantly improve patient outcomes are delivery of
therapeutics to the central nervous system and delivery of chemotherapeutics selectively to
tumor cells.

The blood-brain barrier (BBB) frequently prevents therapeutics from

sufficiently accessing brain tissue, creating a major bottleneck for developing treatments
for diseases like Alzheimer’s disease and brain tumors [1,2]. Often, drug development
efforts for neurological diseases must focus on small molecule candidates constrained by
a set of physicochemical properties that can facilitate their passage across the BBB [3].
Receptor-mediated transcytosis (RMT) is a promising approach being developed to use
native transport pathways to shuttle larger therapeutic complexes across the BBB [4,5].
Initial reports of the ongoing clinical trials for the first RMT-based therapeutic to be used
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in humans have been positive [6], encouraging continued development of therapeutics
using RMT pathways for drug delivery.
Specific targeting of chemotherapeutic agents to tumor cells could significantly
reduce toxic side effects that are currently caused by the systemic distribution of
administered cytotoxic drugs in the body [7]. In recent years, substantial progress has been
made toward the general goal of targeted therapy using both passive and active targeting
approaches [7]. For example, antibody-drug conjugates have been developed that rely on
the specific targeting of tumor biomarkers using antibodies to deliver a toxic payload to
tumor cells [8–10]. There are, however, challenges with finding appropriate chemistries
for conjugating the drug to the antibody, with continued need for improved linkers between
antibodies and their drug payload that do not inhibit antibody targeting and that can release
drug when the conjugate has reached the desired location [8]. Inorganic and polymeric
nanocarriers have also been explored for both passive and active targeting [11,12].
Although several nanocarriers that passively target tumor cells have been approved for
clinical use, no actively targeted nanocarriers have advanced past clinical trials to date [12].
There remains a need for better drug carriers that actively target pathological cells.
Active targeting of drug carriers to particular cell types is generally achieved by
conjugating a drug carrier to a ligand that binds specific cell-surface receptors. Drug
carriers include polymers and nanoparticles, and ligands can be proteins, peptides, or
certain small molecules [7,11,12]. Proteins are particularly useful as targeting ligands
because they exhibit precise binding interactions with molecular partners.

Protein

engineering permits the manipulation of these binding interactions such that a given
targeting protein can be engineered to meet identified design parameters, such as a desired
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affinity or binding epitope on the receptor [13,14]. Consequently, proteins, including
antibodies and other protein classes, have found wide success on their own as therapeutics
for a variety of diseases [15,16]. To be useful as a targeting ligand for drug delivery
applications, proteins that interact with a chosen disease marker need to be chemically
coupled to the drug to be delivered. Versatile and straightforward chemistries to conjugate
drugs to proteins are still needed [8]. Polymers that link targeting proteins to drug
molecules are a promising avenue for developing a modular strategy for synthesizing
targeted drug delivery molecules, where any targeting protein of interest could be readily
coupled to a drug molecule linked by a polymer that couples to protein and to drug. Here,
we report the development of protein-polymer conjugates for targeted drug delivery
applications.
Protein-polymer conjugates are being used in a variety of applications in medicine
and industry [17–19]. The first generation of protein-polymer conjugates were comprised
of polyethylene glycol (PEG) attached to therapeutic proteins to extend the circulation time
and reduce the immunogenicity of the therapeutics. Over the past several decades, more
than a dozen PEGylated molecules have been approved for use in humans [20–22]. While
PEG continues to be the leading polymer for preparing clinically-relevant protein-polymer
conjugates, PEG does have limitations, such as non-degradability and potential
immunogenicity [23], that necessitate the development of protein-polymer conjugates with
an expanded selection of finely tuned functionalities.
Numerous advances in the development of protein-polymer conjugates with
expanded chemistries useful for biomedical applications have been reported in recent years
[17–19,24,25].

Strategies for controlled polymerization [19,24–26] and site-specific
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conjugation [24,25,27–34] of polymers to proteins have facilitated the synthesis of more
well-defined protein-polymer conjugates. Site-specificity and control of polymer synthesis
are jointly achieved with approaches that grow polymers from proteins functionalized with
an initiator at a unique location in the protein sequence [24,31,33]. While growing
polymers from appropriately-functionalized proteins, termed ‘grafting-from,’ affords more
easily purified conjugates [19,25,26], the grafting-from approach does limit to some extent
the chemistries that can be incorporated into the polymer structure. In addition, graftingfrom requires a new polymer to be synthesized each time the bioconjugate is prepared,
which may lead to small variations in the polymer structure, even when controlled methods
are used. In a ‘grafting-to’ approach, preformed polymers bearing end-group or side-chain
reactive functionality are conjugated to proteins [25,35,36].

A number of different

chemistries have been used to facilitate grafting of polymers to proteins, including
polymers bearing amine-reactive functionality such as NHS-esters or anhydrides
[25,36,37], maleimide or dibromomaleimide functionality for reaction with cysteine
residues [25,36,38–40], and biorthogonal “click” reactions [25,34,36,41]. Grafting-to
permits incorporation of both water-soluble and water-insoluble functionalities into the
polymer structure. For example, hydrophobic drugs are an important class of waterinsoluble molecules that can be incorporated into polymer structures when using the
grafting-to approach. Grafting-to also allows conjugation of a defined polymer structure
to a variety of different proteins.
In the work reported here, we explored the use of side-chain reactive polymers for
the preparation of protein-polymer conjugates via a grafting-to approach. Side-chain
reactive polymers and their subsequent post-polymerization modification [42–45] offer
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opportunities for combinatorial synthesis of a broad range of polymer structures such that
the influence of polymer structure on bioconjugate properties can be easily explored [46].
Furthermore, these reactive groups could be used to tether drug molecules to the scaffold
before protein conjugation. In particular, hydrophobic drugs can be more readily coupled
to a polymer in organic solvent compared to directly coupling a hydrophobic drug to a
protein in aqueous solution. From a drug delivery perspective, a polymer with a tunable
number of sites for drug attachment is desirable because it permits intentional selection of
the number of drug molecules per protein-polymer conjugate. Such flexibility in drug
loading enables targeting an appropriate concentration in the body within a particular
drug’s therapeutic window. It is then possible to achieve a sufficiently high concentration
of the drug at the disease site to have a desired therapeutic effect while remaining below
concentrations in the body that cause unacceptable toxicities. The ability to conjugate a
variety of active drug molecules directly to protein residues is more difficult than
approaches that use a delivery scaffold.
We used the reactive polymer poly(2-vinyl-4,4-dimethylazlactone) (PVDMA,
Figure 4.1) to prepare a series of protein-polymer conjugates. PVDMA is attractive for the
preparation of bioconjugates for several reasons. It can be synthesized from the vinyl
monomer using a variety of polymerization methods [43,45,47]. In this current work, we
synthesized PVDMA using reversible addition-fragmentation chain transfer (RAFT)
polymerization, which has been demonstrated previously to yield well-defined azlactonefunctionalized polymers (Figure 4.1A) [47–50]. Importantly for this work, the fivemembered lactone of PVDMA rapidly undergoes ring-opening reactions with
nucleophiles, such as amines and alcohols, including those found in native proteins [45,51].
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Thus, a broad range of polymeric structures and bioconjugates can be readily synthesized
starting from the same template polymer. While azlactone-functionalized polymers have
been used to immobilize proteins on a variety of solid supports or thin films [45,51], only
a few examples of soluble protein-polymer conjugates have been reported [48,52,53]. For
example, Fontaine and coworkers demonstrated the feasibility of using the azlactone
functional group for conjugation of polymers to lysozyme [48,52] while Weeks et al.
reported the conjugation of recombinant elastin-like polypeptides to PVDMA [53].
However, because PVDMA is not inherently water-soluble, these previous reports used
organic solvents to conjugate the protein to the polymer [48,52,53].
In this work, we demonstrate the feasibility of synthesizing water-soluble,
azlactone-functionalized polymers and conjugating these reactive polymers to diseaserelevant proteins. Stover and coworkers reported the synthesis of water-soluble azlactonefunctionalized polymers through copolymerization of the azlactone monomer VDMA with
a series of water-soluble comonomers [54]. Others have demonstrated that PVDMA can
be rendered water soluble by exhaustive functionalization with appropriate side chain
functionality [55]. In this report, we functionalized PVDMA with substoichiometric
amounts of triethylene glycol monomethyl ether (abbreviated mTEG) to prepare reactive,
water-soluble polymers (PVDMA-mTEG, Figure 4.1A). This polymer readily conjugates
to the proteins holo-transferrin (hTF) and ovotransferrin (OTF) in aqueous solution (Figure
4.1B). hTF represents a useful model protein for the development of targeted drug delivery
scaffolds because the protein binds to and is internalized by cell-surface transferrin
receptors (TFR) present on endothelial cells that comprise the blood brain barrier and
expressed at high levels on many tumor cells [56]. hTF has also been used recently in the
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synthesis of protein-polymer conjugates and shown to facilitate receptor-specific targeting
of conjugates to cells expressing the transferrin receptor [57]. Using confocal microscopy
assays, we show that hTF-PVDMA-mTEG conjugates are internalized specifically into a
tumor cell line that expresses TFR. This work exemplifies a modular approach for
synthesizing protein-polymer conjugates and offers a new system that can be easily tailored
for targeted drug delivery to a variety of disease-specific cell types.

4.3 Results and Discussion

4.3.1 Synthesis and characterization of mTEG-functionalized PVDMA
PVDMA was synthesized using RAFT polymerization [58] (Figure 4.1A, step 1)
to yield a well-defined homopolymer with Mn = 13.1 kg/mol (Table 4.1). Water-soluble
azlactone-functionalized polymers for protein conjugation were synthesized by treating the
homopolymer with 0.3 equivalents of mTEG relative to the azlactone repeat unit (Figure
4.1A, step 2). DBU was used as a base catalyst and all reactions were stirred at 40 °C
overnight. Figure 2A shows FT-IR spectra of PVDMA homopolymer and PVDMA treated
with mTEG. The IR spectrum of PVDMA prior to functionalization (Figure 4.2A, black
dashed curve) reveals peaks characteristic of the carbonyl (1820 cm-1) and imine (1670 cm1

) bonds of the azlactone ring. Treatment of PVDMA with 0.3 equivalents of mTEG (red

curve) leads to a decrease in the carbonyl and imine peaks and the appearance of peaks at
1735 cm-1 (ester), 1650 cm-1 (amide I), and 1540 cm-1 (amide II) that result from ringopening of the lactone with an alcohol nucleophile. Quantitative analysis of mTEG
functionalization using NMR spectroscopy revealed that mTEG was incorporated into the
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polymer in nearly quantitative yield (Table 4.1). GPC analysis of PVDMA functionalized
with mTEG revealed an increase in molecular weight consistent with functionalization of
the polymer (Table 4.1). GPC analysis also confirmed that no polymer crosslinking
occurred during treatment with mTEG, based on observing no increase in dispersity
comparing polymer before and after mTEG functionalization. The absence of crosslinking
is expected since mTEG only has one nucleophile that is reactive with the azlactone group.
Finally, while PVDMA can be functionalized with larger amounts of mTEG, polymers
modified with 0.3 equivalents proved to be soluble in water. Thus, this polymer, referred
to hereafter simply as PVDMA-mTEG, was used for all experiments described here to
provide the greatest number of remaining reactive groups in the polymer for additional
modifications and protein conjugation.
One potential challenge associated with using the azlactone moiety for protein
conjugation in aqueous solution is that these groups are susceptible to hydrolysis.
However, hydrolysis reactions are typically slower than reactions of azlactones with
amines. Furthermore, azlactone groups have been shown to persist for several hours in
water when copolymerized with certain water soluble monomers [54]. To qualitatively
characterize the rate of hydrolysis of PVDMA-mTEG, we acquired IR spectra of a polymer
dissolved in water (Figure 4.2B) over time. The series of spectra shown in Figure 4.2B
reveal that the lactone carbonyl peak (1820 cm-1) persists for at least 12 hours. The polymer
fully hydrolyzes in 24 hours as evidenced by the complete disappearance of the lactone
carbonyl peak at 1820 cm-1 (Figure 4.2B). Based on these data, we hypothesized that,
following functionalization with mTEG, sufficient azlactones would remain on the
polymer to permit reaction with amines on a protein (i.e., the N-terminus or lysine
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residues), but that all residual azlactone groups would fully hydrolyze during or after
protein conjugation.

This latter hydrolysis reaction is desirable to avoid unwanted

reactions of the polymer with proteins on cells in cell internalization experiments.

4.3.2 Protein holo-transferrin conjugates to PVDMA-mTEG
For our initial experiments, holo-transferrin (hTF) was selected to determine the
feasibility of conjugating proteins to PVDMA-mTEG. hTF is an 80 kDa glycoprotein
containing 58 lysine residues (UniProt P02787) and is the native protein ligand for the
transferrin receptor (TFR) [56]. Upon binding its receptor, hTF gets internalized into cells
through receptor-mediated endocytosis. The hTF-TFR interaction is of interest for a
variety of clinical applications [56].

For example, receptor-mediated transcytosis

facilitated by TFR has been studied for drug delivery across the blood-brain barrier to the
central nervous system [59]. TFR is also overexpressed in many cancers, which makes it
an interesting receptor system to be used as a model for targeted drug delivery to tumor
cells [60]. Because PVDMA reacts readily with the primary amines in the N-termini and
lysine residues in proteins [45,51], hTF provides ample reactive sites for conjugation.
Conjugates were prepared by incubating PVDMA-mTEG with hTF in phosphate
buffered saline (PBS) containing 15% v/v DMSO at 4 °C. Low concentrations of DMSO
are commonly used to facilitate conjugation of reactive small molecules and polymers to
proteins [37,61]. We examined a range of molar ratios of polymer:protein for hTF
conjugation reactions. Successful conjugation of polymer to protein was assessed using
SDS-PAGE (Figure 4.3). Lane 1 contains pure hTF protein with no polymer. Lane 2
contains PVDMA-mTEG polymer with no protein, which is not detected by the protein gel
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stain. Lanes 3 through 6 include conjugation reactions in which the amount of protein was
kept constant while the amount of PVDMA-mTEG was increased. Lane 3 reveals the
presence of a faint band at higher molecular weight than the hTF protein band. The
apparent molecular weight of this band is consistent with the molecular weight of one
protein and one polymer molecule, suggesting the formation of conjugates at a 1:1 molar
ratio of protein:polymer. With higher amounts of polymer in the conjugation reaction
(Figure 4.3, lane 4-6), we observe a band at a molecular weight consistent with a
protein:polymer molar ratio of 1:2. Increasing the molar amount of polymer relative to
protein resulted in a darkening of this higher molecular weight band. We do not observe
any protein bands at a molecular weight that suggests two or more proteins in a conjugate
molecule with at least one polymer. While all reactions show residual unreacted protein,
as demonstrated by the presence of the original protein band in lanes 3-6, the intensities of
these bands are increasingly reduced compared to the intensity of the protein only sample
shown in lane 1. The same amount of total protein was loaded into lanes 1 and 3-6, and,
therefore, reduction in the original protein band intensity further suggests successful
protein-polymer conjugation. Taken together, these data demonstrate that hTF conjugates
to PVDMA-mTEG through reactive, azlactone functionality in aqueous solution.

4.3.3 Protein-polymer conjugates can be purified by size exclusion chromatography
Prior to use in receptor targeting experiments with a human cell line, proteinpolymer conjugates were purified from unreacted protein and unreacted polymer. Samples
were first concentrated and purified from low molecular weight species by using a
centrifugal filtration device with a 10 kDa molecular weight cut-off (MWCO) before being
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loaded onto a size exclusion chromatography (SEC) column. Samples were analyzed by
detecting absorbance at 220 nm. Pure hTF protein exhibits a single narrow peak on SEC
(Figure 4.4A, red solid curve). PVDMA-mTEG exhibits a broad high molecular weight
peak and a narrow low molecular weight peak (Figure 4.5A). Unpurified protein-polymer
conjugates eluted at shorter retention times (i.e., higher molecular weight) relative to hTF
only and included low molecular weight species similar to polymer only samples (Figure
4.4A, black dashed curve). We were able to collect the high molecular weight proteinpolymer conjugate peak, which no longer contained unreacted protein when analyzed by
SEC (Figure 4.4A, red dashed curve) and SDS-PAGE (Figure 4.4B).

Because the

molecular weight of the polymer is less than the molecular weight of the protein, we
anticipate that most or all of the unreacted polymer was removed through SEC purification.
However, because polymer alone does not stain on the protein gel, it is possible that some
unreacted polymer remains following SEC purification.
The purified protein-polymer conjugates contained a mixture of conjugates at
protein:polymer ratios of 1:1 and 1:2 (Figure 4.4B). On SEC, we did not observe any
products of the conjugation reaction that would suggest more than one protein per
conjugate, based on analysis of retention time of the protein-polymer conjugation reactions.
However, it is possible that any conjugates with two proteins joined by one or more
polymers may elute at a longer retention time than would be predicted for a globular protein
of the same molecular weight, so it remains possible that some protein-polymer conjugates
containing two proteins exist in our reaction mixture. The lack of molecules in the
conjugation reaction mixture eluting at less than 20 min retention time does conclusively
indicate a lack of higher order aggregates.
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4.3.4 Fluorescent, hydrophobic small molecule can be coupled to PVDMA-mTEG
prior to polymer conjugation to protein
To permit visualization of protein-polymer conjugates in the presence of cells using
fluorescence imaging techniques, we fluorescently labeled PVDMA-mTEG with the
amine-functionalized fluorophore fluorescein cadaverine (FC, labeled polymer denoted as
PVDMAFC-mTEG). Coupling a small molecule fluorophore directly to the polymer
models a way in which drugs could be tethered to the polymer for future drug delivery
applications. FC was reacted with PVDMA-mTEG in DMSO in a molar ratio of FC to
VDMA monomer such that 1-2 molecules of FC were coupled to each polymer chain.
Many small molecule drugs are hydrophobic, and the ability to couple drugs to polymer in
organic solvent prior to an aqueous reaction conjugating polymer to protein is an advantage
of our approach. We then coupled the fluorescently labeled PVDMAFC-mTEG to hTF and
to the protein ovotransferrin (OTF). OTF is the chicken homolog of human transferrin. It
has the same overall structure and size as human hTF, but is sufficiently distinct in
sequence that it does not bind to human TFR [62], making OTF conjugates a suitable
negative control for TFR binding and internalization experiments. FC labeled proteinpolymer conjugates were purified from unreacted molecules by SEC as described above,
yielding a single pure peak when analyzed by SEC (Figure 4.6A). The peak exhibits
absorbance at 220 nm (Figure 4.6A, top) and at 494 nm (Figure 4.6A, bottom). Absorbance
at 494 nm is characteristic of the fluorophore, and is absent in the sample of pure protein,
indicating successful conjugation of FC to polymer, and subsequent conjugation of
PVMDAFC-mTEG to protein.

Analysis of the purified FC labeled protein-polymer

conjugates using UV-visible spectroscopy resulted in absorbance peaks at 280 nm and 494
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nm (Figure 4.6B). In pure hTF protein, there is only an absorbance peak at 280 nm. In
PVDMA-mTEG without FC conjugation, we see no absorbance peaks in the UV-visible
range, as expected (Figure 4.5B). The presence of the 494 nm absorbance peak in the FCcoupled PVMDA-mTEG and in the purified protein-polymer conjugates confirms that FC
was successfully conjugated to PVDMA-mTEG and that PVDMAFC-mTEG subsequently
was able to be conjugated to hTF and OTF.

4.3.5 Internalization of protein-polymer conjugates into cells is receptor-specific
We next determined that protein-polymer conjugates are specifically internalized
through receptor-mediated endocytosis. MCF-7 breast cancer cells have been shown to
overexpress the transferrin receptor on their surface and have been previously used to study
internalization of molecules targeted to TFR [63,64]. Flow cytometry with an antibody
that recognizes human TFR confirmed high levels of surface TFR expression on the MCF7 cell line (Figure 4.7A). A titration binding assay was performed with fluorescently
labeled hTF and MCF-7 cells to determine an appropriate concentration of protein or
protein-polymer conjugate for cell internalization experiments.

We determined a

dissociation constant (KD) of 10 ± 5 nM (Figure 4.7B), which is consistent with previously
reported values [56]. A biological interpretation of the KD is that half of the receptors are
occupied by ligand when the ligand concentration is equal to the KD. In subsequent
conjugate internalization experiments, we incubated MCF-7 cells with 10 nM of conjugates
to provide ample ligand to visualize receptor-specific internalization, without
overwhelming the receptor internalization machinery.
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All internalization experiments were conducted by incubating protein-polymer
conjugate samples or control samples with MCF-7 cells for 1 h at 37 °C in culture media
without serum. These conditions are on the time scale and at the relevant temperature for
receptor-mediated endocytosis to occur in MCF-7 cells [65]. Prior to imaging, all cells
were stained with phalloidin (shown by red fluorescence), which binds to actin filaments
and demarcates cell boundaries, and DAPI (shown by blue fluorescence), which stains cell
nuclei. All protein, protein-polymer, and polymer samples were fluorescently labeled with
either Alexa Fluor 488 (AF488, samples with protein only) or FC (all polymer-containing
samples) and are shown as green fluorescence.
Row 1 of Figure 4.8 shows confocal microscopy images for MCF-7 cells stained
with DAPI and phalloidin to identify nuclei and actin filaments, but with no protein,
polymer, or conjugates added; these images show the level of background cellular
autofluorescence in the channel that was used to visualize targeting molecules. Row 2 of
Figure 4.8 shows confocal microscopy images for MCF-7 cells incubated with 10 nM hTF488. The green channel and merged images show punctate regions of green fluorescence
distributed throughout the cell body (cell boundaries shown in red channel), indicating
internalization of the protein. The presence of punctate structures is consistent with protein
localized to endosomes after receptor-mediated endocytosis. When treated with increasing
concentrations of hTF-488, MCF-7 cells show increased levels of internalization (Figure
4.9), also consistent with receptor-mediated endocytosis. To further demonstrate that
ligand-receptor interactions are necessary for internalization, we conducted a competition
experiment in which cells were treated with hTF-488 (10 nM) and a 1000-fold excess of
unlabeled hTF (10 µM) (Figure 4.8, row 3). As expected, when labeled protein was in
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competition with an excess of unlabeled protein, green fluorescence signal within the cell
body was reduced to the level of background autofluorescence (Figure 4.8, row 3). The
results of these control experiments demonstrate that hTF is internalized into our MCF-7
cells via a mechanism consistent with receptor-mediated endocytosis.
Confocal microscopy images of MCF-7 cells treated with hTF conjugated to
PVDMAFC-mTEG (Figure 4.8, row 4) exhibited punctate regions of green fluorescence
throughout the cell body, similar to results observed with hTF-488.

These results

demonstrate successful internalization of the conjugates. A competition experiment similar
to that described above for hTF-488 was performed in which cells were treated with hTFPVDMAFC-mTEG conjugate in the presence of 1000-fold excess (10 µM) unlabeled hTF.
The green channel and merged confocal microscopy images for this experiment (Figure
4.8, row 5) reveal the reduction of green signal to the level of autofluorescence, indicating
that the internalization of hTF-targeted protein-polymer conjugates is dependent on
specific binding of hTF to TFR. Internalization of hTF-488 and of hTF-PVDMAFC-mTEG
molecules was further demonstrated by collecting a series of images from neighboring
confocal planes of clusters of cells, termed z-stacks, confirming that green fluorescence is
present within cells, rather than on the cell surface (Supporting Video 1 and Video 2).
We explored whether non-specific polymer interactions substantially contributed
to the binding and internalization signal we observed for hTF-PVDMAFC-mTEG (Figure
4.10). We co-incubated hTF-PVDMAFC-mTEG with an excess of unlabeled PVDMAmTEG, and observed no noticeable reduction in signal, suggesting that non-specific
interactions of the polymer with the cell surface are not necessary for binding and
internalization (Figure 4.10, row 1). To further confirm that specific ligand-receptor
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interactions are required for internalization, we examined potential binding and
internalization of the negative control protein-polymer conjugate, OTF-PVDMAFC-mTEG,
which was not expected to bind any MCF-7 cell surface receptors. OTF is a chicken
transferrin, and MCF-7 cells express human TFR. We did not observe any MCF-7 cell
binding or internalization of OTF protein directly labeled with AF488 (Figure 4.10, row
2). Similarly, we also did not observe MCF-7 cell binding or internalization of the nontargeted OTF-PVDMAFC-mTEG (Figure 4.10, row 3). Finally, fluorescently labeled
polymer not conjugated to any protein (PVDMAFC-mTEG) does not adhere to or
internalize into MCF-7 cells (Figure 4.10, row 4).

These results provide further

confirmation that hTF-PVDMAFC-mTEG conjugates are internalized via specific
interactions of the hTF ligand with cell surface receptor TFR, rather than through nonspecific interactions of polymer with the cells.
When conjugating polymers to proteins, there is the risk that the polymer will
destabilize the protein structure, or that the polymer will sterically block the interaction of
a protein ligand with its receptor, rendering the protein-polymer conjugate irrelevant for
the intended application.

Importantly, the protein-polymer conjugate internalization

experiments we have conducted demonstrate that hTF protein maintains its ability to bind
and be internalized by TFR when conjugated to PVDMA-mTEG, suggesting that hTF
maintains its structure and function when conjugated to PVDMA-mTEG.

4.4 Conclusion
We have developed a new, modular strategy for conjugating diverse proteins to
hydrophilic polymers using the reactive, azlactone-functionalized polymer PVDMA with

160

the goal of developing conjugates for applications in targeted drug delivery. In our
approach, we first functionalized PVDMA with mTEG to render the polymer watersoluble. We demonstrated the conjugation of this reactive polymer with proteins in
aqueous solution.

When the targeting protein holo-transferrin was conjugated to a

fluorescently-labeled analog of PVDMA-mTEG, protein-polymer conjugates were
internalized into tumor cells expressing the TFR in a receptor-specific manner.
Internalization of hTF-PVDMA-mTEG conjugates into human cells expressing
TFR has implications for targeted delivery to the central nervous system and to tumor cells
with overexpressed receptors [4,56,60,66–68]. Our approach to synthesizing proteinpolymer complexes for drug delivery could be extended to encompass protein ligands that
bind other receptors relevant for a variety of clinical needs to generate protein-polymerdrug conjugates for diverse targeted drug delivery applications. Although in this initial
report proteins were conjugated to PVDMA through primary amines contained naturally
in the native protein sequences, both the targeting protein and the polymer could be further
modified for site-specific conjugation reactions.
While the experiments described here focused on mTEG-modified PVDMA, this
post-polymerization modification approach to the synthesis of multifunctional
bioconjugates permits rapid and straightforward access to a broad range of macromolecular
structures without requiring the synthesis of new polymers each time a new structure is to
be investigated.

For example, diverse side chain chemistries and degrees of

functionalization can readily be explored. In addition, because the polymer modification
reactions are conducted initially in organic solvents, non-water soluble functionality, such
as hydrophobic drugs, may be incorporated into the polymer prior to conjugation to the
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proteins. The synthetic versatility of PVDMA and ease with which it can be conjugated to
proteins offers opportunities for preparing a range of bioconjugates tailored to specific
biomedical applications.

4.5 Experimental Procedures

4.5.1 Materials
Triethylene glycol monomethyl ether (mTEG), 1,8-diazabicylo[5.4.0]undec-7-ene
(DBU), 2,2’-azobis(2-methylpropionitrile) (AIBN), 2-(dodecylthiocarbonothioylthio)-2methylpropionic acid, ovotransferrin (OTF), 4-iodoanisole, and anhydrous dioxane were
purchased from Sigma Aldrich and used without further purification unless otherwise
noted.

The monomer 2-vinyl-4,4-dimethylazlactone (VDMA) was synthesized as

previously described [69]. Fluorescein cadaverine (FC) was purchased from Biotium.
Alexa Fluor 488 tetrafluorophenyl ester, NuPAGE 4-12% Bis-Tris gels, MES buffer, and
LDS buffer were purchased from ThermoFisher Scientific. Inhibitor removal resin was
purchased from Alfa Aesar. Holo-transferrin (HTf, Cat.: 616397) was purchased from
CalBiochem. PBS (10X) were purchased from Fisher Scientific. THF was purified using
alumina drying columns. All other solvents were purchased from Pharmco-AAPER
(Brookfield, CT). Deuterated DMSO (DMSO-d6) and deuterated chloroform (CDCl3) were
purchased from Cambridge Isotope Laboratories, Inc.

Dulbecco’s Modified Eagle’s

Medium (DMEM) was purchased from ATCC, and all other cell culture reagents were
obtained from Gibco. Phalloidin conjugated to Alexa Flour 594 was purchased from
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Thermo Fisher, formaldehyde as a 3.7% solution in PBS was from Fisher Scientific, and
Vectashield mounting medium with DAPI was from Vector Labs.

4.5.2 General considerations
1

H-NMR spectra were collected on a Bruker 500 MHz NMR spectrometer.

Attenuated total reflectance infrared (ATR-IR) spectra were obtained using a Bruker
ALPHA FTIR spectrometer and analyzed using OPUS software version 7.5.

Gel-

permeation chromatography (GPC) was performed on an Agilent 1260 GPC instrument
equipped with PLgel Mixed C and Mixed D columns and an RI detector, operating in THF
at 40 °C with a flow rate of 1 mL/min. Molecular weights and dispersities were measured
against polystyrene calibration standards. SEC was performed using a Superdex 75 10/300
GL column (GE) and an Agilent 1200 series liquid chromatography system.

Flow

cytometry was performed on a Guava easyCyte flow cytometer (Millipore-Sigma). Laser
scanning confocal microscopy images were acquired on a Leica TCS SP5 laser scanning
confocal microscope and analyzed using LAS AF software version 2.7.3.9723.

4.5.3 Synthesis of poly(2-vinyl-4,4’-dimethylazlactone) (PVDMA)
VDMA was passed through a phenolic inhibitor removal resin followed by passage
through a short plug of silica gel prior to polymerization.

The initiator 2,2′-

azobisisobutyronitrile (AIBN) was recrystallized twice from methanol prior to use. AIBN
(5.9 mg, 0.036 mmol, 0.5 equiv.) and CTA (26 mg, 0.072 mmol, 1 equiv.) was weighed
into a 25 mL schlenk-flask equipped with a stir bar. Anhydrous toluene (4.5 mL) was
added to the flask and the mixture was stirred to dissolve the AIBN. VDMA (1.5 g, 10.8
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mmol, 150 equiv.) was added to the flask, the flask was capped with a septum and placed
in a dry ice and isopropanol bath at ~7 torr. Atmosphere was purged from the flask using
three freeze-pump-thaw cycles and filled with nitrogen. The reaction solution was stirred
at 70 °C for 12 h (~85% conversion). The slightly viscous reaction mixture was cooled to
room temperature and acetone (~3 mL) was added to the flask. The polymer was
precipitated twice into hexanes to yield a pale yellow solid (1.26 g, 92% yield). 1H-NMR
(500 MHz, CDCl3): δ = 1.37 (br s, (-CH3)2), 1.62-2.1 (br m, -CH2CH-), 2.69 (br s, -CH2CH
). FT-IR (ATR, cm-1): 2980-2900 (C-H), 1820 (lactone C=O), 1672 (C=N). GPC: Mn =
13.1 kg/mol; PDI = 1.35.

4.5.4 Synthesis of PVDMA-mTEG
PVDMA (100 mg, 0.72 mmol with respect to the molecular weight of the repeat
unit VDMA) and mTEG (35 mg, 0.216 mmol, 0.3 equiv.) were combined in a 5 mL roundbottomed flask and dissolved in anhydrous THF (3 mL). DBU (16.1 µL, 0.108 mmol, 0.15
equiv.) was added to catalyze the reaction. 4-Iodoanisole (50.5 mg, 0.216 mmol, 0.3 equiv)
was added as an internal standard for determining degree of functionalization. The flask
was capped with a rubber septum and purged with nitrogen for 15 minutes. The reaction
was stirred at 40 °C for 10 h. Prior to purification, an aliquot (~0.2 mL) of the reaction
mixture was removed for 1H NMR analysis to determine the degree of mTEG
functionalization. The remaining polymer solution was purified by precipitation into
diethyl ether (100 mL) followed by centrifugation (9,000xg at 4℃, 2 min) to yield a yellow
product.

1

H-NMR (300 MHz, CDCl3): δ = 1.37-1.50 (br m, (-CH3)2), 1.62-2.1 (br m, -

CH2CH-), 2.5 (br s, -CH2CH-), 2.84 (br s, -CH2CH-), 3.38 (br s, CH3-O-), 3.45-3.65 (br m,
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-CH2-O-), 4.22 (br s, -C(=O)O-CH2). FT-IR (ATR, cm-1): 2880-2900 (C-H), 1820 (lactone
C=O), 1735 (ester C=O), 1672 (C=N), 1650 (amide C=O), 1540 (amide II CN and NH).

4.5.4.1 PVDMAFC-mTEG
PVDMA-mTEG (50 mg, 0.26 mmol relative to the repeat unit) was dissolved in
anhydrous DMSO (1 mL) in a 1.5 mL microcentrifuge tube. Fluorescein cadaverine (FC)
(0.95 mg, 1.3 µmol) was dissolved in anhydrous DMSO (9.5 µL) and added to the polymer
solution. The reaction was mixed by gentle rotation for 2 h at room temperature.

4.5.4.2 Hydrolyzed PVDMAFC-mTEG
Unreactive, hydrolyzed PVDMAFC-mTEG used for control experiments was
synthesized by dissolving PVDMAFC-mTEG (100 mg) in DMSO (2 mL) in a 5 mL round
bottom flask. Water (95.7 mg, 5.32 mmol, 10 eq relative to the azlactone repeat unit) and
DBU (202 mg, 1.33 mmol, 2.5 eq relative to the azlactone repeat unit) was added and the
solution was allowed to react at 40 °C for 3 h. Complete hydrolysis was confirmed using
ATR-FTIR spectroscopy. Samples were then dialyzed against PBS for 24 h (MWCO =
3.5 kDa) to remove any small molecule impurities, including unreacted fluorophore, prior
to incubation with cells. FT-IR (ATR, cm-1): 3500-2600 (O-H), 2880-2900 (C-H), 1725
(carboxylic acid C=O), 1650 (amide C=O), 1540 (amide II CN and NH).

4.5.5 PVDMA-mTEG hydrolysis study
PVDMA-mTEG (244 mg, 1.32 mmol relative to the repeat unit) was dissolved in
anhydrous DMSO (4.9 mL). PBS (11 mL) was added to simulate the concentration of
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polymer used in a 1:50 molar ratio conjugation of hTF to polymer. At each time point (0.5,
1, 3, 5, 9, 12, 24, 36 hours), a 1 mL sample (15.3 mg of polymer) was flash frozen in liquid
nitrogen and freeze dried. The samples were dissolved in acetone and cast directly onto
the ATR crystal for analysis by FT-IR spectroscopy.

4.5.6 Synthesis of protein-polymer conjugates
Proteins (i.e., hTF and OTF) were conjugated to polymer using the following
general procedure. Protein stock solutions of 1 mg/ml were prepared in PBS with 0.1 M
sodium bicarbonate (pH = 8.0), to increase the reactivity of the primary amines of the
protein. Polymer samples (i.e., PVDMA-mTEG or PVDMAFC-mTEG) (50 mg) were
dissolved in DMSO (1 mL) in a microcentrifuge tube. A 1 ml aliquot of the desired protein
(1 mg) was added to polymer solution to achieve a protein:polymer molar ratio of 1:50,
where a mole of polymer was calculated using data from GPC analysis. The molecular
weight of a monomer of VDMA is 139 g/mol. Therefore, a molar ratio of 1 mol protein:
50 mol polymer is equivalent to a molar ratio of 1 mol protein: 241 mol VDMA monomer.
For studies examining the effect on conjugation of the molar ratio of protein:polymer
molecules, ratios of 1:5, 1:10, 1:20, and 1:50 were compared. The samples were reacted
at 4 oC with gentle rotation overnight. Samples were then dialyzed against PBS for 24 h
(MWCO = 3.5 kDa) if the sample was not being purified by SEC.

4.5.7 Analysis of protein-polymer conjugates by SDS-PAGE
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used
to analyze conjugation of protein to polymers. NuPAGE LDS buffer (4X) was added to
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each sample to a final concentration of 1X, without reducing agent. All proteins studied
contain disulfide bonds, and therefore the absence of reducing agents can shift their
apparent molecular weight from the predicted molecular weight. The samples were heated
in a water bath for 10 min at 70 °C to denature the proteins. Samples were loaded onto a
NuPAGE 4-12% Bis-Tris gel. The gel was run in NuPAGE MES running buffer (1X).
Gels were then stained with Simply Blue Safe Stain.

4.5.8 Protein-polymer conjugate purification
Protein-polymer conjugation reactions were first concentrated and purified from
low molecular weight species using a centrifugal filtration device with a MWCO of 10 kDa
(EMD Millipore) and extensive washing with PBS. The protein-polymer conjugation
reaction was then purified by SEC on a Superdex 75 10/300 column (GE Healthcare Life
Sciences). Fractions of interest were pooled and concentrated with a centrifugal filtration
device with a 10 kDa MWCO. All samples were analyzed by SDS-PAGE and imaged on
a BioRad ChemiDoc MP imaging system using Image Lab 6.0 software (BioRad).

4.5.9 Cells, cell culture, and receptor detection
The MCF-7 human breast cancer cell line (ATCC #HTB-22, acquired in 2018) was
used to test internalization of protein-polymer conjugates via receptor-mediated
endocytosis of TFR. MCF-7 cells were cultured at 37 °C in a humidified atmosphere with
5% CO2 in DMEM with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml
streptomycin. Cells were subcultured after reaching 80% confluency using 0.25% trypsinEDTA. The presence of human TFR on the surface of MCF-7 cells was confirmed with
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an anti-human TFR antibody directly labeled with fluorescein isothiocyanate (antibody
clone CY1G4, from BioLegend, Cat.: 334103). MCF-7 cells were harvested with 0.05%
trypsin-EDTA. 1 x 106 cells were incubated with antibody at a 1:20 dilution in PBS with
0.1% bovine serum albumin (PBSA) for 30 min at room temperature with gentle rotation.
Cells were washed with PBSA to remove unbound antibody, resuspended in PBSA, and
analyzed by flow cytometry.

4.5.10 Labeling hTF and OTF with Alexa Fluor-488
Holo-transferrin (hTF) or ovotransferrin (OTF) (1-2 mg/mL) were labeled with
AF488 by primary amine chemistry. Sodium bicarbonate (1M stock solution) was added
to the protein to a final concentration of 0.1 M to change the pH of the solution to 8.0. The
fluorescent dye AF488 5-tetrafluorophenyl ester was dissolved in anhydrous DMSO to a
final concentration of 11.3 nM. Dye was added to protein solution, using an amount of dye
calculated following manufacturer’s protocol to achieve a desired molar excess of dye. The
sample was incubated with gentle rotation at room temperature for 1 h. Labeled protein
was purified from free dye and concentrated using an Amicon centrifugal filtration device
with a molecular weight cutoff of 10 kDa by washing extensively with PBS.
Concentrations and degree of labeling were determined by UV-Vis spectroscopy,
measuring dye absorption at 494 nm (e = 71,000 cm-1 M-1).

4.5.11 Titration binding assay of hTF-488 with MCF-7 cells
Titration binding assays were performed to experimentally determine the binding
affinity (dissociation constant, KD) of hTF with MCF-7 cells. MCF-7 cells were harvested
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with 0.05% trypsin-EDTA. Aliquots of 1x105 cells were incubated for 1 h at 4°C with a
range of concentrations of fluorescently labeled hTF (hTF-488, 0.5-500 nM) in PBS with
0.1% BSA (PBSA) with gentle rotation. Following incubation to reach equilibrium
binding, cells were washed in PBSA and resuspended in PBSA for analysis. Data were
collected and analyzed using flow cytometry. Experimental triplicate data were collected
to determine the binding affinity of hTF to its receptor. For each replicate, the data were
fit to a sigmoidal binding curve using Kaleidagraph software (Synergy). The concentration
of hTF-488 that resulted in the half-maximal value of each best-fit line was determined as
the KD. The mean of the three individually fit dissociation constants was determined and
reported with the standard deviation.

4.5.12 Internalization assays and confocal microscopy
MCF-7 cells were seeded in a 4-well Millipore EZ chamber slide using 4x104
cells/well and allowed to establish adherence and reach 50-80% confluency. The media
was then replaced with serum-free DMEM containing the specified conjugate sample in a
500 µl total volume. hTF-488, hTF-PVDMAFC-mTEG, OTF-488, or OTF-PVDMAFCmTEG were added to the wells to a final concentration equivalent to 10 nM of protein per
well. For the internalization sample with hydrolyzed PVDMAFC that was not conjugated
to protein, an amount of polymer equivalent to the amount of polymer in 10 nM of proteinpolymer conjugate was used, as determined by measurement of samples by UV-vis
spectroscopy, using absorbance at 494 nm due to the presence of fluorophore. For
competition experiments with unlabeled hTF, 10 µM unlabeled hTF was included. For
the competition experiment with excess unlabeled polymer, 0.5 mg of hydrolyzed
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PVDMA-mTEG was included. Samples were incubated for 1 h at 37°C in a humidified
environment with 5% CO2. Media with samples were removed, and cells were washed
with PBS. Cells were fixed with 3.7% formaldehyde for 5-10 minutes at room temperature,
and washed with PBS. Cells were permeabilized by incubation with 0.1% Triton X-100 in
PBS at room temperature for 5 min, and washed with PBS. Actin filaments were stained
with an Alexa Fluor 594 conjugate of phalloidin to help identify cell boundaries by adding
250 µl per well of phalloidin in PBS diluted following manufacturer’s protocol, and cells
were washed with PBS. Wells were removed from the slide and Vectashield mounting
media containing DAPI for staining cell nuclei was applied to the fixed samples. Samples
were then covered with 1.5 mm glass coverslips and sealed with transparent nail polish.
Samples were imaged using a 63X oil immersion objective. Images were collected using
sequential scanning, and an overlay of the sequential images was used to analyze
internalization, for single focal plane images and for z-stacks collected as a series of
neighboring focal planes.
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4.7 Tables

Table 4.1 Characterization of polymers by NMR spectroscopy and GPC.
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4.8 Figures

Figure 4.1 Synthesis of protein-polymer conjugates via a modular grafting-to
approach using water-soluble, azlactone-functionalized polymers. (A) PVDMA was
synthesized by RAFT polymerization and functionalized with a substoichiometric
equivalent of mTEG (0.3 molar eq. relative to repeat unit) to make the polymer soluble in
water (PVDMA-mTEG). (B) PVDMA-mTEG can be subsequently grafted to a protein,
including holo-transferrin shown here (PDB 3V83).
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Figure 4.2 Water-soluble, azlactone-functionalized copolymers can be synthesized by
post-polymerization modification of PVDMA. (A) FT-IR spectra of PVDMA (black
dashed curve) and PVDMA modified with 0.3 molar equivalents (Eq.) of mTEG relative
to the repeat unit (red curve). The peaks at 1820 cm-1 (carbonyl) and 1670 cm-1 (imine) are
characteristic of the azlactone ring. Ring opening of the lactone with an alcohol nucleophile
results in the disappearance of the azlactone peaks and the appearance of ester (1720 cm1
), amide I (1650 cm-1), and amide II (1540 cm-1) peaks. (B) FT-IR spectra as a function of
time of PVDMA-mTEG incubated in water. FT-IR spectra revealed the disappearance of
the azlactone carbonyl (1820 cm-1) peak and an increase in the peaks at 1735 cm-1
(ester+carboxylic acid carbonyl), 1650 cm-1 (amide I), and 1540 cm-1 (amide II). The strong
peak at 1710 cm-1 corresponds to acetone, which was used to cast the polymer film on the
ATR crystal. The legend refers to time in hours following dissolution of PVDMA-mTEG
in water.
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Figure 4.3. Protein hTF conjugates to PVDMA-mTEG. Holo-transferrin (hTF)
conjugates to PVDMA-mTEG in aqueous solution. The appearance of higher molecular
weight bands and decrease in intensity of primary protein band indicate protein conjugation
to polymer. Protein amounts in each lane were held constant. Lane 1 contains protein only,
lane 2 contains PVDMA-mTEG only. Lanes 3-6 contain unpurified protein-polymer
conjugation reactions at an increasing amount of polymer relative to protein, keeping
amount of protein constant. Molar ratios of protein to polymer molecules in reactions are:
lane 3 = 1:5; lane 4 = 1:10; lane 5 = 1:20; lane 6 = 1:50. Samples are not reduced. Apparent
molecular weights of the two protein-polymer conjugate bands are most consistent with
protein:polymer conjugate ratios of 1:1 and 1:2.
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Figure 4.4 Purification of hTF-PVDMA-mTEG conjugates. (A) SEC was used to
analyze and purify hTF-PVDMA-mTEG conjugates from unreacted hTF and from
unreacted PVDMA-mTEG. Larger molecules have a shorter retention time. Pure hTF
protein (red solid line) exhibits a single narrow peak for absorbance at 220 nm. The
protein-polymer conjugation reaction (black dashed line) has overlapping peaks that
include an unreacted hTF peak and a new larger molecule with shorter retention time
consistent with protein-polymer conjugates, as well as a low molecular weight peak from
polymer byproducts. There are no peaks in the conjugation reaction that elute < 20 min,
indicating the absence of higher order protein-polymer aggregates. Following collection
of the protein-polymer conjugate peak and reinjection onto SEC, a narrow peak is observed
as purified hTF-PVDMA-mTEG (red dashed line). (B) SDS-PAGE analysis of hTF (lane
1), protein-polymer conjugation reaction before purification (lane 2), and SEC purified
hTF-PVDMA-mTEG conjugate (lane 3) demonstrates successful purification of
conjugates using SEC. In the purified product (lane 3), unreacted hTF is absent. Polymers
are at lower molecular weight than hTF and should therefore also be removed by SEC
purification. Molecular weights of purified conjugates are consistent with protein:polymer
ratios of 1:1 and 1:2. Samples are not reduced.
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Figure 4.5 PVDMA-mTEG analysis by size exclusion chromatography and UV-Vis
spectroscopy. (A) PVDMA functionalized with 0.3 molar equivalents of mTEG was
analyzed on a Superdex 75 30/100 SEC column run at 0.4 ml/min, and absorbance was
detected at 220 nm and at 494 nm. For absorbance at 220 nm, the functionalized polymer
sample contained a broad peak characteristic of polymers with a molecular weight
distribution eluting between 20 and 30 minutes, and a second peak of low molecular weight
byproducts eluting around 50 minutes. There was no absorbance at 494 nm. (B) PVDMAmTEG analyzed using UV-Vis spectroscopy has no absorbance in the 240-700 nm range,
as expected for the polymer.
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Figure 4.6 Fluorescent, hydrophobic small molecule can be coupled to polymer and
protein-polymer conjugates. Small molecule fluorophore fluoresceine cadaverine (FC)
was conjugated to PVDMA-mTEG, and the resulting PVDMAFC-mTEG was conjugated
to hTF or OTF. (A) SEC was used to purify and analyze hTF-PVDMAFC-mTEG and OTFPVDMAFC-mTEG conjugates from unreacted component molecules. A single peak for
hTF-PVDMAFC and for OTF-PVDMAFC with retention time shorter than for the
corresponding protein alone, and with absorbance at 220 nm (top) and for 494 nm (bottom),
demonstrates small molecule fluorophore incorporation into the purified protein-polymer
conjugates. Protein alone does not absorb at 494 nm. The FC molecule absorbs at 494 nm.
(B) UV-Vis absorption spectra for hTF protein, PVDMAFC-mTEG, purified hTFPVDMAFC-mTEG, and purified OTF-PVDMAFC-mTEG. The characteristic absorption
peaks for protein (*) and FC (**) are indicated at 280 nm and 494 nm, respectively.
Concentrations of samples differ, resulting in different heights of absorbance peaks.
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Figure 4.7 MCF-7 cells express TFR and bind hTF. (A) MCF-7 cells, which are a human
breast cancer cell line, express high levels of transferrin receptor (TFR) on their surface, as
detected by an anti-human TFR antibody directly conjugated to fluorescein and analyzed
by flow cytometry. (B) The binding of hTF to TFR was measured as the dissociation
constant (KD) using an equilibrium binding assay. MCF-7 cells were incubated with a range
of concentrations of hTF directly labeled with Alexa Fluor 488 (hTF-488). The assay was
performed in experimental triplicate. Data from each replicate were fit to a sigmoidal curve,
and the KD value was calculated for each replicate. The KD is reported as the mean +/standard deviation. A representative binding curve is shown.
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Figure 4.8 hTF-PVDMAFC-mTEG targeted protein-polymer conjugates are
internalized into MCF-7 cells through receptor-specific interactions. Cells not treated
with protein or protein-polymer conjugate exhibit a low background level of
autofluorescence in the green channel (row 1). As a positive control, holo-transferrin
protein directly labeled with fluorophore (hTF-488) is internalized into MCF-7 cells that
express transferrin receptor, as seen by green punctate structures throughout the cell body
(row 2). hTF-488 internalization can be blocked by competition with an excess of
unlabeled hTF protein (row 3). Fluorescently labeled polymer conjugated to human holotransferrin (hTF-PVDMAFC-mTEG) is similarly internalized into the cell line (row 4).
Competition between hTF-PVDMAFC-mTEG and excess unlabeled hTF blocks
internalization and reduces signal to the level of autofluorescence (row 5), indicating that
binding and internalization of the protein-polymer conjugate is mediated by specific
interactions between hTF its receptor, TFR. Cells were incubated with samples for 1 h at
37 °C to allow receptor-mediated internalization to occur. Blue indicates DAPI stain for
cell nuclei; red indicates phalloidin conjugated to Alexa Fluor 594, which stains actin
filaments and helps to identify cell boundaries; and green indicates the protein or proteinpolymer conjugate, with positive control protein labeled with Alexa Fluor 488 or polymer
labeled with fluorescein cadaverine. Scale bar shown applies to all images.
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Figure 4.9 hTF-488 internalization into MCF-7 cells is concentration dependent.
MCF-7 cells, which are a human breast cancer cell line, express high levels of transferrin
receptor (TFR) on their surface. Fluorescently labeled holo-transferrin (hTF-488) was
internalized into the cells after incubation for 1 h at 37 °C. Increasing the concentration of
hTF-488 from 10 nM to 100 nM to 1000 nM (rows 1, 2, and 3) showed increasing
internalization, as visualized by increasing green signal within the cell boundaries and at
the cell surface. Blue indicates DAPI stain for cell nuclei; red indicates phalloidin
conjugated to Alexa Fluor 594, which stains actin filaments and helped to identify cell
boundaries; and green indicates the protein fluorophore conjugate labeled with Alexa Fluor
488. Scale bar shown applies to all images.
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Figure 4.10 Polymer does not cause non-specific cell staining for protein-polymer
conjugates. Including excess unlabeled polymer during the internalization period of hTFPVDMAFC-mTEG does not block receptor-specific internalization of hTF-PVDMAFCmTEG (row 1). MCF-7 cells neither bind nor internalize non-targeted chicken
ovotransferrin protein labeled directly with fluorophore (OTF-488) (row 2) or fluorescently
labeled OTF-polymer conjugates (OTF-PVDMAFC-mTEG) (row 3). Fluorescently labeled
polymer not conjugated to protein (PVDMAFC-mTEG) similarly does not stain cells (row
4). Blue indicates DAPI stain for cell nuclei; red indicates phalloidin conjugated to Alexa
Fluor 594, which stains actin filaments and helps to identify cell boundaries; and green
indicates the protein or protein-polymer conjugate, with OTF control protein labeled with
Alexa Fluor 488 and polymer labeled with fluorescein cadaverine. Scale bar shown applies
to all images.
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CHAPTER 5
DEVELOPMENT OF MOLECULES AND ANIMAL MODELS FOR FUTURE
MOLECULAR IMAGING STUDIES

5.1 Introduction
Pancreatic cancer, malignant pleural mesothelioma, and ovarian cancer are all
characterized by extremely poor prognoses, with 5-year survival rates of only 9%, 10%
and 48%, respectively [1]. These low survival rates are attributed to non-specific clinical
symptoms, late detection, and the tendency of these cancers to metastasize early. The
majority of these cancer patients are only diagnosed after their cancer has spread distantly
throughout the body, further limiting treatment options and worsening their prognoses.
Early detection of these cancers, when the disease is still confined to the organ of
origin and more easily treatable, has been shown to drastically reduce overall mortality,
morbidity and medical costs [2]. For example, since the introduction of the simple Pap
smear screening test in 1950, there has been a 70% decline in cervical cancer deaths in
developed countries [3]. For many cancers, however, including the abovementioned
malignancies, early diagnostics are not currently available due to a lack of reliable and
sensitive biomarkers. While measuring the levels of the CA-125 protein in the blood of
ovarian cancer patients can be used to help evaluate therapeutic response, and its level often
declines when a treatment is effective, CA-125 is rarely used for screening purposes
because of its high false positive rates due to the elevated levels of CA-125 that occur for
common benign conditions such a pelvic inflammatory disease and endometriosis [4].
Further, not all ovarian cancer patients have high levels of CA-125. Additionally, the
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majority of cancer funding continues to be allocated towards late stage disease treatments
as opposed to prevention and early detection research. In 2018, less than 11% of funding
was used for prevention and early detection [5]. Molecular imaging is a highly sensitive
and noninvasive diagnostic that could help address the unmet need of early detection of
cancer.

As previously discussed, molecular imaging can detect molecular events

associated with early carcinogenesis, as well as guide appropriate treatments regimens and
assess patients’ responses to therapy. Unfortunately, because of the lack of reliable
biomarkers associated with mesothelioma, pancreatic cancer, and ovarian cancer, very few
imaging agents have been developed for these cancers.
Mesothelin (MSLN) has emerged as an attractive tumor biomarker because of its
limited normal expression profile, with low expression only on normal mesothelial cells,
and high expression in a variety of aggressive cancers, including in 80-85% of pancreatic
cancers, 85-90% of mesotheliomas, and 60-65% of ovarian cancers [6]. Currently, patients
with MSLN-expressing tumors are identified by a tumor biopsy and/or blood testing. As
previously discussed, however, heterogeneous expression of tumor biomarkers, including
MSLN, within a tumor and between a primary tumor and metastases, which may not be
accessible for biopsy, is often observed. Further, serum MSLN levels are not upregulated
in all cancers, such as pancreatic cancer, despite their significant overexpression of
membrane-bound MSLN [7].
Recently, MSLN-specific imaging agents have been developed and evaluated in
preclinical trials using a variety of human cancer mouse models [7–13]. Several of these
imaging probes incorporate radioactively-labeled anti-MSLN antibodies for positron
emission tomography (PET) imaging [8,11]. As previously discussed, antibody-based
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imaging agents are often limited in their clinical utility due to their hepatic elimination and
slow blood clearance. In one study, optimal imaging occurred day four post injection of
the imaging agent because that was when there was maximum tumor uptake. However, the
tumor-to-background ratio was significantly lower at day four because of increasing liver
uptake [11]. In another strategy, authors conjugated a radioactive anti-MSLN antibody to
magnetic nanoparticles for dual PET/ magnetic resonance (MR) imaging [9,10]. In
addition to the delayed imaging protocol required due to poor antibody penetration, there
was rapid sequestration of the colloidal particles from the blood into the liver and spleen
by the reticuloendothelial system [14]. The spleen is an especially problematic off-target
organ because it is composed of lymphatic tissue and is, therefore, highly radiosensitive
and it can interfere with imaging pancreatic tumors due to the two organs’ close anatomical
positions [15].

Most recently, anti-MSLN nanobodies, a class of antigen-binding

fragments derived from naturally occurring antibodies in the serum of camelids, have been
evaluated for single photon emission computed tomography (SPECT) imaging [7,12,13].
The smaller size of

the nanobodies, compared with antibodies, provides optimal

pharmacodynamics and biodistribution properties for same day imaging but SPECT
imaging lacks the specificity and sensitivity of PET imaging [16–18].
In the thesis work reported in this chapter, an Fn3 library engineered for MSLN
binding, as described in previous chapters, was further evolved to acquire binding affinities
relevant for molecular imaging applications, as demonstrated in equilibrium binding assays
with human cancer cell lines. Several human cancer cell lines that express either moderate
or high levels of MSLN expression on their surface were successfully used to form tumor
xenografts when injected into immunocompromised mice. These tumor xenografts were
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confirmed to maintain overexpression of MSLN, as determined by immunohistochemistry,
thereby establishing appropriate in vivo models for molecular imaging studies.

5.2 Materials and Methods

5.2.1 Ethics statement
All animal procedures were performed according to approved Institutional Animal
Care and Use Committee (IACUC) protocols (# 288-15) of Smith College. All procedures
were conducted while animals were under general anesthesia and all efforts were made to
minimize discomfort.

5.2.2 Evolution and maturation of fifth generation Fn3 variants
A Gr2 library previously evolved for MSLN-binding Fn3 variants, as reported in
previous chapters, was further affinity matured as a fifth generation library [21–23].
Briefly, following error-prone PCR with nucleotide analogs, the library was sorted twice
by MACS using biotinylated, Fc-tagged recombinant human MSLN (Acro Biosystems
#MSN-H826x) followed by a FACS selection for full-length clones using an antibody
against the C-terminal c-myc epitope tag. Full-length clones were incubated with a chicken
anti-c-myc antibody and the biotinylated Fc-tagged MSLN. To increase the sorting
stringency, concentrations of MSLN were decreased over three iterative rounds of
enrichment, from 5 nM in the first sort to 1 nM in the third sort. Cells were washed and
incubated with a goat anti-chicken Alexa Fluor-647 (AF647) conjugate and AF488conjugated streptavidin. Cells were washed and double-positive yeast cells were collected
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on a BD BioSciences FACSAria II. Plasmid DNA from the enriched library was recovered
using a Zymoprep Yeast Plasmid Miniprep II kit (Zymo Research) following
manufacturer’s protocol, transformed into bacteria, and individual clones were sequenced
by standard Sanger DNA sequencing methods.

5.2.3 Production and purification of Fn3 variants
MSLN-binding Fn3 variants 5.3.1 and 5.3.2 were prepared as previously described
[22,23].

Briefly, the Fn3 genes were cloned into a pET vector with a C-terminal

hexahistadine tag (plasmid provided by B. Hackel, University of Minnesota) and expressed
in BL21(DE3) E. coli. Cultures were grown in LB and induced overnight at 20°C with 0.5
mM Isopropyl-b-D-thiogalactopyranoside (IPTG). Cells were resuspended in lysis buffer
(35 mM Na2HPO4×dibasic, 15 mM NaH2PO4×monobasic, 500 mM NaCl, 5 mM CHAPS,
25 mM imidazole, 5% glycerol) supplemented with an EDTA-free protease inhibitor
(Pierce), and lysed by repeated freezing and thawing. Soluble fractions were isolated by
centrifugation.

Fn3 variants 5.3.1 and 5.3.2 were purified by cobalt affinity

chromatography with HisPur cobalt resin (Thermo Fisher). Protein samples were buffered
exchanged into 1X PBS and analyzed for purity by SDS-PAGE on a BioRad ChemiDoc
MP imaging system.

5.2.4 Alexa Fluor-488 and -680 dye conjugation
Pure Fn3 5.3.2 protein was incubated with either AF488 tetrafluorophenyl (TFP)
ester or AF680 N-Hydroxysuccinimide (NHS) ester (Thermo Fisher) in a 0.1 M sodium
bicarbonate solution (pH 8.3) at a 10:1 dye/protein molar ratio for 2 hr at 23°C and
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overnight at 4°C with gentle mixing. The conjugates were purified by extensive buffer
exchange with PBS using a 3 kDa centrifugal filter unit. Protein concentrations and DOL
were determined using UV-Vis spectroscopy, measuring dye absorption at 494 nm (e =
71,000 cm-1 M-1) or 679 nm (e = 184,000 cm-1 M-1) for AF488 and AF680, respectively.

5.2.5 Reagents and cell lines
PBSA buffer was composed of phosphate buffered saline (PBS) and 0.1% bovine
serum albumin (BSA). TBSA buffer was composed of tris-buffered saline (TBS) and 1%
BSA. A431/H9 cells (gift of M. Ho, National Cancer Institute, 2016) [19] were cultured
in RPMI-1640 supplemented with 10% FBS, 1% penicillin-streptomycin and 700 µg/mL
Geneticin selective antibiotic (G418) (Thermo Fisher).

KB-3-1 cells (gift of M.

Gottesman, National Cancer Institute, 2016) [20] were cultured in DMEM supplemented
with 10% FBS and 1% penicillin-streptomycin. All cells were grown at 37°C in a
humidified atmosphere containing 5% CO2.

5.2.6 Binding affinity measurements of soluble 5.3.2 for MSLN-positive tumor cells
A431/H9 cells were cultured to 80% confluency, as described above, harvested,
washed, and pelleted at 200g for 5 min at 4°C. MSLN expression was detected by a rabbit
monoclonal anti-MSLN antibody (clone EPR 19025-42, Abcam, 1:50) and a goat antirabbit PE conjugate (Abcam, 1:250). Cells were incubated with a range of concentrations
of AF488-labeled 5.3.2 in PBSA for 1 h at 23°C. Cells were washed and pelleted as above,
resuspended with ice cold PBSA, and fluorescence was analyzed using a Guava easyCyte
flow cytometer. Mean fluorescence intensities for Fn3 variant binding were determined
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using InCyte software. Data was plotted and fit with a sigmoidal curve using KaleidaGraph
software. Dissociation constants (KD) were determined as the half-maximal value of the
sigmoidal fit for three separate experiments, and the mean and standard deviation for the
KD are reported.

5.2.7 Mouse xenograft models and tumor processing
Athymic nude mice (Charles River Laboratory) at 20 weeks of age were
anesthetized with 1-4% isofluorane in oxygen (1 L/min). H9/A431 or KB-3-1 cells (5x106
cells) suspended in 50 µL PBS and 50 µL of Matrigel Basement Membrane Matrix (BD
Biosciences), were injected subcutaneously into the right shoulder of mice to generate
human tumor xenografts. Tumor formation was monitored daily and tumors were excised
when they measured greater than 5 mm in at least two dimensions by caliper. Excised
tumors were fixed in 10% buffered formalin (Fisher Scientific) for 24 h at 4°C. After
fixation, tumors were washed in PBS and stored in 70% ethanol at 4°C. Fixed tumors were
processed using a Leica TP1200 automatic tissue processor. Tumors were placed in
individually labeled cassettes and processed in 70% ethanol for 30 min, 80% ethanol for
30 min, 95% ethanol for 90 mins, 100% ethanol for 90 min, xylene for 90 mins, and
paraffin for 2 h. After processing, the cassettes were removed from the tissue processor
and paraffin-embedded.

5.2.8 Mesothelin immunofluorescence microscopy
Sections (5 µm) of formalin-fixed and paraffin-embedded tumor xenografts were
deparaffinized in xylene and progressively rehydrated from 100% to 50% ethanol and
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rinsed in water. All washing steps between incubations were performed in TBS with gentle
agitation. Tissue sections were subjected to heat-induced epitope retrieval using TrisEDTA (10mM Tris, 1mM EDTA, 0.05% Tween 20, pH 9.0) buffer. Sections were washed
and autofluorescence was blocked by incubation in 0.3M glycine buffer for 10 min at 23°C.
Sections were washed and blocked with 10% normal goat serum (Thermo Fisher) for 1 h
at 23°C. Incubation with rabbit anti-MSLN antibody (Abcam, 1:1500) in TBSA was
performed overnight at 4oC in a humidified chamber. After washing, tissue sections were
incubated with an Alexa Fluor 594 (AF594)-conjugated polyclonal goat anti-rabbit
secondary antibody (Abcam, 1:400) in TBSA for 1 h at 23°C, in a humidified chamber,
and protected from light. Sections were washed and mounted with VectaShield Antifade
Mounting Medium with DAPI (Vector Laboratories). Stained sections were examined
with a Zeiss Axio Imager M2 fluorescent microscope. A negative control omitted the
primary antibody.

5.3 Results and Discussion

5.3.1 Fifth generation Fn3 variants exhibit single nanomolar affinities for MSLN
Our previously reported MSLN-binding Fn3 library [22,23] was further sorted and
affinity matured as a fifth generation library using yeast surface display. Following
additional rounds of mutagenesis, the fifth generation library was subjected to two rounds
of magnetic sorting, a fluorescent-activate cell sort (FACS) for full-length expression and
three iterative rounds of dual-color FACS for binding to MSLN. The resultant population
yielded enrichment of evident MSLN-binding clones and sequence analysis of individual
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clones identified two dominant variants: 5.3.1 and 5.3.2. When displayed on the surface
of yeast, these fifth generation variants demonstrated further enhanced affinity for MSLN
(Figure 5.1). Variant 5.3.1 exhibited a binding affinity of KD = 3.2 +/- 0.4 nM and variant
5.3.2 exhibited a binding affinity of KD = 2.5 +/- 0.4 nM (Figure 5.1).

5.3.2 Fn3 variant 5.3.2 retains high affinity binding to cancer cells expressing MSLN
Because of its high recombinant expression and ease of purification by cobalt
affinity chromatography, Fn3 variant 5.3.2 was further pursued (Figure 5.2A). Soluble Fn3
variant 5.3.2 was directly labeled with AF488 (5.3.2-AF488) and evaluated using
equilibrium binding titrations on A431/H9 cells, a MSLN positive cell line (Figure 5.2B).
In an initial titration, Fn3 5.3.2-AF488, bound to MSLN-expressing A431/H9 cells with a
binding affinity of KD = 7.2 nM.

5.3.3 Mesothelin is overexpressed on the surface of tumor xenografts
Female nude mice (age 20 weeks) were inoculated into their right shoulders with
5x106 cells of either the A431/H9 cell or KB-3-1 cell lines. Mice were monitored daily for
tumor formation. Both mice successfully formed tumors within one week (KB-3-1 cells)
or two weeks (A431/H9 cells) post-inoculation. It was observed that the KB-3-1 tumor
appeared irritated, but did not look inflamed or purulent in any way that would suggest it
had become infected. Instead, because of the size and more midline position of the tumor,
it suffered from abrasions as the mouse entered and exited the provided plastic housing.
On the day of excision, the length (as measured from head to tail), width (as measured from
belly to midline) and depth (as measured from deepest to most superficial tumor tissue of
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the KB-3-1 tumor measured 9 mm x 9 mm x 3 mm (Figure 5.3A). The A431/H9 tumor
measured 6 mm x 6mm x 3 mm (L x W x D) (Figure 5.3B). Both tumors were observed
to have several small blood vessels supplying them.
To confirm tumors generated from A431/H9 and KB-3-1 cells express MSLN on
their surface, excised tumors were evaluated by IHC analysis (Figure 5.4). In agreement
with our in vitro data (Chapter 2), KB-3-1 tumor xenografts maintained high levels of
MSLN on their surface (Figure 5.4, Bottom) compared to a no antibody control (Figure 5.4,
top) and a secondary antibody only control (Figure 5.4, middle). These results validate our
established tumor xenografts as appropriate in vivo models for molecular imaging studies.
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5.5 Figures

Figure 5.1 Affinity maturation of fifth generation anti-mesothelin Fn3 proteins.
Dominant proteins recovered from each generation of our affinity matured Fn3 libraries
were individually displayed on the surface of yeast and incubated with a range of
concentrations of soluble MSLN. The assays were performed in experimental triplicate.
Data from each replicate were fit to a sigmoidal curve and a KD value was calculated for
each replicate. The KD is reported as the mean +/- the standard deviation. A representative
binding curve of each protein is shown.
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Figure 5.2 Fn3 variant 5.3.2 selectively binds tumor cell surface mesothelin with high
affinity. (A) Engineered Fn3 variants 5.3.1 and 5.3.2 were expressed in bacteria with a Cterminal hexahistidine tag and purified by cobalt affinity chromatography. Protein samples
were purified to high purity (> 99%), as analyzed by SDS-PAGE, and buffer exchanged
into 1X PBS. (B) Binding of 5.3.2 to cell surface MSLN was measured using a single
equilibrium binding assay. The data were fit to a sigmoidal curve, and a KD value was
calculated as the concentration yielding the half-maximal value.
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Figure 5.3 A431/H9 and KB-3-1 cell lines successfully form tumors in athymic nude
mice. Tumors were measured L x W x D daily and excised when at least two dimensions
surpassed 5 mm. (A) KB-3-1 cells formed a tumor at one week post inoculation, measuring
9 mm x 9mm x 2mm. (B) A431/H9 cells formed a tumor measuring 6 mm x 6 mm x 3 mm
at two weeks post inoculation.
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Figure 5.4 Immunofluorescence confirms mesothelin expression in KB-3-1 tumor
xenografts. Paraffin-embedded tissue sections were stained with a rabbit anti-mesothelin
primary antibody and an AF594-conjugated goat anti-rabbit antibody (Ab). Secondary
antibody only was used as a negative control. Representative immunofluorescence
micrographs of tumor xenograft sections are shown. DAPI (blue), nucleus; AF594 (red),
mesothelin expression. Original magnification 40X. Scale bar applies to all images.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS

6.1 Conclusions
Cancer is a global health concern and many patients suffering from a malignant
disease are in need of more effective and less toxic therapeutic options. Proteins represent
diverse and promising biological entities that can be further developed for both research
and biomedical applications, including targeted cancer diagnostics and therapeutics.
Protein engineering investigates and takes advantage of the unique relationship
between a protein’s structure and function to generate proteins with modified or novel
activities and/or properties. Protein engineering provides approaches by which naturally
existing proteins can be customized, or new proteins can be created, for targeted biomedical
applications. While antibodies have provided significant clinical advances, increased
understanding about the complexities of human diseases, including cancer, demands
additional, and potentially complementary, molecules that expand the therapeutic
spectrum. The work presented in Chapter 2 of this dissertation focused on engineering
proteins based on the non-antibody fibronectin protein scaffold (Fn3) to target tumor
biomarker mesothelin toward applications as targeted cancer diagnostics and therapeutics.
To our knowledge, this was the first report of non-antibody proteins engineered to bind
mesothelin. These results validated that the Fn3 non-antibody protein scaffold can be
engineered to bind to tumor biomarkers, and encourages the continued development of
engineered variants for applications such as targeted diagnostics and therapeutics.
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Targeted drug development has, and will continue to benefit from increased
knowledge about a particular molecular target and its specific roles in disease
pathobiology. Knowing and understanding the beneficial mechanisms of actions to exploit
and/or the mechanisms of resistance needed to overcome will advance rational and
effective drug design. In Chapter 3 of this dissertation, engineered protein variants that
bind mesothelin with high affinity were shown to selectively initiate apoptosis in tumor
cells expressing mesothelin. Interestingly, apoptosis did not occur through a caspasemediated pathway, and did not require downregulation of cell-surface mesothelin. The
absence of these commonly observed pathways for targeted treatment of tumor cells
suggests a currently unknown pathway through which mesothelin contributes to cancer
progression. Importantly, simultaneous treatment with mesothelin-binding protein and
chemotherapeutic mitomycin C had a greater cytotoxic effect on mesothelin-positive cells
compared to either molecule alone, underscoring the potential for combination therapy
including biologics targeting mesothelin.
A primary goal of a targeted therapeutic is to achieve maximum bioavailability, or
active effect, at the site of disease while limiting the toxicity of that therapeutic. Proteinpolymer conjugates, in which a therapeutic entity can be conjugated to a polymer and
specifically delivered to the site of disease by a targeting protein can address limitations
caused by systemic distribution of drugs in the body. The work presented in Chapter 4 of
this dissertation describes a simple, tailorable and modular approach for synthesizing
protein-polymer conjugates for targeted drug delivery to a variety of disease-specific cell
types.

Specifically, we demonstrated that a water-soluble, azlactone-functionalized

polymer can be efficiently labeled with a small molecule fluorophore, modeling how a
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small molecule drug may be attached, and conjugated to a targeting protein. Further, this
conjugation strategy did not interfere with native protein function, and the protein-polymer
conjugate was shown to internalize into target cells through receptor-mediated endocytosis.
Recent successes of targeted therapies have highlighted the importance of matching
the right patient with the right therapy. Companion diagnostics, such as molecular
imaging, allow clinicians to stratify patients and identify those who are more likely to
respond to a particular therapy. Additionally, molecular imaging can provide information
about therapeutic efficacy before traditional end points, such as tumor shrinkage, are
observed. In Chapter 5 of this dissertation, further evolved MSLN-binding proteins with
binding affinities appropriate for molecular imaging applications were identified, and in
vivo models for molecular imaging studies were developed.

6.2 Future Directions

6.2.1 Chapter 2: Fn3 proteins engineered to recognize tumor biomarker mesothelin
internalize upon binding
Directed evolution has proven to be a powerful technology for engineering proteins
with improved properties [1], including, as described in this thesis, evolving proteins for
novel molecular recognition. The success of directed evolution is reliant on the ability to
create highly diverse libraries, effective selection strategies, and iteration of these
processes. Many technological advances have further improved and streamlined these
processes and should be considered for future directed evolution projects [2]. For example,
characterizing the relationship between sequence and function of engineered proteins was
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traditionally limited by the requirement of Sanger sequencing after each round of selection.
While this method provides only a limited glimpse into selected variants, high throughput,
next-generation sequencing (NGS) technologies allow for investigation of selected
populations at a much broader scale [2–4]. Additional advances include sequence analysis
software tailored for protein engineering applications. While the length variability within
diversified regions (i.e. antibody CDRs or Fn3 loops) often make alignment processes
difficult, a recently developed program, the ScaffoldSeq [5] algorithm, exploits conserved
framework sequences to identify and align these diverse regions. Further, ScaffoldSeq can
efficiently filter out the unintended biases in sequence frequency often generated
throughout the directed evolution workflow.

6.2.2 Chapter 3: Engineered Fn3 protein has targeted therapeutic effect on
mesothelin-expressing cancer cells and increases tumor cell sensitivity to
chemotherapy

6.2.2.1 Identify the mechanisms of cytotoxicity of engineered MSLN-binding proteins
To have a therapeutic effect, molecules that are developed for targeted therapy must
interact with a specific cancer biomarker and then exert some change on a molecular
pathway critical for tumor cell survival, maintenance, and/or progression. MSLN is a
relatively new biomarker for targeted cancer therapy, and the molecular pathways by which
MSLN expression promotes cancer progression are not yet completely understood.
Elucidating the molecular pathways that MSLN engages with will inform efforts for
developing targeted therapies for MSLN-expressing cancers.
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The preliminary data

presented in Chapter 3 indicate that our engineered Fn3 proteins are selectively cytotoxic
to (Figure 3.3) and induce apoptosis (Figure 3.4) of MSLN-positive tumor cells, and do so
in the absence of caspase activation (Figure 3.5) and in absence of surface MSLN
downregulation (Figure 3.6).
Apoptosis is a highly-organized, multi-step process that can proceed in either a
caspase-dependent or a caspase-independent manner [6,7]. Apoptosis-inducing factor
(AIF) [8], which is normally localized within the intermitochondrial space and functions
as an NAD-dependent oxidoreductase, has been identified as an integral effector of
caspase-independent apoptosis. In response to a lethal signal, AIF is released from the
mitochondrial intermembrane space into the cytoplasm, after which it translocates into the
nucleus [9–11]. The AIF surface consists of a strong positive electrostatic potential which
allows it to interact with DNA, inducing chromatin condensation and DNA fragmentation
[10]. The Bcl-2 gene family consists of both pro-and anti-apoptotic proteins that are
thought to regulate the release of AIF from the mitochondria and the subsequent caspaseindependent apoptosis [12–14].

The anti-apoptotic proteins, including myeloid cell

leukemia-1 (Mcl-1), interact via BH3 domains with the pro-apoptotic proteins, BAK and
BAX.

BAK and BAX are responsible for forming pores within the mitochondrial

membrane, releasing AIF [15,16]. Increased Mcl-1 expression promotes malignant cell
survival and resistance to apoptosis by conventional therapy in a variety of cancers
including leukemia [17], non-small cell lung cancer [18], prostate cancer [16], ovarian
cancer [19], colon cancer [20] and breast cancer [15]. Studies in which Mcl-1 expression
was knocked down resulted in increased DNA strand breaks and apoptotic and necrotic
cell death, due to mitochondrial release and nuclear translocation of AIF [16]. MSLN
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expression is thought to promote resistance to several chemotherapeutic agents and is
significantly overexpressed in several characteristically chemoresistant cancers including
ovarian [21] and pancreatic [22]. Endogenous MSLN expression enhances the expression
of anti-apoptotic proteins, including Mcl-1 [23]. Studies in which MSLN expression was
increased, either exogenously or via transfection, demonstrated subsequent increased Mcl1 expression [21,24]. One working hypothesis is that treatment of MSLN-positive tumors
with Fn3 variants that bind and are internalized by MSLN leads to a reduction in Mcl-1,
and eventually to release of AIF from the mitochondria, which then induces apoptosis
(Figure 6.1). Future experiments will measure if engineered Fn3 variants influence the
level of Mcl-1 and the subcellular location of AIF in treated, MSLN-positive cancer cells.
Autophagy is a highly regulated, multistep process in which cellular organelles and
proteins are degraded to balance sources of energy and maintain DNA stability,
mitochondrial turnover and tissue homeostasis [25–27]. Autophagy was traditionally
considered a tumor suppression mechanism due to the reported allelic loss of the essential
autophagy gene (BECN1) in many human breast, ovarian and prostate cancers [28]. It is
now known, however, that once a tumor is established, cancer cells can hijack this process
to avoid apoptosis, which contributes to cancer therapy resistance [26,29–31]. Indeed,
autophagy inhibition has been shown to sensitize tumor cells to anticancer agents, and is
currently being evaluated as a therapeutic intervention in many preclinical and clinical
studies [32]. Recent work has identified that the levels of p53 upregulated modulator or
apoptosis (PUMA) increase upon autophagy inhibition, and that this increase in PUMA is
necessary for mediating apoptosis sensitization to anticancer agents [33,34]. Interestingly,
studies in which MSLN has been depleted from MSLN-overexpressing cancer cells, by
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either shRNA or siRNA, resulted in an increase in PUMA expression, and a corresponding
decrease in cancer cell proliferation and invasive capacity [35,36]. Further, MSLN
depletion combined with cisplatin demonstrated a marked increase in apoptosis compared
to cells treated with each agent alone [36]. Future experiments will measure if engineered
Fn3 variants influence the level of PUMA and the sensitivity of MSLN-positive cancer
cells to common anticancer drugs (Figure 6.2).

6.2.2.2 Measure the impact of Fn3 variants on tumor cell invasion and metastasis
Metastasis is driven by increased cell migration and invasion and MSLN expression
has been shown to positively correlate with metastatic potential [37–43]. This increased
tumor cell invasion and metastasis is mediated by the MSLN-CA125 binding interface and
the subsequent homotypic and heterotypic cell adhesions (Figure 1.12).
In our initial protein engineering approach, we sought to specifically engineer Fn3
variants that blocked the MSLN-CA125 interaction, hypothesizing that blocking this
interaction could enhance the therapeutic efficacy of Fn3 variants and enable a reduction
in metastasis. After modifying our protein engineering approach to select for Fn3 variants
that bound anywhere along the extracellular domain of the MSLN protein, we now need to
assess whether our selected variants do alter MSLN-CA125 binding.

In future

experiments, we will determine if our engineered anti-MSLN Fn3 variants reduce binding
of MSLN to CA125. Additionally, migration and invasion of MSLN-positive tumors cells
will be measured after treatment with MSLN-binding Fn3 variants, to determine if Fn3
treatment inhibits cancer cell motility.
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6.2.3 Chapter 4: Protein-polymer conjugates synthesized using water-soluble
azlactone-functionalized polymers enable receptor-specific cellular uptake toward
targeted drug delivery
Preliminary data in Chapter 2 demonstrated that engineered MSLN-targeting
proteins internalize into early endosomes (Figure 2.6 and Figure 2.7), providing an
opportunity for intracellular delivery of toxic molecules into MSLN-positive cancer cells.
The data in Chapter 4 showed that polymer PVDMA-mTEG can be loaded with a small
molecule cargo, by coupling the polymer to a small molecule fluorophore as a model for
loading with a small molecule drug (Figure 4.6). Additionally, polymer PVDMA-mTEG
was shown to readily conjugate to multiple model proteins in aqueous solution through the
primary amines of the protein, including to native transferrin receptor ligand hTF (Figure
4.3). This non-specific conjugation through primary amine chemistry, however, made
controlling the stoichiometry of protein:polymer difficult to control, and the location of
polymer attachment to protein was not define. Continuing with this approach could lead to
variations in conjugation structure.
In future work, our protein-polymer conjugate system will be further developed to
become a versatile approach for delivering small molecule therapeutics to tumor cells
mediated by engineered Fn3 proteins that target MSLN. The Fn3 protein scaffold is ideal
for this proposed work because it contains no cysteine residues, allowing the introduction
of a unique cysteine residue for subsequent site-specific conjugation to polymer and drug
payload. PVDMA polymer functionalized with maleimides could easily couple to the Fn3
proteins with a single cysteine residue. Alternatively, it is possible to mutate all lysine
residues in the Fn3 scaffold and maintain structure and function [45], leaving only the N-
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terminus as a primary amine, enabling site-specific primary amine conjugation for polymer
and drug payload. Coincidentally, I have engineered an Fn3 variant that binds MSLN with
high affinity and contains no lysine residues.
Confocal microscopy will be used to perform cell internalization assays with the
MSLN-targeting polymer conjugates to assess whether the conjugates can be internalized
by MSLN. Preliminary data from Chapter 4 in which the hTF-polymer conjugates are
selectively internalized into cells that express the transferrin receptor demonstrate that
protein remains functional following polymer conjugation (Figure 4.8). Targeting
specificity will be examined with blocking experiments in which unlabeled Fn3 proteins
are co-incubated with Fn3-polymer conjugates. We expect cell lines that express MSLN
to exhibit receptor-specific internalization of the Fn3-polymer conjugates, and we
anticipate cell lines that do not express MSLN will not bind or internalize the MSLNtargeting Fn3-polymer conjugates.

6.2.4 Chapter 5: Development of molecular and animal models for future molecular
imaging studies.
In future work, our proteins will be validated for use as in vivo molecular imaging
diagnostic agents. The high-affinity candidate proteins identified in Chapter 5 (Figure 5.2)
will be labeled with a far-red fluorescent dye, whose excitation and emission spectra are
appropriate for optical imaging. Preliminary tumor contrast measurements using our
developed mouse xenograft models and an IVIS SpectrumCT imaging system will be
performed. Candidate proteins with the greatest tumor contrast and lowest retention in
non-target organs will be selected for further development.
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6.3 Figures

Figure 6.1 Anti-MSLN Fn3 proteins may modulate Mcl-1 levels and induce caspaseindependent apoptosis via AIF. Apoptosis-inducing factor (AIF) is normally localized
within the mitochondria and has been identified as an integral effector of caspaseindependent apoptosis. In response to a lethal signal, AIF is released from the
mitochondria into the cytoplasm and translocates into the nucleus. AIF interacts with
DNA, inducing chromatin condensation and DNA fragmentation. Pro-and anti-apoptotic
proteins regulate the release of AIF. Myeloid cell leukemia-1 (Mcl-1), prevents pore
formation and AIF release from the mitochondria. MSLN expression enhances the
expression of anti-apoptotic proteins, including Mcl-1. One working hypothesis is that
treatment of MSLN-positive tumors with Fn3 variants that bind and are internalized by
MSLN could lead to a reduction in Mcl-1, and eventually to release of AIF from the
mitochondria, which then induces apoptosis.
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Figure 6.2 Anti-MSLN Fn3 proteins may inhibit cancer cell autophagy to sensitize
cancer cells to chemotherapy. Levels of p53 upregulated modulator or apoptosis (PUMA)
increase upon autophagy inhibition, and is required for mediating apoptosis sensitization
to anticancer agents. MSLN depletion is known to increase PUMA expression and when
combined with anticancer drugs, demonstrates a marked increase in apoptosis compared to
cells treated with each agent alone. One working hypothesis is that treatment of MSLNpositive tumors with Fn3 variants inhibits cancer cell autophagy making them more
sensitive to anticancer drugs.
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APPENDIX A:
ABBREVIATIONS USED
8-oxo-dGTP
Abl SH2
ADC
AF488
AF594
AF647
AF680
Aga1p, Aga2p
AIBN
ATR-IR
BBB
BDS
BSA
CA-125
CAR
CCK-8
CDCl3
CDK2
CEA
CT
CTA
DARPins
DBU
DMSO
DMSO-d6
DOL
dPTP
ECD
ECM
EGFR
ER
FACS
FBS
Fc
FC
FDA
FDG
FITC
FLAG
Fn3
FT-IR
Fv

8-oxo-2’-deoxyguanosine-5’-triphosphate
Abelson kinase Src homology 2
antibody-drug conjugate
Alexa Fluor 488 fluorescent dye
Alexa Fluor 594 fluorescent dye
Alexa Fluor 647 fluorescent dye
Alexa Fluor 680 fluorescent dye
yeast agglutinin proteins
2,2’-azobis(2-methylpropionitrile)
attenuated total reflectance infrared spectroscopy
blood brain barrier
bright detail similarity
bovine serum albumin
cancer antigen 125
chimeric antigen receptor
cell counting kit-8
deuterated chloroform
cyclin-dependent kinase 2
carcinoembryonic antigen
computed tomography
chain transfer agent
designed ankyrin repeats
1,8-diazabicylo[5.4.0]undec-7-ene
dimethylsulfoxide
deuterated DMSO
degree of labeling
2’deoxy-p-nucleoside-5’-triphosphate
extracellular domain
extracellular matrix
epidermal growth factor receptor
estrogen receptor
fluorescence activated cell sorting
fetal bovine serum
antibody crystalizable fragment
fluorescein cadaverine
Food and Drug Administration
fluorodeoxyglucose
fluorescein isothiocyanate
epitope tag comprised of the residues DYKDDDDK
fibronectin domain scaffold
Fourier transform infrared spectroscopy
antibody variable domain
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GM-CSF
GPC
GPI
Gr2
HA
HER2
His6
HPLC
hTF
IACUC
IgG
IL-6
IHC
KD
kDa
MACS
MMC
MMP-7
Mn
MPF
MRI
MSLN
mTEG
MW
MWCO
NGS
NHS
NMR
NOPR
OTF
PBS
PBSA
PBST
PCR
PE
PEG
PET
PET/CT
PFA
PI
PNGaseF
PVDMA
RAFT
RDG

granulocyte-macrophage colony-stimulating factor
gas permeation chromatography
glycosylphosphatidylinositol
Gradient 2 fibronectin library
hemagglutinin
human epidermal growth factor 2
hexahistadine tag
high pressure liquid chromatography
holotransferrin
Institutional Animal Care and Use Committee
immunoglobulin G
interleukin-6
immunohistochemistry
equilibrium dissociation constant
kilodaltons
magnetic activated cell sorting
mitomycin C
matrix metalloproteinase-7
number average molecular weight
megakaryocyte-potentiating factor
magnetic resonance imaging
mesothelin
triethylene glycol monomethyl ether)
molecular weight
molecular weight cut-off
next-generation sequencing
N-hydroxysuccinimide
nuclear magnetic resonance
National Oncologic PET Registry
ovotransferrin
phosphate buffered saline
phosphate buffered saline with 0.1% bovine serum albumin
phosphate buffered saline with 0.2% Tween 20 detergent
polymerase chain reaction
phycoerythrin
polyethylene glycol
positron emission tomography
positron emission tomography/ computer tomography dual
imaging modality
paraformaldehyde
propidium iodide
peptide-N-glycosidase
poly(2-vinyl-4,4-dimethylazlactone)
reversible addition-fragmentation transfer
Fn3 variant in which the RGD integrin-binding motif has been
mutated to RDG
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RES
RISC
RIT
RMT
ROI
scFv
SD
SDS-PAGE
SE
SEA
SEC
STAT3
TBST
TEF-1
TFA
TFP
TFR
TME
TR
VEGF
VEGFR-2
YAP1
YPD
YSD
ε

reticuloendothelial system
RNA-induced silencing complex
recombinant immunotoxin
receptor-mediated transcytosis
region of interest
single chain variable fragment of antibodies
standard deviation
sodium dodecyl sulfate – 3polyacrylamide gel electrophoresis
standard error
sea urchin sperm protein, enterokinase and agrin
size exclusion chromatography
signal transducer and activator of transcription 3
tris-buffered saline with 0.1% Tween 20 detergent
transcriptional enhancer factor 1
trifluoroacetic acid
tetrafluorophenyl
transferrin receptor
tumor microenvironment
tandem repeat
vascular endothelial growth factor
vascular endothelial growth factor receptor-2
yes-associated protein 1
yeast peptone dextrose media for yeast
yeast surface display
molar extinction coefficient
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